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ABSTRACT

Characterization of the Product Specificity and Kinetic Mechanism of Protein Arginine
Methyltransferase 1 (PRMT1)

by

Shanying Gui, Doctor of Philosophy
Utah State University, 2013

Major Professor: Dr. Joan M. Hevel
Department: Chemistry and Biochemistry

Protein arginine methylation is an essential post-translational modification
catalyzed by protein arginine methyltransferases (PRMTs). Type I PRMTs transfer the
methyl group from S-adenosyl-L-methionine (AdoMet) to the arginine residues and
catalyze the formation of monomethylarginine (MMA) and asymmetric dimethylarginine
(ADMA). Type II PRMTs generate MMA and symmetric dimethylarginine (SDMA).
PRMT-catalyzed methylation is involved in many biological processes and human
diseases when dysregulated. As the predominant PRMT, PRMT1 catalyzes an estimated
85% of all protein arginine methylation in vivo. Nevertheless, the product specificity of
PRMT1 remains poorly understood. A few articles have been published regarding the
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kinetic mechanism of PRMT1, yet with controversial conclusions.
To gain more insights into the product specificity of PRMT1, we dissected the
active site of PRMT1 and identified two conserved methionines (Met-48 and Met-155)
significant for the enzymatic activity and the product specificity. These two methionines
regulate the final product distribution between MMA and ADMA by differentially
affecting the first and second methyl transfer step. Current data show that Met-48 also
specifies ADMA formation from SDMA. To further understand the kinetic mechanism of
PRMT1, we developed a double turnover experiments to conveniently assay the
processivity of the two-step methyl transfer. Using the double turnover experiments, we
observed that PRMT1-catalyzed dimethylation is semi-processive. The degree of
processivity depends on the substrate sequences, which satisfies the controversy between
the distributive or partially processive mechanisms previously reported. We are using
transient kinetics and single turnover experiments to further investigate the mechanism of
PRMT1. Interestingly, during these studies, we found that PRMT1 may incur oxidative
damage and the histidine affinity tag influences the protein characteristics of PRMT1.
These studies have given important insights into the product specificity and kinetic
mechanism of PRMT1, and provided a strong foundation for future studies on PRMT1.

(200 pages)
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PUBLIC ABSTRACT
Investigation of the chemical properties and cellular function of PRMTs
Protein enzymes perform a vast array of functions within living organisms,
catalyzing various metabolic reactions including DNA replication, DNA repair, protein
synthesis, etc. In order to maintain proper cellular functions, enzymes need to be
accurately regulated under different circumstances. Specifically, enzymes can be
modified after their creation to give them additional functions. These modifications can
do a variety of things including activating (turning on) or inactivating (turning off) an
enzyme, changing what proteins or molecules can interact with the enzyme, changing the
enzyme’s location in the cell, and/or targeting the enzyme for destruction. This
dissertation focuses on a single class of enzymes, protein arginine methyltransferases
(PRMTs), which transfer one or two methyl groups to a specific amino acid, arginine, in
the target protein (substrate).
Arginine methylation is a small but significant modification involved in cellular
processes such as transcriptional regulation, DNA repair, subcellular localization, signal
transduction, and nuclear transport. Moreover, irregular expression and malfunction of
PRMTs, which lead to altered amount and/or type of the methylation products, are
broadly observed in cancer and cardiovascular disease. Thus, detailed study of PRMTs is
essential for the development of therapeutic drugs for diseases associated with arginine
methylation. This dissertation presents continuous studies with broad insight into the
product specificity and catalytic mechanism of PRMT1 by addressing how PRMT1 is
regulated to maintain its specificity and activity to generate the desired amount and type
of methylation products.
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CHAPTER 1
INTRODUCTION

In eukaryotic cells, protein arginine methylation is an essential post-translational
modification that enables organisms to expand upon their limited genome in addition to
phosphorylation, acetylation, and glycosylation. Protein arginine methyltransferases
(PRMTs), which catalyze arginine methylation, are involved in a wide variety of
fundamental cellular pathways including RNA processing, signal transduction, DNA
repair, transcriptional regulation (reviewed in (1-3)), chromatin remodeling (4), and
neuronal cell differentiation (5). Dysregulation of PRMT expression and/or activity has
been observed in numerous diseases, including carcinogenesis (6), viral pathogenesis (7),
multiple sclerosis (8), spinal muscular atrophy (9), lupus (10), cardiovascular disease (11,
12) and stroke (13). Overall, PRMTs play a crucial role in many biological processes.
Although the biological importance of PRMTs has become well accepted, current
understanding of the fundamental biochemistry of these enzymes remains limited,
partially due to the complexity of the system. Thus far, nine PRMT isoforms have been
identified in mammalian cells (PRMT1-9). PRMTs transfer a methyl group from Sadenosyl-L-methionine (AdoMet/SAM) onto a positively charged arginine residue in the
protein

substrate,

generating

monomethylarginine

(MMA)

and

S-adenosyl-L-

homocysteine (AdoHcy/SAH). Type I PRMTs (PRMT1-4, 6, and 8) can further catalyze
the formation of asymmetric dimethylarginine (ADMA); the type II enzyme, PRMT5,
generates MMA and then symmetric dimethylarginine (SDMA), while PRMT7, the type
III enzyme, only generates MMA.
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PRMTs show broad and high substrate specificity, with different products
correlating with specific biological outputs. For instance, PRMT4 methylates histone
H3R2, H3R17, and H3R26 (14, 15), while PRMT1 and PRMT5 specifically target H4R3
and H3R8 (16, 17). Different dimethylation statuses (ADMA or SDMA state) of the same
substrate can lead to distinct transcriptional outputs (18, 19). Importantly, MMA is not
only the intermediate of dimethyl arginine formation, but also a physiologically relevant
methylation status, which has been shown displaying a different transcriptional output
from ADMA (20). Therefore, it is of great significance to understand the regulation of
product specificity of PRMTs.
Many important questions about product specificity of PRMTs remain to be
answered. For instance, it is unknown why Type I PRMTs specifically generate ADMA
instead of SDMA and vice versa, even when the two types of PRMTs target the same
substrates. How do PRMTs govern which arginyl residues are modified and which state
of methylation is achieved? Currently, none of these aspects is clearly understood. To
gain mechanistic insight about product specificity of PRMTs, we chose to start with
PRMT1, the predominant PRMT isoform that performs over 85% of all protein arginine
methylation in vivo (21). The purpose of this dissertation was to understand how PRMT1
modulates its product specificity by dissecting the PRMT1 active site and characterizing
the kinetic mechanism of PRMT1.
In Chapter 3, I followed the discovery of Dr. Whitney Wooderchak-Donahue, a
previous Ph.D. in the Hevel Lab, and further identified that two strictly conserved
methionine residues (Met48 and Met155) in the PRMT1 active site play significant roles
in regulating substrate recognition and product formation of MMA versus ADMA (22).
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From the crystal structure of PRMT1, M155 (23) and M48 (22) were hypothesized to
control ADMA formation instead of SDMA due to steric hindrance afforded by their
bulky side chains. By direct site mutagenesis and product analysis, we found that the
M48L, M48A and M155A mutants showed a decreased enzymatic activity, yet still
generated ADMA instead of SDMA. However, these mutants change the distribution of
final mono- and dimethylated products. To understand the mechanistic basis of the
altered product formation, I developed single turnover experiments for PRMT1 based on
the similar concepts done with DNA methyltransferases (24), which examined each
methyl transfer step separately in the dimethylation process. Single turnover experiments
reveal that M48L transfers the second methyl group much slower than the first one,
especially for arginine residues located in the center of the peptide substrate where
turnover of the monomethylated peptides is negligible. Thus, altered mono- and dimethyl
product distribution in M48L results from the different effect of the mutation on the twostep methylation rates. Characterization of the two active-site methionines reveals for the
first time how the active site of PRMT1 is engineered to modulate the product specificity.
Following the study of active site residues, we further examined what leads to the
specific methylation patterns of PRMT1 with different substrates in vivo (25-27). In
Chapter 4, we investigated the methylation preference of PRMT1 among multi-arginine
substrates, as well as the determinants for the final methyl status on the targeted arginine.
Most protein substrates of PRMT1 contain multiple arginines in close proximity. We
found out that PRMT1 methylates a multisite peptide substrate in a non-stochastic
manner with an N-terminal preference, consistent with the methylation patterns observed
in vivo. With a single targeted arginine, we showed that the final methylation status is
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aﬀected by the amino acid sequence context. Another approach to regulate the
proportion of mono- and dimethylation would be through regulation of dissociative or
processive dimethylation. To conveniently study the processivity of PRMT1, a double
turnover experiment was developed which revealed PRMT1-catalyzed dimethylation in a
semi-processive manner. The degree of processivity is regulated by substrate sequences,
which explained the controversial observations between the distributive and partial
processive mechanism of PRMT1 (28, 29). Our results recognize a novel substrateinduced mechanism for modulating PRMT1 product specificity (30).
In Chapter 5, to further understand the semi-processive mechanism, single turnover
experiments and pre-steady state kinetic studies were performed to examine the
microscopic rates in the arginine dimethylation process. In 2011, a transient kinetics
study (31) was performed with PRMT1 and a fluorescein-labeled peptide, of which the
results were controversial to the previous steady-state kinetic studies (28, 32, 33). Herein,
we chose the underivatized eIF4A1 peptide pair for further mechanistic investigations
due to its relatively high degree of processivity shown in Chapter 4. Results from the
single turnover experiments showed that PRMT1 is slower to bind AdoMet and generate
a productive complex compared to the peptide substrates. Under single turnover
conditions, PRMT1 has a slightly higher preference to the unmodified peptide substrates.
Stopped-flow rapid mixing experiments exposed that AdoMet binding to PRMT1 appears
to be a two-step process. Most surprisingly, a role for the reductant dithiothreitol (DTT)
in substrate binding was revealed in my studies. Data from rapid mixing with PRMT1
and DTT indicated a transient change in protein conformation and/or its oligomeric state,
possibly due to the histidine-tag within the PRMT1 construct. Due to the limited access
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to the stopped-flow equipment (UC, San Francisco), not enough data were collected to
draw a solid conclusion on the mechanism of PRMT1-catalyzed methylation.
Following the discovery of the effect of DTT on His-tagged rat PRMT1, in Chapter 6,
we generated a tagless construct of rat PRMT1 to investigate the influences of affinity
tags and the reductant DTT. The His6-tag was once reported to have a drastic effect on
the substrate specificity of human PRMT1 (34). Although we didn’t observe this with the
hypomethylated cell lysates we used, the His6-tag was found to lower the activity of rat
PRMT1 compared to the tagless construct, and lead to a distinct oligomeric pattern from
the tagless PRMT1, which can be partially recovered by the addition of DTT.
Surprisingly the enzymatic activity of the tagless PRMT1 is barely affected under the
same DTT treatment. Our results indicate that small affinity tags, such as the histidine-tag,
can significantly affect the protein characteristics of PRMT1, which can be partially
recovered by reducing agents. The effect of DTT suggests that His-rat PRMT1 may incur
oxidative damage. Further experiments will be performed to understand more about the
possible oxidative damage of PRMT1 and their influences on the enzymatic activity.
In Chapter 7, results from RNA aptamer development were summarized. RNA
aptamers are small pieces of RNAs which have high binding affinity and specificity
targeting selected molecules. As free ADMA becomes a biomarker for cardiovascular
diseases (35), it is of great significance to develop a convenient and accurate method to
detect and quantitate free ADMA. Unlike antibodies, aptamers are readily available and
can be easily modified. Herein, we aimed to develop RNA aptamers targeting ADMA.
Systematic evolution of ligands by exponential enrichment (SELEX) was performed
against ADMA-coated agarose beads. The binding affinity and specificity of the RNA
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pools generated in these SELEX cycles were tested via two well-accepted binding
assays, an affinity chromatography and a filter-based binding assay. However, the
binding results from these two assays did not agree with each other. Therefore, another
novel scintillation proximity assay is under development to screen the selected RNAs and
investigate the sequence and structural properties of the RNA aptamers.
Chapter 8 includes experimental results from several ongoing projects and their
possible future directions. We previously discovered that the processivity of PRMT1catalyzed dimethylation is substrate dependent (30). To further investigate the influence
of peptide substrates on PRMT1 processivity, single turnover experiments were
performed with series of peptide substrates to measure the methylation rate of the 1st and
2nd methylation step. Results showed that the methylation rate is uncoupled with the
degree of processivity. More factors are involved in the substrate-dependent processivity.
In another experiment, the M48F-PRMT1 mutant was found to generate a small amount
of SDMA, which changes the product specificity of PRMT1 into Type I/II PRMT.
Further experiments are focusing on computing the differences of the active sites of wild
type PRMT1 and M48F-PRMT1 and their influence on achieving the product specificity.
In summary, this dissertation provides more insights into the product specificity and
kinetic mechanism of PRMT1. The in-depth mechanistic analysis as well as the
preliminary experiments from the ongoing projects provides a strong basis for future
studies.
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CHAPTER 2
LITERATURE REVIEW

Biological Methylation
In biological systems, S-adenysol-L-methionine (AdoMet or SAM, Figure 2-1A) is
the second most widely used enzyme substrate following adenosine triphosphate (ATP)
(1). AdoMet can be utilized in a multitude of reactions including transsulfuration,
aminopropylation, and transmethylation. The majority of AdoMet-dependent reactions
involve

methyl

group

transfer.

After

AdoMet

is

generated

by

methionine

adenosyltransferase from methionine and ATP, the methyl group of methionine is
activated (2), and can be transferred to diverse substrates by AdoMet-dependent
methyltransferases (MTases) leaving the product S-adenysol-L-homocysteine (AdoHcy).
The huge preference for AdoMet over other methyl group donors (such as
N5-methyltetrahydrofolate)

reflects

favorable

energetics

from

the

charged

methylsulfonium center. The G ° for (AdoMet + homocysteine  AdoHcy +
methionine) is very low (-17 kcal/mol), more than twice the amount released from ATP
hydrolysis (1). AdoMet is also the most expensive metabolic compound made by cells on
a per carbon basis. The de novo biosynthesis of AdoMet costs twelve equivalents of ATP
in this process (3). However, the generation of AdoMet is also beneficial to the cell,
because in the reactions involving AdoMet, the breakdown products of AdoMet can all be
used in vivo (4).
In the structure of AdoMet (Figure 2-1A), the methyl group (-CH3) attached to the
methionine sulfur atom is chemically reactive and can be transferred to a methyl group
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acceptor. Methylation substrates include small molecules like arsenite (5, 6) and sterol (7,
8), as well as macromolecules such as DNA, RNA, and proteins (reviewed in (9, 10)).
The atomic target for the MTases can be carbon, oxygen, nitrogen, sulfur, and halides
(10-13). With different methyl group acceptors, a wide variety of mechanisms are utilized
to generate a catalytically active nucleophile. However, all MTases are thought to
perform a fundamental SN2-like mechanism (Figure 2-1B), transferring the methyl group
to the substrate with an inversion of symmetry (14, 15).

AdoMet-Dependent Protein Methylation
Following transcription and translation process, most proteins are then chemically
modified at some point. These post-translational modifications (PTMs) extend the range

Figure 2-1. (A) Structure of S-adenysol-L-methionine, which includes the methionine
moiety and the adenosine moiety. The chemically reactive methyl group attaches to the
methionine sulfur atom making the sulfur atom positively charged. (B) A general reaction
mechanism for AdoMet-dependent methyltransferases. A general base (:B) abstracts a
proton from the target atom (X=C, N, O, or S) leading to methyl group transfer from
AdoMet to the target atom.
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of structures and functions of the proteins by attaching other biochemical functional
groups (such as phosphate, acetate, alkyl groups, lipids, etc.), changing the nature of
amino acid side chains (e.g. deimination), or making structural changes (e.g. disulfide
bridges). Specific PTMs serve numerous functions including enzyme regulation and
cellular signaling.
It has been predicted that over 1% of genes in the mammalian genome encode
methyltransferases (16). Protein methylation is one of the post-translational modifications
involving one methyl group transfer mostly from AdoMet. Among protein
methyltransferases, most methylations occur on nitrogen (N-methylation) and oxygen
(O-methylation), and to a lesser extent on carbon (C-methylation) and sulfur
(S-methylation) atoms on amino acids.
Nitrogen is the most common nucleophile for protein MTases, and N-methylation
occurs on the side chains of lysine, arginine, histidine, glutamine and asparagine (17).
N-methylation on lysine and arginines, which are the most common targets, does not
change the positive charge of the amino acid side chains, but it does increase the steric
bulk of residues as well as the hydrophobicity, which in turn influences the
protein-protein and protein-nucleic acid interactions (17). Lysine residues can be mono-,
di- and then tri-methylated at the -amino group, whereas arginine residues can only be
mono-, and then asymmetrically or symmetrically dimethylated on the guanidine moiety
(18, 19). Besides lysine and arginine residues, the imidazole ring of histidine can also be
methylated to 1-methylhistidine (20) and 3-methylhistidine (21), which are both found in
muscle protein and in human urine. Moreover, the side chains of glutamine and
asparagine can be methylated as well, yielding N5-methylglutamine (22) and
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N -methylasparagine (23), respectively. Unlike lysine and arginine methylation,
4

glutamine or asparagine can only be monomethylated, which alters the chemical property
of the amide acid side chain, disturbing its hydrogen bonding potential and significantly
enhancing its hydrophobic character (24). The protein N-methylation in most cases is
considered irreversible except for lysine, of which the demethylation can be catalyzed by
the lysine-specific histone demethylase 1 (LSD1) family and the Jumonji C (JmjC)
family (25, 26).
In addition to nitrogen methylation, proteins can also be methylated on oxygen atoms
resulting in methyl esters (27). O-methylation occurs on the side chain carboxylate of
glutamate and aspartate, which neutralizes the negative charge of the carboxylate group
and adds hydrophobicity to the protein. Hence, O-methylation of glutamate and aspartate
completely disturb the protein-protein and protein-nucleic acid interaction. This
modification is a reversible process in cell, which appears to be hydrolyzed by simple
esterases and these enzymes have been isolated from chemotactic bacteria (27).
To a lesser extent, the electron-rich carbon and sulfur atoms can also be methylated
in methanogenic bacteria. The enzyme methyl-coenzyme M reductase was shown
crystallographically containing C-methylated arginyl and glutamine side chains, an
N-methylated histidine, and an S-methylated cysteine residue (28).

Protein Arginine Methylation
Protein arginine methylation is a common post-translational modification in all
eukaryotic cells. Although arginine residues were first discovered to contain methyl
groups in 1967 (29), arginine methylation was underappreciated until the mid-1990s, yet
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later on shown to be an essential and relatively abundant post-translational modification.
Protein arginine methylation is catalyzed by protein arginine methyltransferases
(PRMTs). A family of nine PRMT enzymes has been identified in mammals (Figure 2-2).
Type I and type II PRMTs catalyze the formation of monomethylarginine (MMA), which
can be further converted to asymmetric dimethylarginine (ADMA) by the type I PRMTs
(PRMT1, 2, 3, 4, 6, and 8), while type II PRMTs (PRMT5) catalyze the formation of
symmetric dimethylarginine (SDMA) (reviewed in (30, 31). PRMT7 is found to generate
MMA predominantly, and is thus classified as a type III PRMT (32). PRMT9 has no
reported activity as yet.

Figure 2-2. Mono- and dimethylation of arginine catalyzed by PRMTs. Type I, II, and III
PRMTs catalyze the addition of a monomethyl group to one of the terminal () guanidine
nitrogens of arginine residue, generating MMA and AdoHcy. Type I and Type II PRMTs
can further methylate MMA forming ADMA and SDMA, respectively. The second
molecules of AdoMet and AdoHcy are omitted for clarity.

Protein Arginine Methyltransferase Family
The PRMT family harbors a common catalytic core for methyltransferases,
containing the set of four signature motifs and the highly conserved THW loop (Figure
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2-3). Although all PRMT isoforms have a conserved AdoMet-binding site, their
N-termini differ in length and the presence or absence of additional motifs, which
facilitate the unique function of each PRMT isoform.
PRMT1 is the predominant mammalian type I enzyme, catalyzing 85% of total
protein arginine methylation in vivo (33). PRMT1 localizes to both the cytoplasm and the
nucleus (34). In both cellular compartments, PRMT1 has numerous substrates and
primarily methylates the glycine-arginine-rich domain in RNA-binding proteins (35). In
the human genome, seven variants of PRMT1 have been found resulting from alternative
splicing (36). These variants have different N-terminal sequences and tissue localization,
with distinct activity, substrate specificity, and subcellular localization. PRMT2 was then
discovered by sequence similarity to PRMT1 (37). PRMT2 can directly interact with
PRMT1 and stimulate PRMT1 activity in cells (38). A novel feature of PRMT2 is that it
harbors a SH3 domain at its N-terminus (37, 39), which is essential for protein-protein
interactions of PRMT2 with the proline-rich proteins (40, 41). PRMT3 was identified as a
PRMT1 binding protein two years after the discovery of PRMT1 (42). PRMT3 is the
only type I PRMT that does not display a nuclear location (34, 42). It is found that
PRMT3 influences ribosomal biosynthesis by catalyzing the dimethylation of the 40S
ribosomal protein, which is dependent on the zinc-finger domain at its N-terminus (43).
PRMT4 was identified in a yeast two-hybrid screen to associate within the p160 family
proteins (44). As a transcriptional coactivator (45), PRMT4 functions synergistically with
PRMT1 (46) and the histone acetyltransferases (HATs) (47). PRMT5 was cloned as a
Jak2-binding protein and shown to be able to generate SDMA (48, 49). PRMT5 is a type
II PRMT (48), which is generally regarded as a transcriptional corepressor (50). PRMT6
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is another type I PRMT with a nuclear restricted pattern of location (34). PRMT7 harbors
two putative AdoMet-binding motifs (51) and is the only PRMT which is classified as a
type III PRMT generating only MMA (32, 51). PRMT8 was identified due to its high
degree of homology with PRMT1 (52), and is capable of automethylation (41), similar to
PRMT6 (34). The N-terminal myristoylation anchors PRMT8 to the plasma membrane.
PRMT9 was discovered through a database search based on sequence homology to the
conserved PRMT AdoMet-binding motif (53). PRMT9 contains an F-box motif at its
N-terminus and a zinc-finger motif at its C-terminus, localized in both the nucleus and
cytoplasm. PRMT9 was shown to generate MMA, ADMA, as well as SDMA (53).

Figure 2-3. Schemes of the nine canonical members of the human PRMT family. The
highly conserved MTase core regions (grey) present in all PRMTs are indicated. Note that
PRMT7 has a duplication of these motifs. PRMT2 and PRMT3 have an N-terminal SH3
domain or a zinc-finger domain, respectively. The N-terminal myristoylation tethers
PRMT8 to the plasma membrane. PRMT9 has an F-box at its N-terminus and a
zinc-finger domain at the C-terminus. The size of individual PRMT is indicated at each
C-terminus.
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Structures of the PRMT Family

A. Overall Structures of PRMTs
So far, crystal structures of PRMTs have been solved for rat PRMT1 (54), yeast
RMT1/Hmt1 (55), rat PRMT3 (56), mouse PRMT4 (57), PRMT5 from Caenorhabditis
elegans (58), and plant-specific PRMT10 from Arabidopsis thaliana (59). The overall
monomeric structures of all PRMT structures contain three conserved parts (Figure 2-4):
AdoMet binding domain (light green),  barrel (light yellow) and the dimerization arm
which is embedded in the  barrel (light blue). The AdoMet binding domain has the
consensus fold conserved in other AdoMet-dependent methyltransferases (9, 16, 56, 60),
whereas the  barrel domain is unique to the PRMT family (54, 56). The type I PRMTs
all have a helical N-terminus (Figure 2-4 A), yet PRMT5 contains an unexpected TIM
barrel domain (Figure 2-4 B, light pink). Notably all PRMTs exist as a homodimer in the
crystal structure. The dimerization is briefly shown to be essential for PRMT activity (54,
55). Different PRMTs contain various lengths of dimerization arms. AtPRMT10 has a
significantly longer dimerization arm (12-20 residues longer than PRMT structures
elucidated previously) and leads to a larger central cavity in the dimeric form than
PRMT1 (59).

B. The Active Site of Type I and II PRMTs
For all type I PRMTs, the active sites shown in the crystal structures are very similar.
As the predominant PRMT in vivo, the crystal structure of rat His-PRMT1 was solved in
2003 with AdoHcy and R3, a 19 amino acid peptide substrate derived from fibrillarin
(GGRGGFGGRGGFGGRGGFG) (54). Until now, this is the only crystal structure of
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Figure 2-4. (A). Overall monomeric structures of Type I PRMT, rat PRMT1 (PDB: 1ORI),
rat PRMT3 (PDB: 1F3L), mouse PRMT4 (PDB: 2V74), and AtPRMT10 (PDB 3R0Q).
(B) The overall monomeric structure of Type II PRMT, C. elegans PRMT5 (PDB: 3UA3).
(C) The dimer structure of rat PRMT1. The N-terminal helix is shown in pink in type I
PRMTs as well as the TIM-barrel at the N-terminus of PRMT5. The AdoMet binding
domains in all structures are shown in light green, the  barrel structure in light yellow,
and the dimerization arm in light blue. The bound AdoHcy is shown in a stick mode in
dark grey. In PRMT1 dimer structure, the other monomer is shown in light grey.
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PRMTs co-crystallized with a peptide substrate. Even though the electron density for the
R3 peptide cannot be clearly observed, this crystal structure provided much important
insight into the reaction mechanism. Two conserved active site glutamates (E144 and
E153 in rat PRMT1, Figure 2-5A), called the “double-E” loop, stabilize the substrate
arginine guanidino nitrogen through hydrogen bonding. Mutating these glutamate
residues causes a dramatic reduction in PRMT1 activity (54).
Our research as well as other groups identified that two methionine residues (M48
and M155) sit very close to the guanidino group of the target arginine residue, regulating
the product formation (further discussed in Chapter 3) (58, 61). The hydrophobic
methylene groups of the target arginine lie parallel to the aromatic ring of Y148. In type
II PRMT, the “double-E” loop is also conserved (E499 and E508, Figure 2-5B) in the

Figure 2-5. The active site structures of type I and II PRMTs. (A) The active structure of
rat His-PRMT1 (PDB: 1OR8, pink) is shown with important amino acid residues shown
in stick model. Substrates AdoHcy and arginine residues are shown in green. (B)
Superimposition of the active site of PRMT1 and PRMT5 (PDB: 3UA3, grey). The
amino acids of PRMT5 are labeled.
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PRMT5 structure and is definitely required for enzymatic activity (58). One important
difference with the PRMT5 active site is that F379, which is conserved among PRMT5
proteins, replaced the M48 residue in rat PRMT1. Mutating the F379 back to a
methionine resulted in a more active enzyme, generating both SDMA and ADMA (58).
Moreover, I also discovered that an M48F mutation in rat PRMT1 makes PRMT1
generating MMA, ADMA, and SDMA (Chapter 8). These observations indicate the
significant role of M48 in PRMT1 in specifying the type of dimethyl arginine generation.

C. The N-terminal Structures of PRMTs
The N-termini of PRMTs vary a lot with specific functional domains for different
PRMTs (Figure 2-3). It has been predicted that the N-terminus of human PRMT1 is
probably involved in protein-protein interactions and substrate recognition (36). However,
in the crystal structure of PRMT1, the electron density for the N-terminus was completely
missing. From this structure, AdoHcy and the arginine residue are exposed on the
PRMT1 surface (Figure 2-6 left panel) indicating that AdoHcy or the peptide can be
released during methylation reaction without conformational change. However, by
superimposing the PRMT1 structure with PRMT3, of which the structure is almost
identical to PRMT1 yet with the N-terminal helix crystallized, I discovered that the
additional N-terminal helix folded right above the substrate binding pocket and trapped
AdoHcy inside (Figure 2-6 right panel). This observation implicates that polypeptide
motion or conformational change might be involved in the methylation process in order
to release AdoHcy and bind another AdoMet for the next turnover. Indeed, research from
the Zheng Group (62) and my pre-steady state kinetic studies (Chapter 5) identified a
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Figure 2-6. Conformational change might be required for PRMT1 in methylation process.
(Left) Solvent accessible molecular surface of PRMT1 shown in gray with bound
AdoHcy and Arg shown in stick models (PDB: 1OR8). (Right) The N-terminal helix of
the PRMT3 structure (PDB: 1F3L) shown in pink was superimposed onto PRMT1, which
trapped AdoHcy and the substrate Arg in the active site pocket.

critical precatalytic step which might be a conformational transition induced by substrate
binding.

PRMT Substrates and Product Specificity
PRMT-catalyzed methylation is a relatively abundant post-translational modification
in vivo. 2% of all protein arginine residues are asymmetrically dimethylated in rat liver
nuclei (63). Within the nuclear compartment, heterogeneous nuclear ribonucleoprotein
(hnRNP) contains about 12% of the arginine residues being asymmetrically dimethylated
(35, 63).
With numerous substrates in vivo, the product specificity of PRMTs includes not only
recognizing the protein substrates, but also targeting specific arginine residues in the
multiple methylation sites. It is known that PRMTs have a sequence preference to the
proteins harboring glycine- and arginine-rich (GAR) motifs in “RGG” or “RXR”
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canonical sequences (64). Although substrate profiling of PRMT1 reveals more amino
acid sequences that extend beyond the “RGG” paradigm (65), most PRMTs have such
preference. PRMT4, on the other hand, displays different substrate specificity and does
not methylate the GAR motif.
Additionally, histone proteins are also common substrates for all PRMTs. Histone H3
can be methylated by PRMT4 (44, 66), -5 (32, 67), and -6 (68), and H4 protein can be
methylated by PRMT1 (44, 69), -2 (70), -3 (42), -5 (49), -6 (68), -7 (32), -9 (53), and -10
(59). PRMTs demonstrate site preference to histone proteins. For instance, on histone H3,
Arg17 and Arg26 are the preferred methylation targets for PRMT4 (44, 45), while Arg8 is
methylated by PRMT5 (67). Methylation of histone arginines by PRMTs is largely
involved in transcriptional regulation. Histone H4 Arg 3 is targeted by PRMT1 and
PRMT5 in vivo, generating ADMA and SDMA, respectively. And these two methyl states
of H4R3 lead to opposite transcription consequences (50, 69, 71-73). Moreover, it has
long been considered that MMA is simply an intermediate of ADMA or SDMA
generation. However, the Kouzarides Group showed that MMA is a methylation state that
occurs in vivo on histone H3 Arg 2 in yeast nucleosomes, leading to a distinct
transcriptional output from ADMA state on H3R2 (74). Thus, regulation of the product
specificity of PRMTs is significant in proper cellular transmission of chemical
information.

Kinetic Mechanism of PRMTs
In order to understand the product specificity of PRMTs, efforts have been put in
exploring the kinetic mechanism of PRMTs. Among a handful of publications on the
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mechanism of PRMT1, the conclusion is still controversial, especially on whether
PRMT1-catalyzed dimethylation is a distributive (monomethylated species released from
the enzyme before rebinding) or processive (mono- and dimethylation occur sequentially
without releasing monomethyl species) mechanism. As a distributive mechanism would
produce a higher concentration of MMA than the enzyme concentration, a processive
mechanism will have an obligated dimethyl arginine formation.
In 2007, Thompson and coworkers first elucidated the mechanism of PRMT1 being
partially processive using histone H4-derived peptides due to the results that PRMT1
generates MMA and ADMA containing peptides in approximately equal amounts (75).
Such partially processive methylation has been observed for a number of protein lysine
methyltransferases (76). Later in 2008, they further reported that human PRMT1 utilizes
a rapid equilibrium random mechanism from initial velocity and inhibition experiments,
which is consistent with the partially processive mechanism (77). However, Wahle and
coworker, in 2009, stated that both PRMT1 and PRMT3 act distributively, i.e. with
intermittent release of the MMA intermediate using a peptide substrate derived from the
PABPN1 protein (78). To solve this disagreement, my research with various peptide
substrates found out that PRMT1-catalyzed dimethylation is semi-processive. The degree
of processivity is dependent on substrate sequences (Chapter 4) (79). Such fine-tuned
semi-processive mechanism allows varied final amounts of MMA and ADMA with
different substrates. Moreover, important active-site residues to product specificity in
PRMT1 were also identified. As stated previously, our research (Chapter 3) and the
Thompson Group discovered that mutation with smaller amino acids at M48 and M155
positions in rat PRMT1 influences the MMA/ADMA product formation but is not
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responsible for the regiospecific formation of ADMA (61, 80). However, intriguing
results were observed with M48F-PRMT1 mutation, which catalyzes a small amount of
SDMA formation along with ADMA formation (Chpater 8).
Similar to the argument in the research of PRMT1 kinetic mechanism, PRMT6 was
also previously reported to proceed via an ordered sequential mechanism in which
AdoMet binds to the enzyme first and the methylated product dissociate first then
AdoHcy, based on product inhibition studies, so that the distributive mechanism is
guaranteed in dimethylation process (81). Four years later, another kinetic study found
that PRMT6 follows a rapid equilibrium random mechanism and has limited processivity
to the peptide substrates (82). Our findings about the semi-processive mechanism of
PRMT1 may also contribute to understanding PRMT6 kinetic mechanism. Additionally,
the resolution to these discrepancies might require some structural evidence. In the
structure of PRMT4, a conformational change was observed upon AdoHcy binding,
which then facilitates peptide substrate binding (57). This observation strongly argues
that release of peptide is required to allow further AdoHcy/AdoMet exchange for the next
methylation event, which would be incompatible with a random partially-processive
mechanism.

Regulation of Product Specificity in Protein Methylation
Besides the kinetic mechanism of enzymes, the amino acid residues in the active site,
regulators in vivo, as well as other post-translational modifications can all influence the
product specificity of PRMTs. As an analogous phenomenon to arginine methylation, the
elegant studies in the lysine methyltransferase field can strongly support the investigation
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of product specificity of arginine methylation.

A. Regulation by Amino Acid Residues in Enzyme Active Site
Regulation of product specificity for both lysine and arginine methyltransferases is
drawing more attention due to the distinct biological outputs from different methylation
states of histones (83). It has been shown that the product specificity of protein lysine
methyltransferases (PKMTs) could be controlled in part by the existence of specific
residues at the active site (84-87). One of the best examples is a Phe/Tyr switch found in
many PKMTs (87, 88). As lysine can be mono-, di-, then tri-methylated, different PKMTs
generally have different product specificity. In SET7/9 and SET8, a tyrosine residue in
the active site occupies the position and only allows for monomethyl lysine formation (85,
89, 90), and in DIM-5 (84), a phenylalanine in that position makes the PKMT a di- or
tri-methyltransferase. Moreover, the substitution at the Phe/Tyr switch position could lead
to changed product specificity, i.e. the FY mutation for DIM-5 altered the enzyme from
a tri-methyltransferase to a mono/di-methyltransferase (84). Such a regulation switch
might also exist in protein arginine methyltransferases. Two methionine residues are
found highly conserved in the type I PRMT active site (61). Although mutating these
methionines in PRMT1 into alanine does not change its ADMA-specificity (61, 80), an M
 F mutation changed PRMT1 into type I/II enzyme (Chapter 8). Mutating the
corresponding phenylalanine in type II PRMT5 back to a methionine resulted in an active
enzyme generating both SDMA and ADMA (58).

B. Regulation by Interacting Proteins
Protein methylation has been shown to be regulated by proteins that bind to them.
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The interaction of the regulator proteins can result in activation, inhibition or modulation
of substrate specificity of protein methyltransferases. Histone H3 Lys 4 (H3K4)
trimethylation is commonly considered as a transcriptional activation signal recruiting
chromatin remodeling and modifying complexes (91-93). The PKMTs which catalyze
this modification, SET1 and MLL1, however, display very weak methylation activity by
themselves, and require additional four proteins, WDR5, RbBP5, ASH2L, and DPY30 to
form a complex to achieve maximal activity (94-96).
The activity and substrate specificity of PRMTs are also regulated by interactions
with other binding partners. PRMT1 activity was found to be stimulated by BTG1 and
TIS2/BTG2 proteins towards tested substrates (97). Another protein, hCAF1, also
interacts with BTG1, regulating PRMT1 activity in a substrate-dependent manner (98).
Moreover, the substrate specificity of PRMTs is influenced by interacting proteins.
PRMT4 is found endogenously in the nucleosomal methylation activator complex
(NUMAC), which switched the methylation specificity from free core histone H3 to
nucleosomal histones (99). Similar to PRMT4, a nuclear protein CORP5 tightly binds to
PRMT5 in vivo, strongly recruits it to histone H4 protein, so that the substrate specificity
of PRMT5 is modulated by CORP5 to preferentially methylate H4R3 when compared
with H3R8 (100).

C. Regulation by Post-Translational Modifications
Besides interacting proteins in vivo, post-translational modifications on enzymes or
substrates can also modulate the product formation of protein methylation. For example,
PRMT4 was found to be phosphorylated at Ser217 which disrupts its hydrogen bond with
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a close-by tyrosine and subsequently abolishes its methylation activity (101). Moreover,
other post-translational modifications close to the methylation site can also mask the
methylation motif. This phenomenon is commonly seen on histone tails. It is found that
PRMT5-catalyzed H3R8 methylation is inhibited by H3K9 acetylation (67). Also H3K4
trimethylation catalyzed by an MLL complex and H3R2 dimethylation by PRMT6 are
mutually exclusive (66, 102, 103). In our recent studies, PRMT1 is suggested to incur
oxidative modification, which also regulates the catalytic activity (Chapter 6). These
modifications could serve as a molecular switch for controlling protein methylation.

D. Is Arginine Methylation Reversible?
Post-translational modifications can also be regulated through the counter reactions.
Unlike phosphorylation or acetylation which is dynamically added or removed,
methylation seems to be stable. Histone lysine methylation is shown being removable by
histone-Lys-specific demethylase (LSD1). LSD1 catalyzes the demethylation of mono- or
dimethyl histone H3 lysine 4 using FAD as a cofactor, generating hydrogen peroxide
(H2O2) and formaldehyde (CHO) as byproducts (104). The observation of histone
arginine demethylase was also reported in 2007 about the Jumonji domain-containing 6
protein (JMJD6), which demethylates histone H3 at arginine 2 (H3R2) and H4 at arginine
3 (H4R3) in both biochemical and cell-based assays (105). However, this observation
cannot be reproduced by other labs. In 2010, the crystal structure of JMJD6 was solved
indicating that JMJD6 can catalyze C-hydroxylation rather than N-demethylation (106).
So far, the existence of arginine demethylase remains unclear.

Biological Importance of PRMTs
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The list of PRMTs and PRMT substrates has rapidly expanded in recent years,
implicating arginine methylation in a wide variety of cellular processes. Proteins known
to be arginine methylated are mainly nucleic-acid-binding proteins and proteins involved
in transcriptional regulation. The guanidino group of arginine residue is positively
charged and capable of hydrogen bonding, which facilitates interactions with the
phosphodiester backbones of RNAs and DNAs (107, 108). After arginine residues are
methylated, molecular modeling suggests that the hydrogen-bonding capability is
restricted and the bulkiness and hydrophobicity of the residue is increased (108).
Although methyl arginine maintains the positive charge, methylation of hnRNP A1 in
vitro showed a lowered pI, indicating a decreased basicity of the protein (109). These
changes in PRMT substrate proteins may influence the ability of arginine residues
interacting with other proteins or nucleic acids, and further lead to different biological
outputs.

A. Transcriptional Regulation
Protein arginine methyltransferases have been involved in transcription regulation
through their methylation of many transcriptional factors and histone proteins. PRMT1
and -4 are often considered as transcriptional activators and have been reported to
cooperatively enhance gene expression (110-112), while PRMT5 activity generally
results in transcriptional repression (50, 67, 73). PRMTs are implicated in the regulation
of numerous transcription factors, such as p53 (113), p300 (114), and YY1 (115).
Histone proteins are methylated by different PRMTs both in vivo and in vitro (Figure
2-7). The amino-terminal tail domains of these proteins can be heavily decorated with

covalent

post-translational

modifications

including

acetylation,
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ubiquitylation,

methylation and phosphorylation. The combinatorial nature of histone modifications are
further referred to as “histone code” (Figure 2-7). PRMT1 catalyzes H4R3 asymmetric
dimethylation which further recruits lysine acetylation leading to transcriptional
activation (69, 71, 72). This modification can be blocked by PRMT5 which
symmetrically dimethylates H4R3 and recruits DNA methyltransferase DNMT3A leading
to transcriptional silencing (73). Due to the distinct biological consequences of different
methylation states, the product specificity of PRMTs is drawing more and more
attentions.

Figure 2-7. Post-translational modifications on the N-terminal tails of histone H3 and H4
proteins. Methylation sites for PRMTs are indicated (116, 117). P: phosphorylation; Me:
methylation; Ac: acetylation.

B. Signal Transduction
Protein arginine methyltransferases have been shown to play a significant role in cell
signaling. PRMT1 was found to interact with the interferon / (IFN /) reporter (118).
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The signal transducer and activation of transcription (STAT) family protein, STAT1, was
suggested to be methylated by PRMT1 and involved in interferon signaling (119). Both
PRMT1 and PRMT5 are involved in T-cell signaling through the nuclear factor of
activated T-cell (NF-AT) transcription factor. PRMT1 methylates the NF-AT-interacting
protein NIP45 both in vitro and in vivo, facilitating the binding event and resulting in
stimulation of cytokine gene expression (120). PRMT5 also plays a positive role in
regulating IL-2 (interleukin 2) gene expression in T lymphocytes (121).
Moreover, PRMTs are found to be involved in cell cycle and morphological control.
The PRMT5 analog in yeast, Hsl7, degrades the kinase Swe1 which targets the
cyclin-dependent kinase (CDK) Cdc28 to prevent entry into mitosis (122, 123). Recently
PRMT6 is also shown regulating cell cycle progression through repression of CDK
inhibitors (124).

C. Pre-mRNA Splicing and mRNA Transport
In the RNA processing procedures, numerous RNA binding proteins are involved,
many of which are substrates of PRMTs. PRMT5 was found to dimethylate arginine
residues in the spliceosomal proteins SmD1, SmD3, and SmB, which are the major
epitopes for autoantibodies for lupus (125-127). Type I PRMTs may be involved in
splicing or spliceosome assembly, due to the fact that nuclear SmB, D1/D2, and D3
contain ADMA residues (128).
In eukaryotic cells, mature mRNAs needs to be exported through the nuclear pore
after processing. In yeast, Hmt1 (the predominant yeast type I PRMT) methylates Npl3
(129, 130) and Hrp1 (131, 132), both of which are implicated in mRNA transportation.

32
These proteins shuttle between the nucleus and cytoplasm, and the deletion of Hmt1
inhibits the nuclear export of both Npl3 and Hrp1 (131, 133).

D. DNA Damage Repair
The DNA repair protein MRE11 was identified containing ADMA residues (134) and
later found to be methylated by PRMT1 both in vitro and in vivo (135). Methylation of
the GAR motif of MRE11 does not affect the assembly of the MRE11/Rad50/NBS11
complex, which initially process the double-strand DNA breaks (135). And
methyltransferase inhibition leads to the failure of MRE11 to localize to DNA damage
sites (136). Another important protein involved in DNA repair is the tumor suppressor
protein p53. Following DNA damage, activated p53 binds DNA and activates expression
of target genes, such as CDK inhibiter p21 which promotes cell cycle arrest (137).
PRMT5 was shown to directly bind and methylate p53, and regulate the target gene
specificity of p53 (113). Recently PRMT6 was also reported to interact with the p53
promoter and negatively regulates p53 gene expression (138).

Protein Arginine Methylation and Diseases
PRMTs have a variety of protein substrates which are involved in many fundamental
cellular pathways. Therefore considering the diverse roles of PRMTs, dysregulation of
these enzymes would result in the appearance of some disease conditions.

A. Cancer
The connections between arginine methylation and cancer were noted since 1970s.
Histones from patients with chronic erythremic myelosis show an increased methyl
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arginine concentration (139). Elevated mRNA levels of PRMT1 was observed in certain
breast cancer cell lines compared to normal controls (36) and high expression level of
PRMT4 has been identified in prostate and breast cancer tumors (140, 141). Recently,
PRMT1 and PRMT6 are found to have a significantly higher expression level in cancer
cells of various tissues than in non-neoplastic cells (142). Furthermore, the serum ADMA
levels of various cancer cases are considerably higher than those of non-tumor control
cases (142). PRMT5 levels have also been shown to be increased in leukemia and
lymphoma cells (143), as well as in gastric cancer (144). Also, the tumor suppressor
protein p53, implicated in over 50% of cancers , can be regulated by PRMT5 (113) and
PRMT6 (138). Due to the overexpression of PRMTs and high ADMA levels found in
many cancer cases, PRMTs are becoming novel potential therapeutic targets, and specific
inhibitors of PRMTs in vivo is becoming a large interest in drug development (145).

B. Cardiovascular Diseases
Free MMA and ADMA in plasma is a potent inhibitor of nitric oxide synthase (NOS)
generated from the degradation of methylated proteins (146). The plasma concentration
of ADMA was found to be elevated in hypertension (147), hypercholesterolemia (148),
and atherosclerosis (149), suggesting that type I PRMTs may involve in cardiovascular
diseases. The free plasma levels of MMA and ADMA can be controlled by
dimethylarginine dimethylaminohydrolase (DDAH), which metabolizes free MMA and
ADMA. The inhibition of DDAH or the overexpression of PRMTs can both lead to an
increase in the MMA and ADMA pool (150). Although SDMA was unable to block the
enzymatic activity of NOS directly (151), it did have an indirect effect competing for
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arginine transport mediated by a cationic amino acid transporter (152).

C. Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a recessive genetic disorder resulting from lesions
in the survival motor neuron (SMN) gene (153). The SMN proteins containing Tudor
domains which bind to both ADMA and SDMA motifs can interact with numerous
PRMT4 and PRMT5 products (154, 155). A point mutation (EK) was discovered in the
Tudor domain in SMA patients, which influences binding the RG domains of Sm proteins
(156). However, mechanisms that may link the spliceosome assembly to SMN function
remain unclear.

D. Viral Pathogenesis and Host Interaction
Numerous viral proteins have been found heavily methylated including HIV-1
proteins, hepatitis proteins, and Epstein-Barr viral proteins (157). PRMT6 methylates
HIV transactivator protein Tat in vivo, which inhibits the stimulation of viral transcription,
indicating a negative role for PRMT6 in HIV replication (158). Also it has been shown
that PRMT1 methylates the small hepatitis delta antigen in vitro, and appears to facilitate
antigenomic replication (159). Epstein-Barr virus nuclear antigen 2 (EBNA2) has been
found to be methylated by PRMT5, which appears to be required for EBNA2 binding to
the host protein SMN (160). The EBNA2-SMN interaction plays a significant role in
viral infection (160).

CONCLUSION
Protein arginine methylation is a pervasive posttranslational modification in all
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eukaryotic cells. It is involved in various cellular pathways. The diverse roles of PRMTs
come from the numerous protein substrates in vivo, ranging from histones, RNA binding
proteins to signaling proteins and many other enzymes. The dysregulation of PRMT
activity and specificity leads to a number of diseases including cancer, cardiovascular
diseases, lupus, and viral pathogenesis. Although the biological functions of PRMTs are
well-accepted, many biochemical bases for arginine methylation remain unclear. We
focused on the predominant PRMT in vivo, PRMT1, aiming to understand how product
specificity of PRMT1 is achieved. This dissertation provides increased understanding of
the detailed mechanism and product specificity of PRMT1, which will contribute to the
PRMT research field, as well as PRMT-targeted drug development.
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CHAPTER 3
INVESTIGATION OF THE MOLECULAR ORIGINS OF PRMT1 PRODUCT
SPECIFICITY REVEALS A ROLE FOR TWO CONSERVED METHIONINE
RESIDUES1

ABSTRACT
Protein arginine methyltransferases (PRMTs) aid in the regulation of many
biological processes

by methylating specific arginyl

groups within targeted

proteins. The varied nature of the response to methylation is, in part, due to the diverse
product specificity displayed by the PRMTs.

In addition to site location within a protein,

biological response is also determined by the degree (mono- /dimethylation) and type of
arginine dimethylation (asymmetric/symmetric). Here we have identified two strictly
conserved methionine residues in the PRMT1 active site that are not only important for
activity, but also control substrate specificity. Mutation of Met155 or Met48 results in a
loss in activity and a change in distribution of mono- and dimethylated products.

The

altered substrate specificity of M155A and M48L mutants is also evidenced by
automethylation.

Investigation into the mechanistic basis of altered substrate

recognition led us to consider each methyl transfer step separately.

Single turnover

experiments reveal that the rate of transfer of the second methyl group is arginine
residues located in the center of the peptide much slower than transfer of the first methyl
group in Met-48L, especially for substrate where turnover of the monomethylated species
1

S. Gui, W.L. Wooderchak, M.P. Daly, P.J. Porter, S.J. Johnson, and J.M. Hevel,
Investigation of the molecular origins of protein-arginine methyltransferase I (PRMT1)
product specificity reveals a role for two conserved methionine residues, J. Biol. Chem
286 (2011) 29118–29126
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is negligible. Thus, altered product specificity in M48L originates from the differential
effect of the mutation on the two rates. Characterization of the two active-site
methionines provides the first insight into how the PRMT1 active site is engineered to
control product specificity.

INTRODUCTION
Protein methylation is a significant post-translational modification in eukaryotic
organisms. Protein arginine residues can be methylated on the guanidino nitrogens by
protein arginine methyltransferases (PRMTs), which use S-adenosyl-L-methionine
(AdoMet, SAM) as a methyl group donor. This post-translational modification is
important in a wide variety of fundamental biological processes including transcription,
RNA splicing, signal transduction, DNA repair, viral replication (reviewed in (1)), and
chromatin remodeling (2). In recent years, the significance of PRMTs in human diseases
has been increasingly studied, especially in cardiovascular disease (3) and cancer (4). In
all, PRMTs play a crucial role in many biological processes.
Although the biological importance of PRMTs has become well accepted, the current
knowledge of the fundamental biochemistry of these enzymes is limited, due in part to
the complexity of the system. So far, 11 PRMT isoforms have been identified. In
mammalian cells, nine PRMTs catalyze monomethyl arginine (MMA) formation and
they can be categorized into two major types; PRMT1, -2, -3, -4 -6, and -8 additionally
catalyze asymmetric dimethyl arginine (ADMA) formation, demonstrating type I activity;
whereas PRMT5, -7, and -9 catalyze symmetric dimethyl arginine (SDMA) formation,
demonstrating type II activity (Figure 3-1A). PRMT10 and -11 were identified as
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putative PRMT genes with no methylation activity shown as yet (5). As with other
enzyme families that post-translationally modify protein substrates, accurate substrate
recognition by the PRMTs is critical for the proper transmission of biochemical
information.

However, very little information is available to explain how or why any of

the PRMT isoforms target their cognate protein substrates, and more so, what determines
which arginine within a protein should be methylated; i.e., a consensus sequence has not
been identified.
Adding to the complexity of the PRMT field, different methylation statuses (MMA,
ADMA or SDMA state) of the same substrate can lead to distinct biological outputs. One
of the most striking examples is Arg-3 of histone H4 (H4R3), which can be either
asymmetrically dimethylated by PRMT1 or symmetrically dimethylated by PRMT5,
resulting in antagonistic effects on gene regulation (reviewed in (6)). Moreover, the two
methylation products of Type I PRMTs, MMA and ADMA, can also have distinct
biological functions. In yeast, MMA present in histone H3 at Arg-2 correlates to active
transcription, while the ADMA state contributes to transcriptional repression (7). In
contrast to the idea that MMA is simply an intermediate for ADMA generation, the
current data point to a bona fide signaling role for MMA residues in much the same way
that mono-, di-, and trimethylation of lysine residues differentially affect signaling (8,9).
A key to understanding the biological function of the PRMTs is to understand how
product specificity may be regulated, in terms of governing which arginyl residues are
modified and which state of methylation is achieved.
In order to gain mechanistic insight regarding the product specificity of the PRMTs,
we have initiated mutational studies of rat PRMT1, a ubiquitously expressed member of
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Figure 3-1. (A) Methylation reactions catalyzed by PRMTs. Type I and Type II PRMTs
make MMA. Type I PRMTs may then go on to make ADMA, while Type II PRMTs
produce SDMA. The second molecules of AdoMet and AdoHcy have been omitted for
clarity. (B) Sequence alignment for rat PRMT1, rat PRMT3, rat PRMT4, yeast
RMT1/Hmt1 and rat PRMT6. The conserved methionine pair is highlighted in dark red in
light grey boxes. (C) The rat PRMT1:AdoHcy:peptide substrate complex shows the
positioning of two strictly conserved methionine residues. The active site of rat PRMT1
(PDB code 1OR8) is shown with AdoHcy in light orange (sulfur in dark orange),
methionines 155 (left) and 48 (right) in dark red, and the substrate arginine group of the
R3 peptide (ac-GGRGGFGGRGGFGGRGGFGG) in blue (terminal guanidino nitrogens
are shown in dark blue).

the PRMT family that has been estimated to perform ~85% of arginine methylations in
mammals (10).

Structural studies of PRMT1 (11) and PRMT3 (12), both Type I

methyltransferases, have identified the component residues of the Type I active site and
have provided a basis from which to probe product specificity.

In particular, it has been

noted that all the type I PRMTs contain an active site methionine (position 155 in rat
PRMT1), which has been hypothesized to dictate the synthesis of ADMA over SDMA by
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preventing the binding of MMA in a configuration conducive for SDMA formation
(12,13). The idea that a single residue can alter product specificity is reminiscent of the
Phe/Tyr “switch” model that is used to explain product specificity in lysine
methyltransferases (13-15). Interestingly, we noted a second active site methionine
(position 48 in rat) that is also strictly conserved in Type I methyltransferases (Figure
3-1B). Together these two methionines are observed to sandwich the incoming substrate
arginyl group in the Type I methyltransferase active site (Figure 3-1C), and thus, be
positioned to affect the type and degree of methylation. Here we report that these two
active site methionine residues are essential for catalytic activity and product specificity
of PRMT1. Our studies show that substitution of Met-48 does not promote the formation
of SDMA, ruling out a methionine switch model. Our data are consistent with Met-48
functioning differentially in the methylation of arginine to MMA versus the methylation
of MMA to ADMA. Surprisingly, our data also show that Met-48 plays a crucial role in
specifying which peptidyl arginine is targeted by PRMT1.

EXPERIMENTAL PROCEDURES
Materials
AdoMet was purchased from Sigma as a chloride salt (≥80%, from yeast).
[methyl-3H]AdoMet was purchased from Perkin Elmer. All the peptides were synthesized
by the Keck Institute and purified to ≥95%. ZipTip®C4/C18 pipette tips were purchased
from Millipore. His-hnRNP K was expressed and purified according to (16).

Expression and purification of mutant PRMT1 proteins

PRMT1 mutant proteins were generated using the QuikChange

®
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Site-Directed

Mutagenesis kit (Stratagene) with sets of complementary oligonucleotide primers
spanning the desired site of mutation.

For each PCR reaction, the pET28b vector

(Novagen) containing the gene that codes for N-terminal histidine tagged rat WT-PRMT1
plasmid (pET28b-PRMT1) (17) was used as a template. Desired mutations (M155A,
M48A, M48L, M48F, M48Y, and M48W) were confirmed through DNA sequencing.
Mutant proteins were purified using the same methods used to express and purify wild
type His-PRMT1 (described in (17)). Purified proteins were ≥95% pure by SDS-PAGE.
Mutant protein sequences were verified using mass spectrometry.

Reverse phase (RP)-HPLC analysis of methylated amino acids
Assays containing 4 μM WT- or mutant-PRMT1 proteins, 800 μM AdoMet, 10 nM
AdoHcy nucleosidase (MTAN, purified as in (18)), and 50 mM sodium phosphate buffer
(pH 7.5) were equilibrated at 37 ºC for 3 minutes. Reactions were initiated with 200
μM R3 peptide and were terminated after 3 hours with 10% (v/v, final concentration)
trichloroacetic acid (TCA).

TCA-precipitated protein was removed through

centrifugation, and the supernatant (containing the peptide) was added to a glass vial.
An equivalent volume of 12 M HCl was added to each vial. Vials were sealed and
heated to 110 ºC for approximately 24 hours for a complete acid hydrolysis.
Hydrolyzed amino acids from WT-PRMT1 and the mutant-catalyzed reactions were
separated using o-phthaldialdehyde (OPA) derivatization (19) with a Gemini® 3 µm C18
110 Å LC Column 75 x 4.6 mm (Phenomenex). Mobile phase A consisted of 40 mM
sodium phosphate buffer (pH 7.8), and mobile phase B was acetonitrile/methanol/H2O

(45/45/10, v/v/v).

56
The HPLC gradient conditions are not shown. To verify the presence

and peak times of the methylated arginine products, sample reactions were spiked with
2.6 μM [3H]AdoMet (specific activity of 2.02 mCi/μmol). Fractions (83.3 μl) were
collected and radioactivity was counted in 5 ml scintillation cocktail (Fisher Scientific).
MMA, ADMA, or SDMA standard amino acids were used to verify the identity of the
methylated products generated. The detection limit for this method is ~10 pmole of
methylated arginine in a 20 μl sample.

Continuous spectrophotometric kinetic assays of PRMT1 mutants
A continuous spectrophotometric assay for AdoMet-dependent methyltransferases
(17) was used to assay PRMT1 mutants with arginine-containing peptides.

Briefly, two

coupling enzymes, MTAN and adenine deaminase, were used to hydrolyze and
deaminate the AdoHcy generated from methyl group transfer, respectively. This assay
avoids any product inhibition that could occur from AdoHcy.

Initial rate data

representing no more than 10% of product formation were fit to the Michaelis Menten
equation (20) to obtain Km,app and kcat, app values. Each reaction was performed at least in
duplicate.

The limit of detection for this assay was 0.1 μM CH3/min (which

corresponds to a kcat of 0.025 min-1).

Discontinuous kinetic assays of PRMT1 mutants
Another discontinuous but more sensitive assay with ZipTipC4/C18 was used in testing
the enzymatic activity under steady-state conditions (21). Unless noted otherwise in the
text, enzyme catalytic activity were tested with 100 nM wt-PRMT1 or mutants, 1 μM
AdoMet and 1 μM [3H]AdoMet, initiated by 200 μM peptide substrates or 1.7 μM
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hnRNP K protein substrate at 37 °C. At different time points, samples were removed
from reactions and processed with ZipTipC4/C18 pipette tips (for protein or peptide
substrates, respectively) to separate the unreacted [3H]AdoMet and the radiolabelled
product.

Dissociation constant measurement by intrinsic fluorescence quenching
An RF-5301PC spectrofluorophotometer (Shimadzu) was used for fluorescence
measurements.

For R3 peptide and AdoMet affinity determinations, an excitation

wavelength of 290 nm was used and emission spectra from 300-420 nm were collected.
The change in fluorescence intensity at the maximum emission (333 nm) was monitored.
The excitation and emission slit was 5 nm and the scan speed was 100 nm/min using
1325 µL containing 1.4 µM PRMT1 in 150 mM sodium phosphate buffer pH 7.1.
Increasing concentrations from 1 to 50 µM peptide ligand (or AdoMet) were added at 2-3
min intervals.

Data from at least two titrations were averaged and analyzed using the

modified Stern Volmer (22) plots. Data were evaluated by nonlinear regression analysis
using SigmaPlot in order to obtain the dissociation constant (KD) using the following
equation:

Fc= F (10

εcd/2

) where Fc is the corrected fluorescence, ε is the extinction

coefficient of AdoMet, c is the concentration of AdoMet, and d is the pathlength.
Finitial/(Finitial-Fc) was then plotted against 1/[AdoMet] and the data was fit to a line where
the yintercept=1/fa, the slope=1/fa*KQ, and the KQ=1/KD.

Protein crystallization
A truncated construct of M48L-PRMT1 was made which lacked the first thirteen
amino acids of the native sequence. Previous crystallographic studies reported better
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diffracting crystals using the truncated proteins (11). Histidine-tagged, truncated M48L
PRMT1 was expressed and initially purified as described previously (17). In addition to
immobilized metal chromatography, M48L was further purified by anion exchange
(MonoQ) and gel filtration chromatography as described previously (11). Purified
fractions were concentrated to 10-20 mg/mL and incubated with 600 µM AdoHcy and
1mM peptide (acGGRmeGGFGGKGGFGGKW) for 10-30 minutes before placing in
crystallization trays. Crystallization was performed using sitting drop vapor diffusion.
Crystals were grown at room temperature (~22 ºC) in 0.1 M Tris pH 9.0 and 1.62 M
ammonium phosphate monobasic at a 1:1 protein:well drop ratio. Crystals were flash
frozen in a cryo solution containing 0.1 M Tris pH 9.0, 1.62 M ammonium phosphate
monobasic, 0.5mM peptide, 300 µM AdoHcy, and 20% glycerol.

Data collection, structure determination and refinement
Diffraction data were collected using a home source generator and detector (Rigaku
RU-200/Raxis IV++). Data were indexed and processed using d*TREK in the program
Crystal Clear (23). Molecular replacement was performed using Phaser (24) from the
CCP4 suite (25,26). The search model was wild-type rat PRMT1:AdoHcy:peptide ternary
complex (Protein Data Bank entry 1OR8). PHENIX (27) was used to perform positional,
b-factor, and TLS refinement. The TLS groups were generated by the TLS Motion
Determination server (28). Coot (29) and MolProbity (30) were used for model building
and structure validation. The model was refined to an R/Rfree of 20.1%/24.5% with no
Ramachandran outliers (data not shown). AdoHcy was observed bound to the active site
(data not shown). No compelling electron density was observed for the peptide substrate.
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Density that could accommodate ~3 covalently bonded atoms was observed in the active
site near Glu-144. The density is inconsistent with solvent molecules included in the
crystallization buffer and may correspond to a portion of the peptide substrate. However,
since the density could not be confidently assigned, it was not included in the final model.
Structure factors and coordinates have been deposited in the Protein Data Bank (PDB ID
3Q7E). Figures were generated with PyMOL (31).

Mass spectrometry peptide methylation analysis and De Novo sequencing study
A reaction with 4 µM PRMT1, 800 µM AdoMet, and 100 nM MTAN in 50 mM
sodium phosphate buffer (pH 7.5) was initiated with 200 µM R3 peptide.

At various

time points, 10 µL aliquots were quenched with TFA (10% v/v final) and analyzed by
LC/MS followed by MS/MS of the desired peaks. 4uL of reaction solution was injected
onto a reverse phase column (75 m × 150 mm, BEH C18-nanoACQUITY column,
Waters, Manchester, UK). Peptides with and without methylation were separated at 40 °C
with a nonlinear gradient (data not shown). Solvent A was 0.1% formic acid in water and
Solvent Bs was 0.1% formic acid in acetonitrile. Monomethylated peptides
([M+H]3+=575.9) were then analyzed using a tandem mass spectrometer (Synapt Q-Tof,
Waters, Manchester, UK) to determine the position of monomethylation.

Single turnover experiments
Single turnover experiments were carried out by mixing a solution containing the
pre-incubated complex of 20 μM wild type or M48L-PRMT1, 20 μM AdoMet (along
with 1 μM of [3H]-AdoMet), and 10 nM MTAN in 50 mM sodium phosphate buffer (pH
7.5) at 23 °C for 3 minutes. Commercially available AdoMet was purified as described
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(32,33) before use. Reactions were initiated with 200 μM peptide substrates. Radiolabel
incorporation over time was measured using the discontinuous ZipTip® assay described
previously. Briefly, 10 μL reaction samples of different time points were taken out and
quenched by 6 M guanidine HCl solution and processed with ZipTip®C18 assay to
quantitate the amount of methylated product (21). The resulting time course of
[3H]AdoMet incorporation was fit into single exponential curve y=a*(1-exp(-b*x)) to
determine the parameters, a (maximum product concentration) and b (kchem).

RESULTS

Analysis of the products formed by M48A- and M48L-PRMT1
Previous analysis of the PRMT1 crystal structure suggested that the conserved Met at
position 155 may be important for governing ADMA formation over SDMA formation
by providing steric bulk in the active site and preventing free rotation of the MMA
intermediate (12,13). A closer examination of the PRMT1 structure identified Met-48, a
similarly conserved active site residue located opposite Met-155. Given the potential for
either methionine to influence substrate geometry in the active site, we investigated
whether these residues are involved in specifying ADMA formation versus SDMA.
Met-48 and Met-155 were individually mutated to alanines. We analyzed whether
ADMA or SDMA was formed in the mutant-catalyzed reaction by amino acid analysis of
the acid-hydrolyzed peptide products, using [3H]AdoMet as a tracer. M48A produced
only MMA and ADMA, albeit with a higher MMA:ADMA ratio compared to wt-PRMT1
(Figure 3-2A,B). Because of the low activity of M48A observed in the 3-hour reaction,
Met-48 was further mutated to leucine in order to determine if activity could be rescued
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by reintroducing more steric bulk. Like M48A, M48L also generated only MMA and
ADMA, but in a much larger amount, with an even higher ratio of MMA:ADMA than
that of M48A (Figure 3-2C). No SDMA was detected. Similar results were observed with
the M155A mutant, consistent with the recent report that Met-155 is not involved in
SDMA formation (34). Standards of MMA, ADMA, SDMA, as well as other amino acids
in the R3 peptide (Gly, Arg and Phe) were analyzed by the same method to verify the
methylated product (data not shown). Our results show that removing the steric bulk
afforded by Met-155 or Met-48 in the PRMT1 active site was not enough to transform
the Type I PRMT into a Type II PRMT. Thus, Met-48 or Met-155 do not, by themselves,
dictate ADMA formation over SDMA formation.

Steady-state methylation activities of PRMT1 mutants
The altered product ratios obtained for M48L and M48A in the previous experiments
suggested that the activity of the mutants may be impaired. In order to determine if
Met-48 has an effect on the ability of PRMT1 to catalyze peptide methylation, the rate of
methylation was measured with wt-PRMT1, M155A and M48A.

The activity was

followed using an enzyme-coupled continuous spectrophotometric assay and the R3
peptide,

a

common

peptide

substrate

used

in

arginine

methylation

(ac-GGRGGFGGRGGFGGRGGFGG) (Table 3-1) (17). The R3 peptide is a good
substrate for wt-PRMT1 with a catalytic efficiency (kcat/Km) = 4460 M-1s-1. When the two
methionines in question were mutated to small amino acid residues, i.e. alanine, mutants
still utilized R3 as a peptide substrate but at varying efficiencies (Table 3-1 and data not
shown). Substitution of Ala for Met at position 155 resulted in a 90% decrease in kcat/Km.
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The M155A mutation did not affect turnover velocity, but Km increased by a factor of ten
compared to wt-PRMT1. Substitution of Ala for Met-48 also decreased catalytic
efficiency. However an increase in Km was coupled with a 10-fold drop in kcat, leaving
this mutant with just under 2% of WT activity. These results suggest that Met-48 might
be more important for activity than Met-155. Increasing the size of the residue at position
48 from Ala to Leu restored 40% of wild type activity with the R3 peptide. The activity
results indicate that the Type I conserved Met residues at positions 48 and 155 play
important roles in enzymatic activity. Furthermore, the size of Met 48 is critical for
maintaining the catalytic activity of PRMT1.
To further explore the effect of the residue size at position 48 on the catalytic activity,
we further mutated the methionine to amino acids with larger-size side chains, such as
phenylalanine, tyrosine, and tryptophan. The same kinetic assay was employed to
measure the activity of these three mutants with R3 peptide; however the turnover rate
was very slow and beyond the limit of detection for this method (data not shown). We
turned to a more sensitive method that we recently reported on (21) and examined mutant
activity on a protein substrate, heterogeneous nuclear ribonucleoprotein K (hnRNP K)
(data not shown). With all larger-sized mutations, the activity was severely impaired.
M48F had the highest activity among these three mutants, displaying no more than 3% of
WT activity. Mutants with the even bigger amino acid tryptophan lost >95% activity.
Overall the kinetic analyses of the mutants show that residues smaller or larger than
methionine at position 48 result in less efficient methyl group transfer.
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Figure 3-2. Analysis of M48 mutants-catalyzed methylation products by amino acid
analysis. Products from reactions catalyzed by (A) wild type, (B) M48A, or (C)
M48L-PRMT1, were analyzed using reverse phase HPLC. [ 3H]AdoMet was used as a
tracer to verify the presence of the methylated species in each reaction (open circles).
MMA, ADMA, and SDMA standard amino acids were used to identify the methylated
species in each sample (solid line).
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Table 3-1. Steady-state kinetic activity of PRMT1 mutants with small-sized side chains
with R3 peptide via an enzyme-coupled continuous spectrophotometric assay
PRMT1

Km (µM)

kcat (s-1)

kcat/Km (M-1s-1)

% activitya of
wt-PRMT1

WT

<10

0.045 ± 0.003

4500 ± 330

100

M155A

120 ± 30

0.054 ± 0.005

460 ± 120

10

M48A

300 ± 210

0.0040 ± 0.0020

13 ± 13

1.4

M48L

18 ± 2.7

0.030 ± 0.0009

1700 ± 260

37

a

The percentage activity is based on the catalytic efficiency kcat/Km of mutants compared to wild
type.

Substrate binding affinity of PRMT1 mutants
The decrease in activity observed with mutations of either Met-155 or Met-48 could
be a result of impaired substrate binding or an inability to catalyze methyl transfer. In
order to discern if Met-155 or Met-48 mutations affect the binding of either AdoMet or
peptide substrates, we measured the dissociation constants of PRMT1, both wild type and
mutants, with AdoMet and the R3 peptide substrate. The crystal structure of PRMT1
indicates that there are two tryptophans at positions 145 and 294 which lie in the catalytic
region near the substrate arginine residue and opposite the AdoMet binding region (11).
The intrinsic fluorescence from these residues was exploited in a fluorescence-quenching
assay to determine the dissociation constants for the R3 peptide and AdoMet with
PRMT1. Lehrer’s modified Stern-Volmer plot (22) was used to analyze the
fluorescence-quenching data for wt-PRMT1 (data not shown) and the mutants.
Dissociation constants of either AdoMet or R3 peptide with wt-PRMT1 and all the
mutants were similar to each other in the low micromolar range (Table 3-2). The
observed fluorescent quenching was consistent with the number of active site tryptophans
relative to the total number of tryptophans. These results indicate that the decrease in
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Table 3-2. Binding affinity of R3 peptide substrate and AdoMet with intrinsic
fluorescence quenching.
PRMT1

KD, R3 (µM)

Fluorescent
quenching (%)

KD, AdoMet (µM)

Fluorescent
quenching (%)

WT

5.7 ± 0.52

28 ± 1.9

4.2 ± 1.5

17 ± 0.13

M48A

3.4 ± 0.32

37 ± 1.3

7.1 ± 1.8

15 ± 0.17

M48L

2.4 ± 0.29

28 ± 1.5

7.1 ± 0.94

29 ± 4.2

M48F

4.9 ± 0.38

30 ± 1.4

4.4 ± 0.93

23 ± 3.1

M155A

3.9 ± 0.53

34 ± 1.3

3.8 ± 0.87

19 ± 2.6

activity observed with the methionine PRMT1 mutants is not due to impaired substrate
binding in the enzyme active site.

Automethylation activity of PRMT1 mutants
In addition to the methylation of peptide and protein substrates, automethylation of
some PRMTs has been documented. For example, automethylation has been observed
with PRMT6 and PRMT8 (35,36). Additionally Frankel and coworkers recently reported
that histidine-tagged human PRMT1 also catalyzes automethylation (37). Although we
have never observed automethylation with his-tagged rat PRMT1, we hypothesized that
the methionine mutants of rat PRMT1 may show altered substrate recognition, and hence,
altered product formation. Therefore, the ability of each of the PRMT1 mutants to
catalyze automethylation was tested using [3H]AdoMet. Under our reaction conditions,
wt-PRMT1 showed no tritium incorporation after 4 hours incubation. Unlike wt-PRMT1,
the M48L and M155A mutants clearly showed a strong capacity for automethylation
(Figure 3-3). We quantified the amount of automethylation using our ZipTip®C4 assay
(21). A sample of 15 M M48L and M155A incorporated 2.14 ± 0.59 M (14.3%) and
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0.68 ± 0.24 M (4.5%) methyl groups in a 4-hour period, respectively. We also
confirmed the product of the automethylation by digesting the methylated M48L and
resolving the derivatized amino acids by HPLC.

The presence of radiolabel was

associated with ADMA (data not shown). These results show that mutation of either
Met-155 or Met-48 gives rise to a PRMT1 enzyme capable of automethylation. We
conclude that both Met-155 and Met-48 are important for substrate recognition.

SDS-PAGE

Autoradiograph
Figure 3-3. Automethylation of PRMT1 mutants. Reactions were carried out at 37 °C for
4 hrs with 15 μM PRMT1 (wt- or mutants), 8.57 μM AdoMet (0.9 μM of [3H]-AdoMet
added) in 50 mM sodium phosphate buffer, pH 7.5. The top panel is an SDS
polyacrylamide gel stained with coomassie blue to detect total protein, and the bottom
panel is an autoradiograph to detect radiolabel incorporation. The gel was exposed to
film for 5 days.

Analyzing for changes in protein structure
In order to confirm that mutations of the conserved methionine had no deleterious
effect on the PRMT1 structure, we determined the crystal structure of the M48L mutant.
Using conditions described for the crystallization of wt-PRMT1, we obtained a 2.2 Å
structure of M48L bound to AdoHcy (Figure 3-4). No significant differences were
observed between the wild-type and mutant structures (RMS deviation of 0.23 Å over
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299 residues), consistent with the kinetic data showing similar binding of AdoMet to WT
and M48L.

Figure 3-4. Superposition of the overall structure (A) and the active site (B) of M48L
(blue) and wild type PRMT1 (grey). Met-48/Leu-48, Met-155 and AdoHcy are shown in
sticks with wt-PRMT1 residues colored tan and M48L residues colored orange.

The positional preference of M48L-PRMT1
Although the crystal structure of M48L indicates that there are no significant changes
in the structure of the M48L mutant, the automethylation experiments suggested that
substrate recognition is altered in M48L. To further explore the effect that the M48L
mutation has on substrate specificity, we asked whether M48L strongly prefers substrate
arginines at certain positions and compared the results to wt-PRMT1. We employed the
R3 peptide in which all three arginines can be methylated, with one arginine at the
N-terminus, one in the middle, and one at the C-terminus. The short-time methylation
products of R3 peptide were analyzed by tandem mass spectrometry (MS/MS) to find out
which arginine was first methylated by wt-PRMT1 and M48L (data not shown). MS/MS
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showed that the N-terminal arginine is strongly preferred by both wt-PRMT1 and M48L,
with 55% and 65% of the first methylation located on the N-terminal arginine,
respectively (Table 3-3). The middle arginine is the second most preferred, however the
percentage for M48L was reduced by almost 50% compared to the wt-PRMT1. These
results suggest that although recognition of the N-terminal arginine of the R3 peptide
appears unaltered in M48L, recognition and/or catalysis at the central Arg of R3 is
impaired by M48L.

Table 3-3. The first methylation position in the R3 peptide catalyzed by wt-PRMT1 and
M48L from MS/MSMS analysis
PRMT1

% of the first methylation position
1st R

2nd R

3rd R

Wt-PRMT1

55

39

6

M48L

65

21

14

Peptide substrate specificity change for M48L-PRMT1
As a way of complementing the above studies, we also tested the activity of M48L
with a series of peptides that differ in the location of the targeted arginine within the
peptide and methylation status (listed in Table 3-4) with the M48L-PRMT1 mutant. All
the peptides listed could be easily methylated by wild type PRMT1 (Table 3-4). M48L
was able to methylate R3 at a relatively lower rate compared to wild type enzyme. We
tested peptides containing a single arginine along with its monomethylated counterpart.
M48L could methylate the RKK peptide pair (single arginine at N-terminus) at a rate
close to the R3 peptide. Surprisingly, even though the sequence of RKK and KRK
peptides is the same around the targeted arginyl group (GGRGG), the ability of M48L to
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methylate the centrally-located Arg in KRK was severely hampered. We conclude that
the inactivity observed with M48L and KRK peptide is most likely due to the central
position of the arginine in KRK peptide pair.
The previous experiments predict that the M48L mutant would be unable to
stoichiometrically methylate all arginine residues in the R3 peptide. In other words, the
amount of methyl groups transferred by M48L is expected to be lower, while wt-PRMT1
can fully methylate the R3 peptide, transferring six methyl groups to one peptide. When
allowed to react with 10 µM, 20 µM, and 30 µM R3 and excess AdoMet (60 µM, 120
µM, and 180 µM total methyl group transfer expected, respectively), M48L catalyzed the
transfer of 35 µM, 48 µM, and 83 µM methyl groups, respectively (data not shown).
This indicated that each peptidyl arginine was not being fully dimethylated by M48L.
Given our current data, it is likely that M48L-PRMT1 methylated the R3 peptide on the
first terminal arginine but was unable to fully access, or got aborted at the central arginine
residue. Overall wt-PRMT1 and M48L mutant strongly prefer the N-terminal arginine
and the methylation activity of M48L decreased dramatically with a single arginine in the
middle position.

Single turnover experiments with M48L-PRMT1
In order to investigate why the KRK pair cannot be methylated well by
M48L-PRMT1, we set up single turnover experiments that would allow us to evaluate the
effect of the M48 mutation on the conversion of arginine to MMA, and the conversion of
MMA to ADMA in separate experiments. Reactions were conducted under conditions
where the AdoMet concentration was the same as or slightly higher than the enzyme
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Table 3-4. Peptide substrate specificity of wt-PRMT1 and M48L under steady-state
conditions
Sequence

Activity of
wt-PRMT
1 (s-1)

Activity of
M48L (s-1)

% activitya
of
wt-PRMT1

R3

acGGRGGFGGRGGFGGRGG

0.045

0.029

65.9

RKK

acGGRGGFGGKGGFGGKW

0.0051

0.0026

50.5

RKK-CH3

acGGRmeGGFGGKGGFGGKW

0.011

0.0053

47.9

KRK

acKGGFGGRGGFGGKW

0.0071

0.000075

1.06

KRK-CH3

acKGGFGGRmeGGFGGKW

0.0039

0.000023

0.577

Peptide
substrate

a

The methylation velocity is tested under one saturating condition for both AdoMet and peptide
substrates, representing the activity of enzymes. The percentage activity is calculated based on
the methylation velocity.

concentration, so as to observe only one turnover of the methylation reaction (Figure 3-5).
Maximal product concentration and kchem for each reaction were obtained (Table 3-5).
Wt-PRMT1 fully methylated the KRK peptide with the maximum product
concentration equal to 20 μM (Table 3-5). With the KRK-CH3 peptide, the total methyl
group transfer decreased slightly, but the turnover rate (0.029 s-1) was very close to the
naked peptide (0.020 s-1). With M48L, the reaction only went to 20% completion with the
KRK peptide, with the turnover rate reduced by 50%. However, when the M48L reaction
was initiated with the monomethylated peptide, hardly any methylation occurred, with
the maximum product concentration of around 0.16 μM, and the turnover rate kchem close
to 0 s-1. Control experiments were set up under the same conditions without the peptide
substrates, to rule out radiolabel incorporation as a result of M48L automethylation. Our
results show impaired monomethylation of the internal arginine by M48L PRMT1, and
nearly abolished dimethylation.
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The lack of activity that was observed with M48L and KRK-CH3 could be due to the
inability of the peptide to bind the mutated active site. To determine whether the KRK
monomethylated peptide binds to M48L, we set up a competitive reaction using the
RKK-CH3 peptide as a substrate with or without the KRK peptide pair. The concentration
of RKK-CH3 peptide was close to its Km and KRK-CH3 peptide was one third the
RKK-CH3 concentration. With KRK added into the reaction, the methyl group transfer
rate was close to the one without KRK (0.0012 and 0.0011 μM/s, respectively) (Figure
3-6). However with the monomethylated peptide KRK-CH3 added into the pre-incubation
solution, the reaction rate was decreased to half of the original rate (0.0012 and 0.0006
μM/s, respectively). These data suggest that the KRK-CH3 peptide was actually a
PRMT1 inhibitor in the methylation reaction. With the KRK peptide in the
pre-incubation mixture, the rate was slightly decreased, possibly because the KRK
peptide would bind to M48L but could not be methylated as fast as the RKK-CH3 peptide,
as shown in Table 3-5. The fact that KRK-CH3 could inhibit the methylation of
RKK-CH3 suggests that the KRK-CH3 peptide can bind M48L-PRMT1, but is not turned
over by the enzyme in appreciable amounts.
We also observed impairment in the rate at which M48L dimethylated argininyl
groups located at the Nt of the peptide, albeit to a lesser extent. Although dimethylation
by wild type was 26% slower than monomethylation, dimethylation by M48L was 60%
slower than monomethylation of the RKK peptide (Table 3-5). Clearly, substitution of
methionine 48 with leucine in PRMT1 results in differential effects on the conversion of
arginine to MMA versus the conversion of MMA to ADMA. Furthermore, the ability of
M48L mutants to covalently transfer methyl groups to all targeted arginines in a substrate
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Figure 3-5. Single turnover kinetics of wt-PRMT1 (A) and M48L (B) with KRK and
KRK-CH3 peptide pair. Filled circles and open circles indicate the KRK peptide and the
monomethylated counterpart KRK-CH3 peptide, respectively.

Table 3-5. Pre-steady state kinetic parameters of M48L with wt-PRMT1
peptide

Maximal product
concentration (μM)

kchem (s-1)

KRK
KRK-CH3
RKK
RKK-CH3
KRK

20.31 ± 0.25
14.96 ± 1.15
14.53 ± 1.82
13.08 ± 0.85
3.85 ± 0.11

0.020 ± 0.0008
0.029 ± 0.0082
0.073 ± 0.037
0.054 ± 0.016
0.0087 ± 0.0006

KRK-CH3

0.16 ± 0.084

ND

RKK
RKK-CH3
ND stands for “not detectable”.

4.71 ± 0.20
9.37 ± 1.43

0.044 ± 0.008
0.018 ± 0.008

Enzyme

20 μM
wt-PRMT1

20 μM
M48L
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is impaired. We conclude that the Type I-conserved methionine 48 in rat PRMT1 plays a
significant role in determining product specificity.

Figure 3-6. Competitive methylation experiments of the KRK-CH3 peptide. The reactions
were carried out with 100 nM M48L, 60 μM RKK-CH3 peptide as a substrate, 1 μM
AdoMet (1 μM of [3H]AdoMet added) in 100 mM HEPES buffer at 37 °C, pH 8.0. 20
μM KRK-CH3 peptide were tested as an inhibitor. The filled circles indicate the control
group without the KRK-CH3 peptide, and the open circles for the test group with
KRK-CH3 added.

DISCUSSION
In mammals, the PRMT family of enzymes is capable of generating three different
methylated arginyl species within protein targets, MMA, ADMA, and SDMA. Coupled
with the observation that many PRMT targets have multiple arginines that are methylated
(38,39), the diversity of potential protein products is large, and suggests the possibility
for a methylarginine code.

The biological relevance of such a code has most recently

been validated as part of the complex set of posttranslational histone modifications
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affecting gene expression (2,6,7). Yet, the molecular details of how each of the PRMTs
selectively controls the position and degree of methylation have remained elusive. In
this work we provide the first insight into how the Type I arginine methyltransferase
active site is engineered for product specificity.

The absence of a methionine switch to specify ADMA and SDMA formation
When the first structures (11,12) of Type I arginine methyltransferases were solved,
a strictly conserved methionine (Met-155 in the rat PRMT1 sequence) was located very
close to the substrate arginine. Given the fact that this residue is strictly conserved in all
Type I methyltransferases, but much smaller (e.g., alanine or serine) in Type II
methyltransferases, a hypothesis was put forth that the methionine provided enough steric
bulk to block the binding of monomethylated
allow symmetric dimethylation (12,13).

arginine in a conformation that would

Likewise, we questioned whether Met-48,

which resides on the opposite side of the active site (Figure 3-1C) could function in the
same manner. The idea of a single residue switch to control product specificity was
supported by the elegant studies in the lysine methyltransferase field, which showed that
a Phe/Tyr switch in the active site regulates the ability of the SET domain lysine methyl
transferases to perform successive methylations (13-15).

Surprisingly, M155A and

M48A mutants generated only MMA and ADMA after three-hour reactions. Even at
the picomole detection limit of our monitoring system, no SDMA was detected (Figure
3-2). Therefore, removing the steric bulk afforded by either Met-155 or Met-48 in the
active site of PRMT1 is not by itself sufficient to transform PRMT1 into a Type II PRMT,
and rules out the idea of a simple methionine switch.

How the Type I arginine
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methyltransferases discriminate between ADMA and SDMA is more complex than
previously thought, and will likely not be answered until a Type II PRMT structure
becomes available.

Met-155 and Met-48 are important for enzyme activity
The kinetic results presented here show that both conserved methionines are
important for catalytic activity of PRMT1 but in different ways (Table 3-1). The
similarity between the WT and M48L crystal structures (Figure 3-4) indicates that the
impaired activity of the mutants is not due to global changes in protein structure. Similar
binding affinity of both AdoMet and R3 peptides for wt-PRMT1 and all the mutants
(Table 3-2) illustrates that decreased activity in the mutants is also not due to changes in
binding affinity.
As a third possibility to explain the altered activity of the methionine mutants, we
considered the mechanism of methyl transfer. Given that methyl transfer occurs by way
of an SN2 reaction (40), the orientation of the arginine substrate and the thioether moiety
of AdoMet in the active site becomes critical. Mutation of the methionines to smaller
residues increases the space in the active site, and potentially allows more orientations to
be sampled by the incoming arginyl substrate, not all of which may be productive or as
productive as in wild type. Mutation of the methionines may change the ability of the
mutant enzyme to undergo compression during catalysis (41) or affect the pKa of the
guanidino nitrogen of arginine as it approaches the positively charged sulfonium of
AdoMet (42). Consistent with the idea that Met48 is important for catalysis, our single
turnover experiments (Table 3-5) showed that kchem is decreased in the M48L mutant.
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With the larger aromatic amino acid mutants, the positioning of the substrate arginine is
likely fixed in an orientation which results in slow methyl transfer. We propose that the
two type I methionines may work as molecular tweezers to align arginyl substrates at
proper orientations. Interestingly, this methionine clamp is not only conserved in Type I
PRMTs, but also exists in some other methyltransferases, such as salicylic acid carboxyl
methyltransferase (SAMT), isoflavone O-methyltransferase (IOMT) and caffeic acid
O-methyltransferase (COMT) (43-45), suggesting a common mechanism for optimizing
methyl transfer among certain AdoMet-dependent methyltransferases.

Met-48 influences product specificity
Accurate product specificity by PRMT1 is a combination of targeting the correct
arginine within a protein, as well as catalyzing the correct number of methylations on a
particular residue. The work presented here shows that Met-48 plays a role at both levels.
Curiously, substitution of Met-48, as well as Met-155, caused the enzyme to recognize a
new substrate, observed as automethylation (Figure 3-3).

On the other hand, several

experiments (Table 3-4, Table 3-5, Figure 3-5) provided results which indicate that the
Met-48 mutation differentially impaired the ability of the mutant to dimethylate arginine
residues, especially those located near the center of the peptide substrate.

Although it is

difficult to tease out which step in arginine methylation is hindered in M48L using
steady-state data, our single turnover experiments measuring kchem limit the choices to
peptide binding or the actual chemical transfer step. When the peptide is already
monomethylated, one or both of these steps is hampered. When the monomethylated
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residue is presented in the center of the peptide substrate, very little if any substrate
appears to be bound in the M48L mutant in a catalytically-productive manner.

CONCLUSION
Product specificity as it relates to PRMT1 is a multifaceted. Site selection within a
protein (sequence and location), degree of methylation (mono- or dimethylation) and
number of methylations in each target can produce a dizzying number of different
products. How the enzyme is designed to control each one of these aspects is a
challenging question that is likely to lead to overlapping/interdependent mechanisms. In
the work presented here, we provide the first insight into product specificity in PRMT1.
We show that the conserved methionine 48 is important for activity and accurate site
selection, which also impacts the degree of methylation in the final product.
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CHAPTER 4
SUBSTRATE-INDUCED CONTROL OF PRODUCT FORMATION BY PROTEIN
ARGININE METHYLTRANSFERASE 1 (PRMT1)1

ABSTRACT
Protein arginine methyltransferases (PRMTs) aid in the regulation of many
biological processes. Accurate control of PRMT activity includes recognition of specific
arginyl groups within targeted proteins, and also the generation of the correct level of
methylation, none of which are fully understood. The predominant PRMT in vivo,
PRMT1, has wide substrate specificity and is capable of both mono- and dimethylation,
which can induce distinct biological outputs. What regulates the specific methylation
pattern of PRMT1 in vivo is unclear. We report that PRMT1 methylates a multisite
peptide substrate in a non-stochastic manner, with less C-terminal preference, consistent
with the methylation patterns observed in vivo. With a single targeted arginine, PRMT1
catalyzed the dimethylation in a semi-processive manner. The degree of processivity is
regulated by substrate sequences. Our results identify a novel substrate-induced
mechanism for modulating PRMT1 product specificity. Considering the numerous
physiological PRMT1 substrates, as well as the distinct biological outputs of mono- and
dimethylation products, such fine-tuned regulation would significantly contribute to the
accurate product specificity of PRMT1 in vivo and the proper transmission of
biochemical information.

1

S. Gui, W.L. Wooderchak-Donahue, T. Zang, D. Chen, M.P. Daly, Z.S. Zhou, and J.M.
Hevel, Substrate-induced control of product formation by protein arginine
methyltransferase 1 (PRMT1), Biochemistry (in press)
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INTRODUCTION
Protein arginine methylation has emerged as a major mechanism for regulating protein
function in eukaryotic cells (1-8).

This post-translational modification (PTM) is

catalyzed by a family of enzymes called protein arginine methyltransferases (PRMTs).
Nine human PRMT isoforms form monomethylarginine (MMA), asymmetric
dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) on targeted
proteins (Figure 4-1). Type I PRMTs (such as PRMT1) form MMA and/or ADMA, and
represent the majority of identified PRMTs. Type III enzymes only produce MMA.
Like the type I and III enzymes, type II PRMTs catalyze monomethylation; however, a
second round of turnover results in the biologically distinct SDMA.
Each of the methylated arginines (MMA, ADMA and SDMA) can induce different
biological responses in the cell (9-12).

It follows that controlling the type of

methylation, the amount of methylation (many proteins contain multiple arginines that
are methylated in various patterns), and what proteins are methylated is necessary for a
healthy cell.

In fact, PRMT1 knockouts are lethal in mice (13) and dysregulated

arginine methylation has been associated with heart (14-16), lung (17, 18), and kidney
(19) pathologies, cancer etiology (20), and other diseases (21-24). Consequently, the
exogenous control of PRMT activity by small molecule inhibitors is one of the newest
targets in medicinal and chemical biology (25-32). Despite the pivotal role in human
biology and health, little to no mechanistic information is available about how the
deposition of methyl marks is regulated, especially between MMA and ADMA.
PRMT1 is capable of both mono- and dimethylating target arginine residues.
Contrary to the idea that MMA is simply an intermediate for further ADMA generation,
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Figure 4-1. Methylation reactions catalyzed by PRMTs. Type I and Type II PRMTs make
MMA. Type I PRMTs may then go on to make ADMA, while Type II PRMTs produce
SDMA. The second molecules of AdoMet and AdoHcy have been omitted for clarity.

studies have shown that MMA residues display a bona fide signaling role in vivo.
Kirmizis and coworkers showed that distinct transcriptional consequences in yeast are
correlated to the mono- and asymmetric dimethyl states of histone H3 at Arg-2 (12).
Moreover, due to the technical advances in detecting the physiological PTM status,
PRMT1 was shown to methylate numerous protein substrates in a distinctive
MMA/ADMA pattern in vivo, including heterogeneous nuclear ribonucleoprotein K
(hnRNP K) (33), hnRNP-like protein Npl3 (34), and Src substrate associated in mitosis of
68 kDa (Sam68) (35) (Table 4-1). Considering the existence of multiple methylation sites
in various protein substrates, such specificity of MMA and ADMA deposition catalyzed
by PRMT1 suggests a high level of endogenous regulation. Thus, it is of great interest
and fundamental importance to elucidate the molecular basis of PRMT1 product
specificity, in terms of selecting methylation site(s) in multi-arginine containing
substrates, and determining the final methylation states on the targeted arginine.
In our recent work, we probed the active site of rat PRMT1 and identified key
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residues for substrate recognition and the differential regulation of mono- and
dimethylation (36). To follow up on this study and understand the specific methylation
patterns observed in vivo, we have further examined the product specificity of PRMT1
from a substrate-centered perspective. From the observed methylation status of Npl3,
hnRNP K and Sam68 protein substrates in vivo (Table 4-1), we hypothesized that
different local amino acid sequences or the location of a targeted arginine in the protein
substrate may help to govern the specific products of PRMT1. To test this hypothesis, we
designed and characterized several series of peptides, including multi- and single-arginine
containing peptides with varied amino acid sequences and arginine locations (Table 4-2).
All peptides used had similar catalytic efficiencies, regardless of the length and the amino
acid sequence of the peptides. Our results show that PRMT1 methylates a multi-arginine
substrate in a non-stochastic fashion, with less preference towards the C-terminal arginine.
When a single arginine is targeted, PRMT1-catalyzed dimethylation occurs in a
semi-processive

manner;

however,

the

degree

of

processivity

observed

is

substrate-dependent. Our results provide a mechanistic explanation for developing the

Table 4-1. The methylation status of Npl3, hnRNP K and Sam68 in vivo*. Methylated
arginines are highlighted in bold.
Npl3
hnRNP K
Sam68
ADMA in
vivo

MMA or
partial
ADMA in
vivo

290

254

307

265

RGGFRGGFRGGFRGG
RGGFGGPRGGF
321
RGGYGGYSRGG

PMRGRGG
PPGRGG
294
PGRGGRGG

45
52

SRGGGGGSR
SRGGGGGSGRGGAR

310
344

RGGYDSPRGGY
351
RGGYDSPRGG
377
RGSYGGSRGGY

285
301

PRRGP
GSRAR

GVGPPRGALVR
GALVRGTPVR
320
GTPVRGAITR
325
GAITRGATVTR
315

*The methylation statuses shown above were determined by mass spectrometry (33-35).
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Table 4-2. List of peptide substrates (R* indicates monomethylated arginine)
Peptide name

Peptide Sequence

R3

GGRGGFGGRGGFGGRGGFG

R2
RKR-CH3

GGRGGFGGKGGFGGRGGFG

Category

Fibrillarin-based multi-Arg

GGRGGFGGKGGFGGR*GGFG

RKK
RKK-CH3
KRK

GGR*GGFGGKGGFGGKW

KRK-CH3

KGGFGGR*GGFGGKW

eIF4A1
eIF4A1-CH3
eIF4A1-Y
eIF4A1-S

YIHRIGRGGR
YIHRIGR*GGR
YIHRIGRYGR

H4

SGRGKGGKGLGKGGAKR

GGRGGFGGKGGFGGKW

R3-based
single Arg
(for R location)

KGGFGGRGGFGGKW

YIHRIGRSGR

eukaryotic initiation factor
4A-1 (eIF4A1)-based
(for sequence)
Histone 4-based
single Arg

patterns of specific MMA and ADMA deposition on the targeted arginine residues in vivo,
which reveals a previously unidentified mechanism for regulating arginine methylation.

Experimental Procedures
Materials— AdoMet was purchased from Sigma as a chloride salt (≥80%, from
yeast). [methyl-3H]AdoMet was purchased from Perkin Elmer.
Recombinant Proteins— Full length his-tagged PRMT1 (residues 1-353) was
expressed and purified as described (36). Purified proteins were ≥95% pure judged by
SDS-PAGE. Protein concentrations were determined by UV spectroscopy using the
theoretical absorption coefficients and by the Bradford assay with bovine serum albumin
as standard.
Synthetic peptides— All the peptides were synthesized by the Keck Institute (Yale
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University) with acetylated N-termini and free carboxyl termini, and purified to ≥95%.
The lyophilized peptides were dissolved in water. Their concentrations were determined
by mass and/or by UV spectroscopy using their theoretical absorption coefficients.
Even though some of the peptides used in this study are less than 21 amino acids long,
the kcat/Km values for all the peptides used in this study are within an order of magnitude
of the previously characterized 21-amino acid peptide derived from histone 4 (H4-21).
Mass spectrometry analysis of peptide methylation and De Novo sequencing
study— Conditions of methylation reactions were as published (36). If not stated
otherwise, the methylation reaction contained 4 M PRMT1, 250 M AdoMet, and 100
nM AdoHcy nucleosidase (MTAN, purified as in (37)) in 50 mM sodium phosphate
buffer (pH 7.1).

Independent reactions were initiated with 200 M of each peptide

substrate. At various times points (2.5, 5, 10, 12.5, 15, 20, 30 min), 10 L aliquots were
quenched with trifluoroacetic acid (TFA) (10% final) and analyzed by LC/MS followed
by MS/MS of the desired peaks. Samples that showed a maximum amount of
monomethylation yet no or minimal amount of the enzymatically formed dimethyl
species were further analyzed with LCMS/MS. The time point used for each peptide
shown in Table 4-3 was 20 min, 10 min, and 10 min for the R2, RKRm and R3 peptide,
respectively.

Peptides with monomethylation and without methylation were analyzed

using nano-LC-MS-MS on a Q-Tof Primer tandem mass spectrometer (Waters,
Manchester, UK). Peptide samples were loaded (3 L) using a NanoACQUITY Sample
Manager (Waters, Manchester, UK) onto a trapping column (Symmetry® C18, 180M x
20mm) (Waters, Manchester, UK). Samples were washed with 99% H2O and 1% TFA
for one minute at 15 µL/min to a waste container and then eluted with a 30 min gradient

87
(1-4% B in 0.1 minutes, 4-60% B in 20 minutes, 60-85% B in 3 minutes, 85-1% B in 1
minute, and 1% B for 6 minutes where A = 0.1% formic acid in water and B = 0.1%
formic acid in acetonitrile) at 800 nL/min using an NanoACQUITY UPLC (Waters,
Manchester, UK) over a 100 m x 100 mm BEH 130 C18 column. MS survey and
product ion MS/MS scan times were 1.0 second.

The collision offset was automatically

determined based on precursor mass and ion charge state. MS/MS data was used for the
De Novo sequencing of methylated peptides by Waters BioLynx software (Waters,
Manchester, UK).
For the eIF4A1 peptide samples shown in Figure 4-3, reactions were diluted to 2 M
using acetonitrile/water/TFA (v:v:v, 50:50:0.05). Diluted peptide samples (0.5 L) were
spotted on a polished standard 192-well stainless steel MALDI sample plate followed by
the addition of α-cyano-4-hydroxy cinnamic acid (CHCA) matrix solution (0.4 L, 10
mg/mL in a mixture of acetonitrile/water/TFA, v:v:v, 50:50:0.05).

The resulting

mixtures were air-dried and analyzed using an AB 4700 MALDI-TOF/TOF Proteomics
Analyzer (Applied Biosystems, Framingham, MA).

MS and MS/MS spectra were

acquired in reflector positive mode. Typically, 2500 shots/spectrum were accumulated in
the MS mode and 5000 shots/spectrum in the MS/MS mode. A standard peptide, human
angiotensin I ([M + H]+) 1296.67), was used for the external calibration and the data were
analyzed using Data Explorer software 4.6. The sequences of peptides were analyzed
using ProteinProspector (an online program, version 5.10.2).

In order to construct a

reaction time course (Figure 4-3), the relative height of each peak (naked,
monomethylated, and dimethylates species) was calculated by dividing the individual
peak height by the sum of peak heights from all peptide species (non-methylation,

mono-methylation and di-methylation) observed in mass spectra at each time point.
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The

intensity of each peak from non-methylated peptide or methylated peptide was based on
peak height.
Continuous spectrophotometric kinetic assays of PRMT1— A continuous
spectrophotometric assay for AdoMet-dependent methyltransferases (38) was used to
assay PRMT1 with arginine-containing peptides.

Briefly, two coupling enzymes,

MTAN and adenine deaminase, were used to hydrolyze and deaminate the AdoHcy
generated from methyl group transfer, respectively. This assay minimized product
inhibition that could occur from AdoHcy. Initial rate data representing no more than 10%
of product formation were fit to the Michaelis Menten equation (39) to obtain Km,app and
kcat, app values. Each reaction was performed at least in duplicate. The limit of detection
for this assay was 0.01 M methyl group transfer.
Double turnover experiments— A reaction containing 20 M PRMT1, 40 M
AdoMet (2.6 M [3H]AdoMet (specific activity of 2.02 mCi/mol)), 100 nM MTAN in
50 mM sodium phosphate buffer (pH 7.5) was initiated with 200 M peptide substrates at
37 ºC. After 1 hour, proteins were precipitated with 10% TFA (final) and removed
through centrifugation. An equivalent volume of 12 M HCl was added to each mini vial
(Deltaware).

Vials were then sealed and heated to 110 ºC for approximately 24 hours

for complete acid hydrolysis. Due to the small inner space, sample oxidation is
minimized (36). The methylation status of hydrolyzed peptide products were analyzed by
HPLC and MS.
Identification and quantification of methylated arginines by HPLC— Hydrolyzed
amino acids were neutralized by equivalent volume of 6 M NaOH and then separated
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using o-phthaldialdehyde (OPA) derivatization (40) with a Gemini® 3 m C18 110 Å LC
Column 75 x 4.6 mm (Phenomenex). Mobile phase A consisted of 40 mM sodium
phosphate buffer (pH 7.8), and mobile phase B was acetonitrile/methanol/H2O (45/45/10,
v/v/v). Fractions (83 L) were collected and radioactivity was counted in 5 mL
scintillation cocktail (Fisher Scientific). MMA and ADMA standard amino acids were
used to verify the identity of the methylated products generated. The detection limit for
this method is ~10 pmole of methylated arginine in a 20 L sample.

RESULTS AND DISCUSSION
PRMT1 methylation of a multiple arginine-containing substrate is non-stochastic.
Many PRMT protein substrates harbor repetitive “RGG” or “RGG-like” regions that are
targets for arginine methylation (1, 33-35, 41). For instance, the C-terminus (CT) of Npl3
contains an extensive arginine-glycine rich domain composed of 15 ‘RGG’ tripeptide
repeats, of which nine consecutive N-terminal (NT) ‘RGG’ motif arginines (R290-R337)
were found exclusively dimethylated. On the other hand, variable levels of methylation
were associated with the C-terminal RGG motif arginines (Table 4-1). Such cumulative
methylation of Npl3 is important for protein function, especially at the N-terminal ‘RGG’
motifs (34).

However, the molecular origins of such distinct methylation patterns

remain unclear. In order to understand whether particular patterns of methylation can be
preferentially deposited in such repetitive regions, we investigated whether PRMT1
functions as a systematic (preferred sites) or stochastic (random) modifier.

We

examined the sequential methylation of a simple multi-arginine containing peptide, the
R2 peptide (GGRGGFGGKGGFGGRGGFG). Because both arginine residues exist
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within the same amino acid context (GGRGG), we avoided the variability that local
sequences might induce (42) and instead were able to test whether PRMT1 displays a
regional (NT or CT) preference in a multi-arginine substrate.
Methylation of the R2 peptide over time was analyzed by tandem mass spectrometry
(MS/MS). MS/MS analysis showed that the N-terminal arginine of the R2 peptide was
first mono-, then dimethylated (data not shown). No methylation of the C-terminal
arginine of the R2 peptide was detected until the NT arginine was fully dimethylated. The
catalytic competency of both arginine residues was confirmed in an extended reaction (8
hours) where MS/MS analysis demonstrated the presence of the tetramethylated R2
peptide (data not shown). Figure 4-2 summarizes the series of methylation events
observed on the R2 peptide. These results demonstrate that the PRMT1-catalyzed
methylation of a multi-arginine substrate is not stochastic. PRMT1 preferentially

AcGGRGGFGGKGGFGGRGGFG
AdoMet

PRMT1
AdoHcy

CH3

AcGGRGGFGGKGGFGGRGGFG
AdoMet

PRMT1
CH3

CH3

AdoHcy

AcGGRGGFGGKGGFGGRGGFG
AdoMet

PRMT1
CH3

AdoHcy
CH3

CH3

AcGGRGGFGGKGGFGGRGGFG
AdoMet

PRMT1
CH3

CH3

AdoHcy
CH3

CH3

AcGGRGGFGGKGGFGGRGGFG

Figure 4-2. Methylation events observed on the R2 peptide. Time-dependent MS/MS
product analysis showed a systematic methylation of the R2 peptide.
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methylates one arginine over another, suggesting a systematic or regulated recognition of
a specific target arginine in multi-arginine substrates.
PRMT1 exhibits regioselectivity in multi-arginine substrates. In the previous
experiment, we showed that PRMT1 displays a strong preference for an N-terminally
located arginine compared to a CT arginine in the R2 peptide. We further questioned
whether such a preference still exists under more challenging situations; i.e., when either
a monomethylated arginine or more arginine residues exist within the peptide.
The RKR-CH3 peptide (GGRGGFGGKGGFGGRMeGGFG) contains two arginine
residues where the CT arginine is monomethylated. Our previous studies (36) and data
supplied herein using single-arginine peptide substrates suggested that a monomethylated
arginine in R2 would be a better substrate (based on catalytic efficiency, kcat/Km) than the
unmodified one. The first methylation event in the RKR-CH3 peptide was mapped using
MS/MS (data not shown). Although methylation of the CT arginine was observed (13%),
PRMT1 still showed a strong preference for the N-terminal arginine site (Table 4-3).
We also tested PRMT1 substrates that contain more than two arginines. We mapped
the first methylation event in the R3 peptide (GGRGGFGGRGGFGGRGGFG), which
contains three potential target sites (data not shown). Compared to the R2 peptide, the
distance between the terminal arginine residues is maintained, but an additional arginine
replaces a positively charged lysine residue in the middle of the peptide. Mapping the
initial methylation event in the R3 peptide demonstrated three things: 1) as observed
above, the majority of the first methylation again occurred at the NT arginine (55%), 2)
the internal arginine was targeted in a significant amount (39%) and 3) minimal
methylation (6%) occurred on the CT arginine (Table 4-3). These in vitro observations are
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consistent with the physiological methylation status of Npl3 and Sam68 proteins. The
repeated N-terminal ‘RGG’ motif arginines of Npl3 (34) and Sam68 (35) were found to
be exclusively dimethylated, and evidence showed mono- or partial dimethylation
associated with the C-terminal ‘RGG’ motif arginines (Table 4-1).
The preference of PRMT1 for the NT arginines might be seen as a consequence of a
high degree of flexibility at this position and easy accessibility. However, the internal
arginine in the R3 peptide, which has less structural flexibility compared to the NT
arginine, is also targeted in a significant amount for the first methylation. Therefore the
basis of the preference is not the immediate flanking amino acid context or the flexibility
afforded by an N-terminal arginine. One hypothesis that would be consistent with our
observations would entail using the CT arginine of the peptide substrate in a distal binding
event. Osborne and coworkers (43) showed that positively charged residues distal to the
methylation site (11-14 amino acids interval) are very important for PRMT1 substrate
binding and catalytic activity.

Interestingly, the peptides used in the Osborne study were

based on Histone 4, where the targeted arginine is located at the NT and the necessary

Table 4-3. Location of the first PRMT1-catalyzed methylation event (R* indicates
monomethylated arginine)
% of the 1st methylation
position a
Peptide
Peptide Sequence
NT-R
center R
CT-R

a

R2

GGRGGFGGKGGFGGRGGFG

100

/

0

RKR-CH3

GGRGGFGGKGGFGGR*GGFG

87

/

13

R3

GGRGGFGGRGGFGGRGGFG

55

39

6

The standard error of the percentage was typically less than 5%.
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positive charges that were identified were all located downstream (C-terminal) to the
arginine.
When more than one arginine is present in the targeted protein, the distance between
them may also influence processing. Many proteins have been identified that contain
‘RGG’ repeats (44); however, whether they are all PRMT1 substrates and what the in
vivo pattern of methylation looks like is unknown. The limited studies of in vivo
methylation patterns of PRMT1 show that the common distance between targeted
arginines is either 2-3 amino acids (e.g. RGGRGG in hnRNP K) or 5-7 amino acids (e.g.
RGGFGGPRGG in Npl3) within the repetitive arginine-glycine rich region. In such
repetitive ‘RGG’ regions, extensive and consecutive dimethylation is often observed. Due
to the 5 amino acids between the arginine residues in the R3 peptide, we would classify
the R3 peptide as an ‘RGG-repeats’ substrate. The spacing of the ‘RGG’-repeats possibly
correlates to a high percentage of methylation occurring in both the N-terminal and the
center-located arginines. In contrast, the R2 peptide contains a longer interval (11 amino
acids) between the two arginines, which may cause the distal ‘RGG’ motif to be
considered as a discrete substrate. In most physiological methylation patterns we are
aware of, methylation of the C-terminal arginine in the arginine-rich domain is
infrequently observed (33-35).
Overall our results show that PRMT1 methylates multi-arginine substrates in a
non-stochastic and regioselective manner wherein more extensive methylation is
predicted at the N-terminal or internal arginines. The center and/or the C-terminal
arginines (or positive charges) are necessary for the N-terminal preference of PRMT1,
which is consistent with the importance of the distal positive charges in the substrates
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shown by Osborne and coworkers (43). We also note that the distance between arginine
residues in the substrate may affect the process of methylation-site targeting, and await
the analyses of additional in vivo PRMT1 substrates to test this hypothesis.
Although we have shown that PRMT1 can preferentially target specific arginine
residues in multi-arginine substrates, it is unclear how product specificity at the targeted
arginine (mono- or dimethylation) is governed. Because of the potential distinct
biological effects of MMA and AMDA (12), it is important to understand the
determinants or regulators of the final methylation status at a particular arginine residue.
We started to explore the mechanistic basis of this control by 1) probing the efficiency of
methylation (as defined by kcat/Km) for a variety of peptide sequences, and 2) probing the
possibility of regulated processive dimethylation. Since comparisons of synthetic
peptides with full-length proteins from which they were derived indicate that, at least in
some cases, both substrates are methylated with similar kinetic efficiencies (43, 45),
peptide substrates were used hereinafter.
Catalytic efficiency for a single-arginine containing peptide increases with
monomethylation. Although previous steady-state kinetic studies of PRMT1 have shown
a slight or no preference for a monomethylated arginine against an unmodified substrate,
all the experiments were based on single peptide substrates, derived from Histone 4 or
PABPN1 (46, 47). Our data have shown that different characteristics of the target arginine,
for example, the location of the arginine residue within the peptide, and the flanking
amino acid sequence (42), influence the activity of PRMT1. In order to more thoroughly
understand whether PRMT1 displays a kinetic preference for the naked or
monomethylated arginine residue, steady-state kinetic experiments were performed using
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three different peptide pairs as a primary comparison of arginine residue location and
peptide sequence (Table 4-4). Two fibrillarin-based peptides with the identical amino acid
sequences denoted KRK and RKK represent the alternation of the target arginine position
in the peptides. The eIF4A1 peptide (YIHRIGRGGR), derived from eukaryotic initiation
factor 4A-I, bears an entirely different peptide sequence from the fibrillarin-based
peptides. Although eIF4A1 peptides contain three arginines, we previously showed that
the central arginine in the eIF4A1 peptide (YIHRIGRGGR) was the only one modified
by PRMT1 (42). Hence, this peptide pair is still considered a single-arginine containing
substrate with the same center-located arginine residue as the KRK peptides. These three
peptide pairs serve as a start to systematically probe whether PRMT1 methylates both
naked and monomethylated substrates with the same catalytic efficiency.
Data for the KRK and KRK-CH3 peptides with PRMT1 showed saturation kinetics at
a variety of fixed AdoMet concentrations (data not shown). Similar results were observed
with eIF4A1 and RKK peptide pairs (data not shown). Under saturating concentrations of
AdoMet, the apparent catalytic efficiency (kcat/Km) for the eIF4A1-CH3 peptide was
nearly double that of the eIF4A1 peptide (Table 4-4). The RKK peptide pair showed
similar results. Although the effect was minimal, the KRK-CH3 peptide also showed a
higher value of kcat/Km than the KRK peptide (Table 4-4). We note that the increased
apparent catalytic efficiency is observed with the monomethylated substrate regardless of
the location of the single arginine (KRK vs RKK peptide pairs) or the peptide sequences
(KRK vs eIF4A1 pairs).

Further support for this observation comes from our previous

data (Table 4-3) which showed that monomethylation of the CT arginine in the R2 peptide
redirected 13% of the first methylation event to this arginine. Although the effect of

96
between

monomethyl arginine is apparent in this study, the difference in kcat/Km

non-modified and monomethylated substrates would likely need to be much greater to
contribute to ADMA generation in vivo, especially in cases where excess unmodified
substrates are present.
Consistent with our observations, Zheng and coworkers (48) reported a higher
catalytic efficiency with the monomethyl H4 peptide (kcat/Km = 1.6 ± 0.3 M-1min-1) than
the unmodified counterpart (kcat/Km = 0.9 ± 0.1 M-1min-1). On the other hand, Kölbel
and coworkers (47) found no significant changes in catalytic efficiency (kcat/Km) of
PRMT1 based on one MMA-peptide derived from PABPN1, Importantly, this
PABPN1-derived

peptide

substrate

bears

an

“RXR”

amino

acid

paradigm

(FYSGFNSRPRGRVYATSWY) instead of the canonical “RGG” sequence. The
difference between the observations of Kölbel and our study is possibly due to the
different amino acid sequences of peptide substrates used in the kinetic assays, which

Table 4-4. Steady-state kinetic parameters of PRMT1 with unmodified and
monomethylated peptide pairs.
Peptide Name

Km, peptide* (μM)

kcat* (×10-2 s-1)

kcat/Km (×102 M-1s-1)

eIF4A1

72 ± 9.6

9.0 ± 0.3

13 ± 1.7

eIF4A1-CH3

26 ± 6.2

5.8 ± 0.2

23 ± 5.5

KRK

105 ± 4.4

6.0 ± 0.1

5.7 ± 0.3

KRK-CH3

32 ± 7.5

2.5 ± 0.2

7.6 ± 1.8

RKK

21 ± 6.7

3.7 ± 0.2

17 ± 5.5

52 ± 16.8
14 ± 1.1
27 ± 8.9
RKK- CH3
*Apparent Km and kcat are reported using a single saturating concentration of AdoMet
(250 M).
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indicates a possibility that the higher catalytic efficiency of monomethyl peptides is
substrate-dependent. Within the “RGG” substrate paradigm, we found a preference of
PRMT1 to the monomethylated substrate compared to the unmodified ones regardless of
the peptide origins or the location of the arginine residue. Although the effect is modest at
best, such a preference of PRMT1 would contribute to making ADMA the favored
product in certain substrates. Interestingly, PRMT1 has been shown to display substrate
overlap and/or interactions with PRMT2 (49), -3 (50), -4 (51-53), -6 (54) and -8 (55, 56),
which gives rise to a possibility that PRMT1 can methylate the monomethyl products
from other PRMTs (12, 57). With other PRMTs involved, the preference of PRMT1 for
the MMA residues advances the probability of a higher regulated system. In all, our
results show a higher catalytic efficiency of PRMT1 with monomethylated substrates,
which provides one explanation for the physiological higher percentage of ADMA than
MMA.
The final methylation status is affected by amino acid sequence context. Although
ADMA appears to be the major product of PRMT1 in vivo (58), under certain
circumstances only monomethylated product is found at specific arginine residues in the
protein substrates, such as hnRNP K and Sam68 (Table 4-1). While examining product
deposition in these PRMT1 substrates, we noted that the final mono- or dimethylation
status was loosely correlated to differences in the amino acid sequences flanking the
targeted arginine. This led us to hypothesize that sequence context may inherently control
product specificity. To determine whether amino acid context affects PRMT1 mono- or
dimethylation, we selected a series of eIF4A1 peptide substrates based on our previous
study (42): wild type (WT) that harbors the RGG sequence; eIF4A1-S; and eIF4A1-Y
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with the RGG sequence changed to RSG and RYG, respectively. As stated previously,
among all three arginine residues, only the central arginine is methylated by PRMT1, so
the eIF4A1 peptide series are considered single-arginine substrates. Importantly, the
steady state kinetic parameters for these three peptides were previously determined (42)
and do not vary more than an order of magnitude from each peptide.
End-products generated from all three eIF4A1 peptides were analyzed by MS as a
function of time. After an extended reaction (105 min), the WT-eIF4A1 sequence (‘RGG’)
was stoichiometrically dimethylated (Figure 4-3A).

However, the eIF4A1 peptides

bearing the ‘RSG’ and ‘RYG’ sequences demonstrated incomplete methylation in the
reaction (Figure 4-3B, 3C). Surprisingly, less than 10% turnover was observed with
eIF4A1-S/Y samples from even longer reaction time periods (400 or 600 min, data not
shown). In order to rule out the possibility that PRMT1 was inactivated or reaction
conditions had been altered during the course of the eIF4A1-S/Y reactions, the R3
peptide was added into the reaction mixture after the 105-min reaction and monitored for
methylation activity (data not shown). We observed a significant increase in activity,
suggesting that PRMT1 and AdoMet were still viable during the extended reaction time
period. Consistent with our former observations with eIF4A1/3 protein substrates (42),
the eIF4A1 peptides bearing the ‘RSG’ and ‘RYG’ sequences are poor substrates for
PRMT1 and cannot be stoichiometrically methylated.
Furthermore, MS analysis also revealed that the proportion of the mono- and
dimethylated arginine products observed was quite different in the three eIF4A1 peptides
(Figure 4-3). After the 105-min reaction, the ‘RGG’ containing WT-eIF4A1 peptide was
mostly dimethylated (97%) while the ‘RSG’ and ‘RYG’ containing peptides were mainly
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Figure 4-3. Effect of flanking amino acid sequence on methylated product distribution.
Reactions were prepared as described in steady-state kinetics and were initiated with
WT-eIF4A1 in (A), eIF4A1-S in (B), and eIF4A1-Y in (C). The time-dependent
modification of the peptides was monitored by MALDI mass spectrometry. The relative
amount of the parent (gray lines), monomethylated (solid lines), and dimethylated
(dashed lines) peptide species was determined using peak intensities of the individual
species at various reaction times.
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monomethylated (7% and 4%, respectively). The presence of MMA in the reaction of
eIF4A1-S/Y was confirmed using amino acid analysis and HPLC (data not shown). These
data show that, although these three peptide substrates showed similar catalytic efficiency
under steady state conditions (42), sequence differences around the substrate arginyl
group have a significant effect on whether mono- or dimethylation is the major
end-product in long term course reactions, and suggest that the amino acid sequence of a
PRMT1 substrate could dictate how a protein arginine is modified in vivo.
Design of a double turnover experiment to probe the degree of distributive versus
processive dimethylation. Besides the effect of flanking amino acid sequences, another
way to regulate the proportion of mono- and dimethylation products would be through
regulation of dissociative or processive dimethylation. As several articles have been
published about the kinetic mechanism of PRMT1 (43, 46, 47, 59), two major views of
this topic are that it is partially processive or completely distributive. In order to
investigate the processivity of PRMT1-catalyzed dimethylation, we designed double
turnover experiments containing 20 M PRMT1, 40 M AdoMet ([3H]-AdoMet added)
and an excess of peptide substrate. With the concentration of AdoMet higher than 10-fold
KD(AdoMet), the majority of the enzyme is bound with AdoMet when the reaction is
initiated with peptide substrate. Assuming the reaction is completely distributive,
monomethylated peptides will be released after the first turnover, and replaced by bound
non-modified peptides. As the amount of AdoMet is sufficient for only two turnovers,
MMA would be detected as the final product. On the other hand, if the mechanism is
fully processive, monomethyl peptides will remain bound and only ADMA would be
generated after two turnovers. The double turnover experimental design was used with
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the eIF4A1 peptide. MTAN was also added to prevent AdoHcy inhibition. When the
reactions products were analyzed, both MMA and ADMA were clearly observed (Figure
4-4A, 4B). The same result was obtained using MS (data not shown). Quantification of
the radioactivity present in both the MMA and ADMA peak showed that the reaction had
gone to completion (data not shown).
The formation of both MMA and ADMA indicates a semi-processive mechanism
where some substrate molecules were processed through a dissociative dimethylation
mechanism (MMA released before the second AdoMet binds to PRMT1) and others
through a processive dimethylation mechanism (MMA remains bound after the second
AdoMet binds to PRMT1). Such semi-processive dimethylation provides a rationale for
the observations that ADMA is the major product of PRMT1 in vivo, but that the
generation of ADMA is not obligatory (46, 59). Our experimental design strategy also
provides us with a method to quantify how much substrate was processed either
distributively or processively by measuring the final amount of MMA and ADMA
products in the double turnover experiment. In the double turnover experiment of eIF4A1,
17.1 M MMA and 11.4 M ADMA were generated from 40 M of AdoMet.
Quantification was based on radiolabel incorporation into each of the MMA and ADMA
peaks, and the ratio of MMA to ADMA was further verified using mass spectrometry.
Previously (36) we showed that 20 M PRMT1-AdoMet bicomplex is fully functional
and generates 20 M MMA under single turnover conditions. In the current double
turnover experiment, we can deduce that the amount of MMA that was generated in the
1st turnover, but remained bound to PRMT1 and was subsequently dimethylated, is equal
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to the final ADMA concentration (11.4 M). We can further approximate the amount of
2

MMA released from PRMT1 after the first turnover (20-11.4 = 8.6 M). Therefore, we
approximate that 57% of the bound peptide underwent processive dimethylation, while
43% was released after the first turnover, indicating distributive behavior (Figure 4-4C).

Figure 4-4. Reverse-phase HPLC analysis of methylation products of the eIF4A1 peptide
from double turnover experiments. (A) MMA and ADMA standard amino acids were
used to identify the elution time for each methylated species under our HPLC conditions.
(B) Product analysis from double turnover reactions of eIF4A1 peptide showing both the
fluorescence (black lines) from amino acid derivatization and radioactivity (grey dots)
from tritium in the methyl group. (C) Scheme showing the partitioning of reaction
products through distributive and processive mechanisms by PRMT1. Proportions of
distributive and processive dimethylation are labeled based on the calculation from
eIF4A1 peptide discussed in the text.
2

Approximations assume that the small difference observed in kcat/Km between the naked
and monomethylated peptide substrates in the steady state do not alter product
partitioning by an appreciable amount in the double turnover experiments.
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Although such a calculation cannot discriminate the small amount of ADMA
generated due to MMA rebinding, it is sufficient to estimate the partitioning between the
two pathways. Moreover, due to the similar KD of the eIF4A1 and eIF4A1-CH3 peptides
(data not shown), the presence of excess eIF4A1 peptide should make MMA rebinding
negligible.
The degree of the processivity varies depending on the sequence of the peptide
substrate. We performed the double turnover reactions using three other single-arginine
containing peptide substrates to investigate processivity. With all the peptides we tested,
both MMA and ADMA were observed (data not shown), suggesting a general
semi-processive mechanism. Remarkably, the proportion of MMA and ADMA generated
from the double turnover experiments are distinct among certain peptide substrates (Table
4-5). These results were further confirmed with MS, and the reactions were shown to go
to completion (data not shown).
Similar to calculating the percentage of MMA processed distributively or
processively, the ratio of MMA:ADMA is directly related to the amount of MMA
released and the amount that remains bound to PRMT1 (respectively), so it can be
viewed as an easier measurement of the degree of processive dimethylation. By definition,
a higher degree of processivity leads to a larger proportion of ADMA compared to MMA
and a smaller ratio of MMA:ADMA, and vice versa. As can be seen from Table 4-5, the
eIF4A1 and H4 peptides, which have a small ratio of MMA:ADMA (close to 1:1),
demonstrate a much higher degree of processivity than the KRK or RKK peptides (MMA:
ADMA close to 5:1). Such distinct ratios from the double-turnover experiments indicate
that certain peptide sequences are processed through a processive mechanism, leading
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Table 4-5. The degree of PRMT1-catalyzed processive dimethylation as represented by
the MMA/ADMA ratio using different peptide substrates.
Peptide

Sequence

MMA:ADMA

H4

SGRGKGGKGLGKGGAKR

0.967 : 1

eIF4A1

YIHRIGRGGR

1.50 : 1

KRK

KGGFGGRGGFGGKW

4.10 : 1

RKK

GGRGGFGGKGGFGGKW

4.73 : 1

to a dimethylated product, while other sequences partition more frequently through a
distributive mechanism where both monomethyl- and dimethylated products are possible.
To investigate what leads to the different ratios of MMA:ADMA, we tested the binding
affinity of the naked and monomethylated eIF4A1 peptides to PRMT1 using intrinsic
fluorescence quenching (data not shown). The KDs for the eIF4A1 pair as well as an
H4-based peptide pair (48) and another R3-based peptide pair were all similar (data not
shown), indicating that the differences observed in processivity are not due to differences
in binding affinity. Comparison between the RKK and KRK peptides indicates that the
location of substrate arginine does not influence the degree of processivity between these
two peptides. Instead, the general sequences differentiate the degree of dimethylation
processivity among the substrates. While it is quite conceivable that the precise degree of
processivity may be different with the intact protein substrates, our results clearly
demonstrate that the semi-processive nature of PRMT1 to dimethylate substrate arginines
can be fine-tuned in a substrate-dependent manner.
We note that the use of single peptide substrates in the previous research may be the
cause of the conflicting conclusions. Indeed, Obianyo and co-workers (43, 46) used a
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series of peptides based on the Histone 4 protein, showing a partially processive
mechanism, while Kölbel et al. (47) tested the dimethylation mechanism with one of the
peptides very similar to the RKK and KRK peptides, demonstrating a completely
distributive dimethylation. Our results from double turnover experiments clearly revealed
the degree of processivity is substrate dependent. The H4 peptide showed a much higher
processivity than fibrillarin-based peptides, consistent with previous studies of Obianyo
and co-workers (43, 46). We also note that the semi-processive dimethylation we observe
is consistent with the rapid equilibrium random mechanism proposed by Obianyo and
coworkers (46). Lastly, we question whether conflicting observations regarding the
processive nature of PRMT6 (60, 61) may also be partially due to changes in
substrate-induced processivity.
Given a tunable, semi-processive reaction for PRMT1, the degree of processivity
will significantly affect the final product. Therefore, modulation of the processivity
becomes essential in accurate product formation. In the case of PRMT1, modulation most
likely results from a combination of factors.
For enzymes with broad substrate specificity like PRMT1, flux through a fully
distributive or fully processive mechanism is possibly insufficient to instill such complex
deposition codes. Therefore, a fine-tuned degree of processivity is required, such as the
substrate-induced

control

described

in

the

current

study.

Besides

PRMT1,

substrate-regulated processivity has also been described for two DNA methyltransferases,
Dam and DNMT3A, where the inherent processivity depends on the flanking sequences
of the DNA substrates (62, 63) and the substrate DNA topology (64), respectively. These
mechanisms facilitate controlling the substrate specificity in epigenetics. Such fine-tuned
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processivity in posttranslational modification reactions is also observed with multisite
phosphorylation (reviewed in (65, 66)). Although originally considered as an all-or-none
signal, studies now support a combinatorial regulation of switch properties, somewhat
akin to how the histone code may function (67). The similarity between the multisite
phosphorylation and the repetitive “RGG” paradigm in PRMT1 substrates (reviewed in
(1, 68)) highly suggests that the sequential arginine methylation (Figure 4-2) may also
serve as a fundamental switch for protein function.
On a final note, a tunable semi-processive mechanism opens the door for a higher
order of modulation using substrate interacting partners or PRMT1-interacting partners to
influence PRMT1 product formation. For example, during nuclear processing of
pre-mRNAs, control of the poly(A) tail length requires regulating the processivity of
poly(A) polymerase induced by two RNA-binding proteins (69, 70). These auxiliary
proteins are known as processivity factors, such as DNMT3L which enhances the
DNMT3A processivity in de novo DNA methylation (64), and Doc1 which is required for
efficient substrate recruitment and processive ubiquitylation of the ubiquitin-protein
ligase (E3) APC (71-73). Such “higher order” regulation of processivity modulates the
enzymatic mechanism via specific interacting partners. Although interaction partners of
PRMT1 have been documented (74, 75), the molecular basis for these regulators remains,
as of yet unclear.
Conclusions.

In this study, we provide the first insight into the effect of the

substrate on PRMT1 product specificity. We show that PRMT1 exhibits regional
selectivity

with

multi-arginine

containing

peptide

substrates

and

utilizes

a

semi-processive mechanism that is controlled in a substrate-dependent manner.

107
Considering the broad substrate specificity of PRMT1, as well as the distinct biological
outputs of MMA and ADMA, such a ‘substrate-induced’ mechanism helps to explain how
patterns of methylation can be deposited, thus insuring the proper transmission of
biochemical information.
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CHAPTER 5
SINGLE TURNOVER AND PRE-STEADY STATE KINETIC STUDIES OF PRMT1
MECHANISM

ABSTRACT
Protein arginine methylation is a wide-spread eukaryotic posttranslational
modification catalyzed by a family of enzymes known as protein arginine
methyltransferases (PRMTs). PRMTs play a critical role in fundamental cellular
pathways and the maintenance of a healthy cellular state, and contribute to disease when
dysregulated. Regulation of arginine methylation not only includes correct target
recognition and activity, but also correct product deposition (monomethylarginine, MMA;
asymmetric dimethylarginine, ADMA; and symmetric dimethylarginine, SDMA), neither
of which are fully understood. We previously discovered that PRMT1, the predominant
PRMT in vivo, catalyzes arginine dimethylation semi-processively. The degree of
processivity is in a substrate-dependent manner, which can contribute to determine the
major final product to be MMA or ADMA (Chapter 4). We further explored the
semi-processive dimethylation via single turnover experiments and pre-steady state
kinetics. Both approaches provide us insight into the microscopic rate constants for each
step in the mechanism. From single turnover experiments we found that the monomethyl
peptide substrate has a lower methylation rate compared to the unmodified peptide, but a
higher catalytic efficiency under the steady state. Although the complete mechanism is
not fully understood, the methodologies I developed and discussed in this chapter are
shown to be useful for investigating the detailed mechanism of PRMT1. Further research

will be needed to

fully understand

the substrate-dependent

115
semi-processive

dimethylation.

INTRODUCTION
Over the last decade, protein arginine methyltransferases (PRMTs) have been
implicated in various biological pathways, such as transcriptional regulation, signal
transduction, RNA metabolism, and DNA damage repair (1-3). The expression and
enzymatic activity of PRMTs are found to be dysregulated in many human diseases
including cardiovascular diseases (4-6) and cancer (7-9). As the predominant PRMT
catalyzing 85% of arginine methylation in vivo (10), PRMT1 is capable of transferring
the methyl group from S-adenosyl-L-methionine (AdoMet or SAM) to the guanadino
group of the arginyl residue generating monomethylarginine (MMA) as well as the
byproduct S-adenosyl-L-homocysteine (AdoHcy or SAH) (Figure 5-1). MMA can be
further dimethylated by PRMT1 forming asymmetric dimethylarginine (ADMA). For
decades, MMA was simply considered to be the intermediate for generating
dimethylarginines (11). However, the biological significance of MMA became clear after

Figure 5-1. Methylation reactions catalyzed by PRMT1. PRMT1 catalyzes the methyl
group transfer from AdoMet to protein arginine residues generating AdoHcy and
monomethylarginine (MMA). MMA can be further methylated to asymmetric
dimethylarginine (ADMA).

116
MMA was detected in vivo as a physiologically relevant modification on yeast and
mammalian histones (12, 13). Moreover, MMA induces distinct transcriptional outputs
from ADMA when deposited on the same arginine residue (13). Thus it is of great
importance to investigate the product specificity of PRMT1 and the regulation of MMA
and ADMA generation.
As a foundation for the development of pharmaceutical inhibitors/activators of
PRMT activity, the kinetic mechanism of PRMT1 has been studied (11, 14-17). Steady
state data from Thompson and colleagues (16) suggests that PRMT1 follows a partially
processive mechanism, with the production of ADMA occurring in significant amounts,
but not in an obligate fashion. A fully processive mechanism would produce only ADMA
without the release of MMA, and a distributive mechanism would require free MMA
rebound to PRMT1 for further dimethylation (Scheme 5-1). Thompson further proposed
that partially-processive dimethylation could result from the occasional fast dissociation
of AdoHcy and AdoMet binding prior to the release of MMA, and thereby allow the
transfer of a second methyl group (Scheme 5-1). On the other hand, a recent transient

Scheme 5-1. The processive versus distributive mechanism of PRMT1-catalyzed
dimethylation. (E: PRMT1; SAM: AdoMet; SAH: AdoHcy; pepme: monomethyl peptide;
pepme2: dimethyl peptide)
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kinetic study (18) suggests that methylated peptide release is much faster than the
chemical transfer of the methyl group during turnover. Although both studies utilized a
peptide substrate derived from the H4 protein substrate, the steady state study was
performed with underivatized peptides while the transient kinetic study was performed
with peptides containing a fluorescein molecule to monitor binding events. These two
kinetic studies are inconsistent with each other and provide an unsatisfactory
understanding of the mechanism for PRMT1.
Our most recent work showed that modifying the peptide sequence can alter the
partitioning between distributive and processive dimethylation mechanisms (19). This
suggested to us that some of the disparity observed between the two published kinetic
studies may be based on the use of the fluorescein-labeling of the peptide substrate in the
transient kinetic study. Additionally, we hypothesized that our results showing varying
degrees of processive dimethylation with varying peptide sequences (19) could be
explained by varying dissociation rates for monomethylated peptides of differing
sequences.
To understand more about the mechanism of PRMT1, single turnover experiments
and stopped-flow rapid mixing were utilized to explore the microscopic rates which
contribute the distributive or processive pathway (Scheme 5-1). In this chapter, the
underivatized eIF4A1 and eIF4A1-CH3 peptides are used as the substrates, due to their
relatively high degree of processivity (see Table 4-4). The same experiments will be
performed with other peptide substrates in order to understand the substrate-dependent
processivity. Although solid conclusions about the substrate-dependent processivity of
PRMT1 cannot be drawn yet, my research showed that single turnover experiments and
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the stopped-flow measurement can both be used as powerful tools in the pre-steady state
kinetic research of PRMTs. Our results are consistent with the rate-limiting step in
PRMT1-catalyzed methylation being the chemical step of –CH3 transfer, as shown in the
previous transient kinetic study (18). The binding and orienting process of AdoMet is
slower than that of peptide substrates. Data from stopped-flow experiments showed that
AdoMet binding appears to be a two-step process. Most surprisingly, a role for a
reductant in substrate binding was revealed in my studies.

MATERIALS AND METHODS
AdoMet was purchased from Sigma as a chloride salt (≥80%, from yeast).
[methyl-3H]AdoMet was purchased from Perkin Elmer. All the peptides were synthesized
by the Keck Institute and purified to ≥95%. ZipTip®C18 pipette tips were purchased from
Millipore.

Expression and purification of mutant PRMT1 proteins
His-tagged rat PRMT1 was expressed and purified as described (17). Purified
proteins were ≥95% pure judged by SDS-PAGE. Protein concentrations were determined
by UV spectroscopy using the theoretical absorption coefficients and by the Bradford
assay with bovine serum albumin as standard.

Dissociation constant measurement by intrinsic fluorescence quenching
An RF-5301PC spectrofluorophotometer (Shimadzu) was used for fluorescence
measurements.

For peptide and AdoMet affinity determinations, an excitation

wavelength of 290 nm was used and emission spectra from 300-420 nm were collected.
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The change in fluorescence intensity at the maximum emission (333 nm) was monitored.
The excitation and emission slit was 5 nm and the scan speed was 100 nm/min using
1325 µL containing 1.4 µM PRMT1 in 150 mM sodium phosphate buffer pH 7.8.
Increasing concentrations from 1 to 50 µM peptide ligand (or AdoMet) were added at 2-3
min intervals.

Data from at least two titrations were averaged and analyzed using the

modified Stern Volmer (20) plots. Data were evaluated by nonlinear regression analysis
using SigmaPlot in order to obtain the dissociation constant (KD) using the following
equation Fc= F (10

εcd/2

) where Fc is the corrected fluorescence, ε is the extinction

coefficient of AdoMet, c is the concentration of AdoMet, and d is the pathlength.
Finitial/(Finitial-Fc) was then plotted against 1/[AdoMet] and the data was fit to a line where
the yintercept=1/fa, the slope=1/fa*KQ, and the KQ=1/KD.

Single turnover experiments
Single turnover experiments were performed to evaluate the rate of substrate
incorporation and the chemical catalysis step. Hence the single turnover reactions were
initiated with either peptide substrate or AdoMet in order to find out the differences in
rates of peptide and AdoMet incorporation. Reactions initiated by peptides were carried
out by mixing a solution containing the pre-incubated complex of 21 μM wild type
PRMT1, 20 μM AdoMet (along with 1 μM of [3H]-AdoMet), and 10 nM MTAN in 50
mM sodium phosphate buffer (pH 7.5) at 23 °C for 3 minutes. Commercially available
AdoMet was purified as described (21, 22) before use. Reactions were initiated with 200
μM peptide substrates. Reactions initiated by AdoMet were performed with the same 20
μM wild type PRMT1, 200 μM peptide, and 10 nM MTAN in 50 mM sodium phosphate
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buffer (pH 7.5) at 23 °C for 3 min. 50 μM AdoMet (along with 1 μM of [ H]-AdoMet)
3

was used to initiate the reaction. Radiolabel incorporation over time from each reaction
was measured using the discontinuous ZipTip® assay described previously. Briefly, 10 μL
reaction samples of different time points were taken out and quenched by 6 M guanidine
HCl solution and processed with ZipTip®C18 assay to quantitate the amount of methylated
product (23). The resulting time course of [3H]AdoMet incorporation was fit into single
exponential curve
y= Ao *(1-exp(-b*x))

(1)

to determine the parameters, where Ao represents the amplitude of the exponential phase
and b(kchem) is the observed rate constant associated with that process.

Stopped-flow fluorescence measurement
The transient-state kinetics of AdoMet association with PRMT1 was determined by
stopped-flow fluorescence assays using a HiTech SF-61DX2 instrument (Hi-Tech Ltd.,
Salisbury, U.K. at University of California, San Francisco). The transient fluorescence
signal change was detected at 23 °C on stopped-flow equipment using an excitation
wavelength of 280 nm and an emission wavelength at 300-350 nm. Each reaction was at
least triplicated. A high concentration of PRMT1 (5 M) was used in the fluorescent
measurement in order to provide sufficient fluorescent signals. PRMT1 was
pre-incubated with 1 mM DTT to achieve a reliable quenching curve. PRMT1 solution
was then mixed with increasing concentration (50 M, 100 M, and 250M) of AdoMet
in the reaction buffer (50 mM sodium phosphate, pH 7.6). After averaging the shot data,
the association time courses were fitted to a double-exponential function:
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F = A1 exp(-k1t) + A2 exp(-k2t) + C

(2)

F is the fluorescence intensity at time t, A is the amplitude of the fluorescence change,
and k is the rate constant. The observed rate constants were plotted against AdoMet
concentration, and the data were fit to the following equation:
kobs = kon[AdoMet] + koff`

(3)

to derive the association rate constants kon as well as the dissociation rate koff. The
dissociation constant KD can then be calculated as
KD = koff / kon`

(4)

RESULTS
Similar binding affinity of the eIF4A1 and eIF4A1-CH3 peptides with PRMT1
In the semi-processive mechanism, if the binding of monomethyl peptides is highly
preferred, it may lead to a pseudo-processive observation in which the MMA species is
first released from PRMT1 but quickly rebinds to the enzyme. Thus the binding affinity
of PRMT1 with the eIF4A1 and eIF4A1-CH3 peptides was first tested via the intrinsic
fluorescence quenching experiments (Figure 5-2). The modified Stern-Volmer plot was
applied to analyze the quenching data (20). The KD values of both peptides are very
similar to each other in low M range (Table 5-1) revealing that PRMT1 binds the
unmodified and the monomethylated peptides with comparable affinity.

Single turnover experiments of the eIF4A1 peptide pair
To gain more information about the microscopic rates of PRMT1-catalyzed
methylation, single turnover experiments were conducted where the chemistry step (kchem)
could be isolated from substrate binding or product release steps (Scheme 5-2).
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Additionally, single turnover experiments allow us to analyze the two-step methylation
separately

with

unmodified

and

monomethyl

peptides,

and

thus

ascertain

the intrinsic reactivity of the 1st versus the 2nd methyl group transfer (17). The single
turnover experiments were conducted at 22 ºC with a slight excess of PRMT1 (21 M)
pre-incubated with a limiting amount of AdoMet (20 M) (~10-fold higher than KD).
Reactions were initiated with saturating peptide substrates (200 M). Samples from
different time points were taken out and analyzed via ZipTip assays (Figure 5-3). The
maximal product concentration (A0) and kchem for peptide incorporation and methylation

Figure 5-2. Modified Stern-Volmer plot showing the intrinsic fluorescence quenching of
PRMT1 by the eIF4A1 and eIF4A1-CH3 peptides. The data was fit to a line with
nonlinear regression where the yintercept=1/fa, the slope=1/fa*KQ and the KQ=1/KD.
Table 5-1. Peptide dissociation constants from the modified Stern-Volmer plots.
Peptide ligand

Peptide sequence

KD (M)

Fluorescent
quenching (%)

eIF4A1
eIF4A1-CH3

YIHRIGRGGR
YIHRIGRMeGGR

1.3 ± 0.1
2.6 ± 0.2

30 ± 2.0
27 ± 4.7
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Scheme 5-2. Meaning of the kinetic parameters under the pre-steady state and the steady
state of a simplified methyltransfer reaction. The expressions for kchem, kcat and kcat/Km
include steps within the brackets in each case. E: enzyme (PRMT1), A and B: two
substrates (AdoMet and peptide substrate for PRMT1); EAB’: a transient state of
methylation; P and Q: two products (AdoHcy and methyl peptide generated by PRMT1).

were obtained (Table 5-2). The eIF4A1 peptide shows a slightly higher kchem (3.3±0.6
x10-2 s-1) than the eIF4A1-CH3 peptide (2.6±0.2 x10-2 s-1). We further calculated the
pre-steady state efficiency constant kchem/KD, which is a similar concept to kcat/KM in
steady state kinetics (24). The unmodified eIF4A1 peptide has a 2.5-fold higher kchem/KD
than the monomethyl counterpart (Table 5-2), indicating that PRMT1 has a slightly
higher preference for the naked peptide under single turnover conditions.
As a bi-substrate reaction, PRMT1-catalyzed methylation involves substrate binding
steps of both AdoMet and the peptide substrate. The rate of AdoMet forming a productive
complex also contributes to the degree of processivity. Therefore, single turnover
experiments were also performed with limited amount of peptides. 21 M of PRMT1 was
pre-incubated with limited peptides (20 M) with reactions initiated by saturating
AdoMet (50 M, 1 M 3H-AdoMet included), so that the process of ternary complex
formation and methyl group transfer was monitored with AdoMet initiation (single
turnover plots not shown). For eIF4A1 and eIF4A1-CH3 peptides, the methylation rate
kchem and the pre-steady state catalytic efficiency kchem/KD were very similar (1.5 x10-2 s-1
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Figure 5-3. Single turnover experiments of PRMT1 initiated with peptide substrates. Data
were fitted with equation (1).

and 3.5 x103 M-1s-1, respectively, Table 5-2). These observations showed that
pre-incubating PRMT1 with the peptide substrates eliminated the differentials in kchem/KD
previously observed between unmodified or monomethylated arginine residues.
Reactions initiated with the eIF4A1 or eIF4A1-CH3 peptides (PRMT1 pre-incubated
with AdoMet) eliminate the AdoMet binding and/or orienting step, providing a 7-fold or
3-fold higher kchem/KD compared to the AdoMet-initiation reactions. Because the
mechanism of PRMT1 was previously described as a random equilibrium mechanism
(16), the rate of methyl group transfer (the EAB’EPQ step in Scheme 5-2) should be
the same with the same peptide substrate, no matter whether the reaction is initiated with
AdoMet or peptides. Therefore, the lower kchem/KD in AdoMet-initiation reactions
indicates that a slower step is involved in AdoMet binding and/or forming the productive
ternary complex (EAB’) before the methyl group transfer. This novel observation is
essential in understanding the methylation catalyzed by PRMT1, due to the fact that in a
fully processive dimethylation (Scheme 5-1), AdoMet is the substrate that binds to the
PRMT1- eIF4A1-CH3 complex and initiates the methyl group transfer.
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Table 5-2. Pre-steady state parameters of PRMT1 with unmodified and monomethylated
eIF4A1 peptide under different initiation orders

Peptide initiation
eIF4A1
eIF4A1-CH3
AdoMet initiation
eIF4A1
eIF4A1-CH3

A0 (M)

kchem (x10-2 s-1)

kchem/KD
(x103 M-1s-1)

16.6 ± 0.5
13.0 ± 0.3

3.3 ± 0.6
2.6 ± 0.2

25.4
10.0

8.2 ± 0.7
12.9 ± 1.6

1.5 ± 0.4
1.5 ± 0.5

3.7
3.5

Comparison of the eIF4A1 and eIF4A1-CH3 peptides under steady-state and single
turnover conditions
Results from both steady-state kinetics and single turnover experiments were
combined together to analyze the two-step methyl group transfer. Since the single
turnover experiments were all performed under room temperature, parameters in
steady-state kinetics were further collected at 22 ºC instead of 37 ºC as tested previously.
Unsurprisingly, the apparent kcat under room temperature is much lower than at 37 ºC for
both unmodified and monomethyl peptides (Table 5-3). The eIF4A1-CH3 peptide is
barely a better substrate under steady-state kinetics (a slightly higher value of kcat/Km).
Under single turnover conditions, the eIF4A1-CH3 peptide has a slightly lower
methylation rate (kchem). Along with the higher KD, the monomethyl peptide has a lower
pre-steady state catalytic efficiency (kchem/KD) than the unmodified one. Although these
differences are modest at best, the different preference of PRMT1 to the naked or
monomethylated peptides under steady-state and single turnover conditions provides
further insights into the mechanism of PRMT1-catalyzed dimethylation, which will be
further discussed.
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Table 5-3. Comparison of the steady-state and single turnover kinetic efficiency of the
eIF4A1 peptide pair. The catalytic efficiency under steady-state kinetics or single
turnover conditions is highlighted in bold face.
kcat (x10-2 s-1)
37 ºC

Km, peptide (μM)
2

-1 -1

kcat/Km (x10 M s )
22 ºC

-2

-1

5.8 ± 0.2

72 ± 9.6

26 ± 6.2

13 ± 1.7

23 ± 5.5

a

0.50 a

Km (μM)

NDb

ND

3.3 ± 0.6

2.6 ± 0.2

1.3 ± 0.1

2.6 ± 0.2

25.4

10.0

-1

KD (Μ)
3

-1 -1

kchem/KD (x10 M s )
b

9.0 ± 0.3

0.62

kchem (x10 s )

a

eIF4A1-CH3

kcat, app (x10 s )
-2

22 ºC

eIF4A1

The standard error for the kcat, app at 22 ºC is about 10-15%.
ND stands for ‘not determined’.

Measurement of the substrate binding rates of PRMT1
In the single turnover experiments, both naked and monomethylated peptide reaction
that were initiated with AdoMet had equally low kchem/KD compared to the
peptide-initiated reactions. To further investigate the slower step in AdoMet initiation,
stopped-flow rapid mixing experiments were performed to explore the substrate binding
rates via measuring the intrinsic fluorescence quenching of PRMT1 by AdoMet. Due to
the relatively low fluorescent signal given by PRMT1, a high concentration of enzyme (5
M) was used to monitor the binding event. Binding reactions were carried out with both
AdoMet and peptide substrates under saturating concentrations. However, no reliable
binding curve could be obtained, especially with peptide substrates. Quite surprisingly, it
was not until PRMT1 was pre-incubated with a reductant dithiothreitol (DTT), that
AdoMet was capable of quenching the intrinsic fluorescence of PRMT1. Measurements
were then carried out as described in Materials and Methods.
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The stopped-flow traces from various concentrations of AdoMet binding experiments
(Figure 5-4) fit well to the double exponential equation (eq. 2) with two observed rate
constants. Plots of the fast phase rates versus the AdoMet concentration (eq. 3) are linear
with y-intercepts equal to the dissociation rate koff (8.40 s-1), and the slope representing
the association rate kon (4.7x104 M-1s-1). The plot gave an average KD(AdoMet) equal to
koff/kon = 0.18 mM. Notably, the value of KD(AdoMet) measured by the stopped-flow
experiment is significantly larger than the one measured by fluorescent quenching
method without the presence of DTT (17). This may be due to the fact that the
HPLC-purified AdoMet was used in the previous KD measurements (intrinsic
fluorescence quenching), but not in the stopped-flow measurements. Also the presence of
1 mM DTT in the stopped-flow measurement could possibly influence the binding
affinity of AdoMet.
Although not much information can be gained yet from the kon and koff of AdoMet or
peptide substrates, it suggests a potential two-step binding event, possibly including a
conformational change. Our observation is consistent with the previous transient kinetic
study based on a fluorescence-labeled peptide substrate (18). Additionally, the
requirement for a reductant to observe reliable binding curves poses new questions about
PRMT1 and the mechanism which are explored in more details in the next chapter of this
dissertation.

DISCUSSION
In all eukaryotic cells, PRMT1 is the predominant PRMT in vivo generating
MMA and ADMA within protein targets (1, 10). Coupled with the observation that MMA
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Figure 5-4. Stopped-flow measurements of AdoMet association with PRMT1.
Fluorescence changes of PRMT1 (5 M) were shown upon mixing with different
concentrations of AdoMet at room temperature. All the curves are fit with eq 2. The
bottom right panel shows the observed association rate constant of AdoMet (phase 1
shown in squares and phase 2 in triangles) plotted against the concentration of AdoMet.
The data were fit to linear eq 3.

and ADMA modifications in histone H4 Arg 3 are capable of inducing distinct
transcriptional consequences, the determinants for PRMT1 generating mono- or dimethyl
arginines become essential to understand the specific in vivo methylation pattern of
PRMT1. We previously showed that PRMT1-catalyzed dimethylation is semi-processive
and the degree of processivity is in a substrate-dependent manner (19). Hence the
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substrates of PRMT1 intrinsically participate in encoding the MMA/ADMA product
formed. To further understand the determinants of the semi-processive mechanism, single
turnover experiments and stopped-flow rapid mixing were performed to elucidate the
microscopic rate constants in the dimethylation process. Combined with the steady-state
kinetic studies (Table 5-3), the detailed mechanism of PRMT1 catalysis was studied
based on the eIF4A1 peptide pair chosen as the studying model due to its high degree of
processivity (see Table 4-4).
Kinetic parameters from steady-state and pre-steady-state kinetics can tell us stories
bracketing different steps in the whole methylation process. As shown in Scheme 5-2, the
expression of kcat includes all first order steps including the conformational changes
(EABEAB’),

the

chemistry

step

(EAB’EPQ),

and

product

dissociation

(EPQE+P+Q), while the kcat/Km expressions include all steps from binding of
substrate through the first irreversible step (25-27). For methyltransferases, the first
irreversible step is methylation (the chemistry step). Under the steady-state kinetic
conditions, multiple turnovers occur including substrate binding and product release.
From the steady state kinetic study of the eIF4A1 peptide pair (Table 5-3), Km of the
peptide substrates (>20 M) is 10 fold higher than the value of KD (~2 M), indicating
that the rate of product release is fast. Due to the fact that Km = krelease/kcapture (25), the
lower Km for the eIF4A1-CH3 peptide shows that the monomethylated peptide has either
a larger kcapture (faster to be captured by PRMT1) and/or a smaller krelease (slower to release
from PRMT1), in another word, “stickier” than the unmodified peptide substrate. Also,
the eIF4A1-CH3 peptide shows a slightly smaller kcat than the eIF4A1 peptide,
demonstrating a longer chemistry step and/or product release process from Scheme 5-2.
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Overall, the monomethyl eIF4A1-CH3 peptide shows a larger kcat/Km indicating a higher
catalytic efficiency and a better substrate under steady state kinetics.
With pre-steady state kinetics, kchem obtained from single turnover experiments
includes steps from generation of the EAB complex and potential conformational
changes to methyl group transfer (EABEAB’EPQ in Scheme 5-2). For both
unmodified and monomethyl eIF4A1 peptide substrates, similar kchem was observed
(Table 5-3), showing that both peptides have similar rates of EAB complex formation,
and methyl group transfer. However, when the pre-steady state catalytic efficiency
kchem/KD was calculated, the eIF4A1 peptide showed a higher kchem/KD, indicating that the
naked peptide is a more efficient substrate under single turnover conditions. The altered
preference of PRMT1 under steady state and single turnover conditions may be due to the
different concentrations and oligomeric forms of PRMT1 under single turnover (high
enzyme, high peptide) and steady state (low enzyme, high peptide) conditions.
Additionally, the differences at the two temperatures (22 ºC in single turnover, 37 ºC in
steady state studies) could affect the protein-peptide interaction and lead to a different
preference.
On a final note, the semi-processive mechanism indicates that the groove on the
surface of PRMT1 active site (28), which is a common structure for enzymes performing
processive turnover (29), provides binding capacity to the monomethyl product to some
extent, but not enough to hold it through the AdoHcy–AdoMet exchange (Scheme 5-3).
To further investigate the mechanism of PRMT1-catalyzed dimethylation, the rate of
AdoMet–AdoHcy exchange (kon

(AdoMet)

and koff

(AdoHcy))

with the presence of the

monomethyl peptide will need to be tested. The measurement of kon(eIF4A1), kon(eIF4A1me),
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and koff(eIF4A1me) will be necessary in order to understand the semi-processivity of PRMT1
by comparing the peptide release rate with the AdoHcy-AdoMet exchange velocity.
Moreover, kon for other peptide substrates with and without the presence of AdoMet will
also be desirable in order to find out whether the difference in kon is the reason for the
substrate-dependent processivity.
As a brief summary, the stopped-flow fluorescent measurement and the single
turnover experiments have been optimized and can be used as very powerful tools to
investigate the detailed mechanism of PRMT1-catalyzed dimethylation. Due to the
limited access to the stopped-flow rapid mixing equipment (Dr. Susan Miller at UC San
Francisco), further experiments will be required to measure the unknown association or
dissociation rates and understand the semi-processive mechanism of PRMT1 (Scheme
5-3). Additionally, during the research with the stopped-flow fluorescent measurement, I
found out that no reliable binding event can be detected unless PRMT1 was preincubated

Scheme 5-3. The proposed semi-processive mechanism of PRMT1-catalyzed
dimethylation. The important yet unknown kon, koff and KS are indicated in red. (E:
PRMT1; SAM: AdoMet; SAH: AdoHcy; eIF4A1me: the eIF4A1-CH3 peptide; eIF4A1me2:
the asymmetric dimethyl eIF4A1 peptide)
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with the reductant DTT. Data from rapid mixing with PRMT1 and DTT indicated a
transient change in protein conformation and/or its oligomeric state (data not shown),
which may at least partially result from the histidine6-tag flanking our PRMT1 construct.
We generated a tagless construct of PRMT1 and further experiments were carried out
exploring the effect of DTT and the affinity tags on the protein characteristics of PRMT1
(Chapter 6).
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CHAPTER 6
EFFECTS OF AFFINITY TAGS AND REDUCING AGENTS ON THE PROTEIN
CHARACTERISTICS OF RAT PRMT1

ABSTRACT
Protein arginine methylation is a significant post-translational modification catalyzed
by protein arginine methyltransferases (PRMTs). PRMTs are widely involved in various
cellular pathways and their dysregulation lead to many human diseases. Although PRMTs
have been studied for more than 10 years, the research of PRMTs mainly uses
recombinant proteins, of which the affinity tags may significantly influence the protein
characteristics. Herein, we report that the small affinity tag, the histidine-6 tag, impairs
the enzymatic activity of rat PRMT1 and displays a distinct oligomerization pattern from
the tagless rat PRMT1. Surprisingly, the reductant dithiothreitol (DTT) greatly increases
the enzymatic activity of His-rPRMT1 and reduces the His-PRMT1 aggregation, while it
does not influence the oligomerization form of the tagless rPRMT1. A caveat of these
experiments lies in the instability of the tagless construct, suggesting that rPRMT1
expressed without tags may incur damage that is not recoverable by an exogenous
reductant. Due to the effect of DTT, we hypothesize that rPRMT1 suffers from potential
oxidative damage, possibly on one or more cysteine residues. In all, our results show that
the small His-tag can affect the protein characteristics of PRMT1 and lead to
misinterpreted conclusions. Further experiments will be performed to find out the
possible oxidative sites and the cause of PRMT1 oxidation. Future research will be
focused on the possible oxidative regulation of PRMT1 in vitro and in vivo.
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INTRODUCTION
In all eukaryotic cells, protein arginine methylation is one of the abundant
post-translational modifications in vivo catalyzed by protein arginine methyltransferases
(PRMTs). PRMTs transfer the methyl group from S-adenosyl-L-methionine (AdoMet) to
a targeted arginine and generate monomethylarginine (MMA), asymmetric and
symmetric dimethyl arginine (ADMA/SDMA). PRMT activity has been associated with a
variety of biological pathways (reviewed in (1-3)), and has most recently garnered
interest as a pharmaceutical target due to its involvement in various human diseases (4-8).
In most publications about PRMTs, recombinant proteins with peptide or protein affinity
tags were examined in kinetic or product specificity assays. Although affinity tags are
highly efficient in purifying recombinant proteins from the crude extracts, these
additional amino acids may affect the inherent characteristics of PRMTs. It is shown that
the N-terminal sequences of PRMTs (either from the affinity tags or different native
isoforms) can alter the enzymatic activity of PRMT1, -7, and -8 (9-11). In one short
report, the commonly used hexa-histidine (His6) tag was shown to alter the product
specificity of human PRMT1 (12).
The concern over using affinity tags extends beyond just the PRMT field into the
general biochemistry community. Small peptide tags such as Strep tag II or His6 tag are
shown to influence the protein expression (13), protein dynamics (14) and crystallization
(15). Although the effects of affinity tags are drawing increasing attention, His 6-tagged or
glutathione S-transferase (GST)-tagged PRMTs are still the most commonly-used PRMT
constructs, with little understanding about the effects of affinity tags on protein features.
During our previous transient kinetic studies (Chapter 5), His-tagged rat PRMT1 did
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not show any reliable binding curve data until it was pre-incubated with dithiothreitol
(DTT). Stopped-flow rapid mixing measurement indicates a protein environment change
of His-PRMT1 in the presence of DTT. Additionally, DTT was reported to significantly
enhance the in vitro activity of GST-PRMT2 (16) and GST-PRMT7 (17). These
observations bring us to question how the histidine-tag influences PRMT1, and whether
the effect of DTT is on the intact PRMT protein or actually an artifact from the affinity
tags. Herein, we report the studies based on the effects of the His-tag and DTT using the
tagged and tag-free rat PRMT1 as our model protein. Our results indicate that the His-tag
lowers the enzymatic activity and changes the oligomeric state of rat PRMT1, which can
be partially recovered by the reducing agent DTT. PRMT1 is shown to play significant
roles in oxidative-stress-induced apoptosis (18) and PRMT1 activity is upregulated with
hydrogen peroxide or reactive oxygen species (ROS) (18, 19). PRMT1 may be regulated
through oxidation under oxidative stress. Further experiments will focus on identifying
the potential oxidative damages on rPRMT1, as well as the changes on downstream
effects due to PRMT1 oxidation.

EXPERIMENTAL PROCEDURES
Materials
AdoMet was purchased from Sigma as a chloride salt (≥80%, from yeast).
[methyl-3H]AdoMet was purchased from Perkin Elmer. All the peptides were synthesized
by the Keck Institute (Yale University) and purified to ≥95%. The lyophilized peptides
were dissolved in water. Peptide concentrations were determined by mass or by UV

-1

-1

spectroscopy (280 nm= 5,690 M cm ).

ZipTip®C4/C18
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pipette tips were purchased from

Millipore.

Recombinant proteins
His-tagged rat PRMT1 was expressed and purified as described (20). The plasmid
expressing tagless rat PRMT1 was constructed by subcloning the rPRMT1 sequence into
an NdeI and BamHI site within the pGEMEX-2-Nde1 vector (21). The tagless rPRMT1
was expressed similarly to His-rPRMT1 and purified as follows. Frozen cells were
resuspended in 3x cell mass volume of lysis buffer (50 mM sodium phosphate pH 7.6
with 1 mg DNase) and subjected to freeze and thaw lysis 3 times. Soluble proteins were
clarified by centrifugation at 20,000 RPM and the filtered supernatant was applied to a
5.0 mL HiTrap MonoQ anion exchange column (GE Healthcare). The fractions
containing the tagless rPRMT1 were applied to a 1.0 ml HisTrap column (GE Healthcare),
and finally a 1.0 mL HiTrap MonoQ anion exchange column (GE Healthcare) for
additional separation and concentration. Purified proteins were ≥95% pure by
SDS-PAGE. His-hnRNP K protein was expressed and purified as described previously
(22). Protein concentrations were determined by UV spectroscopy and by the Bradford
assay with bovine serum albumin as standard.

Kinetic assays of PRMT1 constructs
A sensitive methylation assay using ZipTipC4/C18 pipette tips was used in testing the
enzymatic activity under steady-state conditions (22). Unless noted otherwise in the text,
enzyme catalytic activity was tested with 100 nM PRMT1 constructs, 2 μM AdoMet (1
μM [3H]AdoMet), and 10 nM MTAN (5'-methylthioadenosine /S-adenosylhomocysteine
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nucleosidase) in 50 mM NaPO4 (pH 7.6), initiated by 200 μM peptide substrates or 2 μM
protein substrate at 37 °C. The effect of DTT was tested by pre-incubation for 10 min
prior to reaction initiation with peptide or protein substrates. At different time points,
samples were removed from reactions and processed with ZipTipC4/C18 pipette tips (for
protein or peptide substrates, respectively) to separate the unreacted [3H]AdoMet and the
radiolabelled product.

Size exclusion chromatography
Samples (500L at 1 mg/mL) of His-rPRMT1 and tagless rPRMT1 were analyzed in
50 mM sodium phosphate and 150 mM NaCl at 0.5 mL/min on a 24 mL gel filtration
column. The effect of DTT on oligomerization was tested by pre-incubating the enzymes
with the appropriate concentration of DTT for 30 min prior to loading.

RESULTS
DTT significantly enhances the enzymatic activity of His-rPRMT1
Dithiothreitol (DTT) is a common reducing agent used during purification and/or
protein arginine methylation assays (16, 17), but the requirement by PRMT1 has never
been assessed. To rationalize the need for DTT in PRMT1 methylation reactions, we first
tested its effect on the enzymatic activity of His-rat PRMT1 (rPRMT1). Pre-incubation of
His-rPRMT1 with 1 mM DTT increased methyl transferase activity by 13-17-fold with
the R3 peptide substrate (acGGRGGFGGRGGFGGRGGFG) (Figure 6-1A). DTT-treated
His-rPRMT1 also showed a 5-fold increase in activity with the hnRNP K protein
substrate (data not shown). To understand such significant enhancement of His-rPRMT1
activity by DTT, we first examined the duration of this effect by removing DTT in the

140
reaction buffer with a desalting step following the 10 min pre-incubation. The activity of
the desalted His-rPRMT1 was increased only by 2-fold using the R3 peptide (Figure
6-1A), indicating that the effect of DTT is transient.
We further studied the relationship between enzymatic activity and the concentration
of DTT by comparing His-rPRMT1 activity using a wide range of DTT concentrations
from 0.1 mM to 100 mM (Figure 6-1B). Our results indicate that the effect of DTT is
concentration-dependent, achieving maximal methyl transferase enhancement at 1.5-2
mM DTT (apparent kcat = 1.94 min-1) (Figure 6-1B).

Maximum His-rPRMT1 activity requires a reductant
By analyzing the structure of DTT and AdoMet (Figure 6-2A), DTT could increase
the His-rPRMT1 activity through the sulfhydryl groups acting as an intermediate

Figure 6-1.The effect of DTT on the enzymatic activity of His-rPRMT1. (A) The effect of
DTT on the enzymatic activityofHis-rPRMT1in the absence of DTT (closed circles), in
the presence of 1mM DTT (closed squares), pre-incubated in 1mM DTT followed by a
desalting step (open circles), and a control reaction with no substrates (open squares). (B)
The apparent kcat was measured as a function of DTT concentration.
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acceptor molecule as part of the methyl group transfer process. Methylation of sulfhydryl
groups in DTT was previously observed with small molecule plant O-methyltransferases
(23). Although we did not detect any DTT methylation in the control experiments (Figure
6-1A, open squares), we further tested this hypothesis with an alternative thiol-free
reducing agent, Tris(2-carboxyethyl)phosphine (TCEP). When the activity of
His-rPRMT1 in 1 mM TCEP was examined with the R3 peptide (Figure 6-2B), the
observed rate enhancement in the presence of TCEP (1 mM) was identical to that
observed in the presence of DTT (1 mM). Hence, the rate enhancement of His-rPRMT1
is due to the reducing power of the DTT or TCEP additives.

Figure 6-2.The effect of reducing agents on the ability of His-rPRMT1 to methylate the
R3 peptide. (A) Structures of DTT, TCEP, and S-adenosyl methionine. (D)The
comparison of enzymatic activitywith1mM DTT (closed squares) and 1 mM TCEP (open
circles), together with methylation rates measured with no DTT (closed circles) and no
substrates (open squares).
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DTT does not affect the enzymatic activity of tagless rPRMT1
In order to understand the observed rate enhancement of His-rPRMT1 by reducing
agents, we questioned whether the effect of DTT was truly due to PRMT1, or was
observed because of the addition of the His6 affinity tag. To answer these questions, we
generated and purified the tagless rPRMT1 construct (expressed with no tag). In the
absence of DTT, the enzymatic activity of freshly prepared tagless rPRMT1 is higher
than that of His-rPRMT1 with the R3 peptide substrate (shown as the apparent kcat in
Figure 6-3). Therefore, despite of the small size of His-tag, the attached histidine-tag
reduced the enzymatic activity of rPRMT1.
We further examined the effect of DTT on the catalytic activity of the tagless
rPRMT1. Surprisingly, the activity of the tagless rPRMT1 did not show significant rate
changes upon addition of 0.5 mM and 1 mM DTT (Figure 6-3). Such differences between
His-rPRMT1 and tagless rPRMT1 indicate that the His6-tag changes the protein
characteristics of rPRMT1, possibly the oxidative states, which can be recovered by DTT
or other reducing agents. A caveat to these experiments lies in the observed instability of
the rPRMT1 expressed as the tagless construct; this recombinant protein could not be
dialyzed or frozen without losing nearly all activity. Additionally, it is noted that the
activity of tagless rPRMT1 is eclipsed by His-rPRMT1 when DTT is present in the
reaction. This may suggest that PRMT1 expressed as a tagless construct incurs damage
that is not recoverable by an exogenous reductant. Nonetheless, the differential effects
that DTT has on His6-tagged and tagless rPRMT1 enzymes led us to further investigate
what protein characteristic(s) the His6-tag alters to induce these observed effects.
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Figure 6-3. The differential effects of DTT on the enzymatic activity of His-rPRMT1
(grey bars) and tagless rPRMT1 (black bars) with increasing DTT concentration.

Oligomerization of PRMT1 is influenced by the His6-tag
DTT was previously found to alter the oligomerization pattern of FLAG-PRMT1
(24), but it is unclear whether or not the effect was due to the FLAG tag or an inherent
quality of PRMT1. In order to investigate the reason for the different responses of
His6-tagged and tagless rPRMT1 to DTT, we first examined the oligomeric states of
His6-tagged and tagless rPRMT1 constructs via size-exclusion chromatography. A
standard curve for the size-exclusion column was first achieved with high correlation
efficiency (data not shown). In the absence of DTT, the tagless rPRMT1 elutes as a single
peak at the same retention time as would be expected for a solution containing mostly the
dimeric form (Figure 6-4A), while the His-tagged rPRMT1 eluted from gel filtration at an
ultra-high molecular weight greater than 2000 kDa and various oligomers ranging from
monomers through icosomers (20-mer) (Figure 6-4C). These distinct chromatograms of
His-rPRMT1 and tagless rPRMT1 show that the His6 tag, a tiny addition on PRMT1,
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Figure 6-4. The oligomerization pattern of PRMT1 influenced by the His6-tag and DTT
via size-exclusion chromatography including the tagless rPRMT1 in 0 mM DTT (A) and
1 mM DTT (B), and His-rPRMT1 in 0 mM (C), 1 mM (D), and 10 mM DTT (E).

substantially alters the oligomeric state of rPRMT1.

Oligomerization of His-rPRMT1is influenced by DTT
We further examined whether DTT influenced the oligomerization patterns of the
His-tagged and tagless rPRMT1 differently. 1mM or 10 mM DTT was pre-incubated with
the proteins for 30 min. In the presence of DTT, the higher-order oligomers of
His-rPRMT1 were dissociated and shifted towards lower molecular weight oligomers
(Figure 6-4D, 4E). However, size-exclusion chromatogram of the tagless rPRMT1 in 1
mM DTT showed no change in the single peak retention time (Figure 6-4B). Our results
indicate that His-tag leads to a distinct oligomerization pattern of His-rPRMT1 from the
tagless rPRMT1, and such difference can be recovered to some extent by addition of
DTT.
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DISCUSSION
In this chapter, we investigated the effect of the histidine affinity tag and the reducing
agent DTT. Overall, our results showed that the His-tag impairs activity of PRMT1
(Figure 6-3). Reductants (DTT or TCEP) increased the enzymatic activity of His-tagged
rat PRMT1, but not the untagged rPRMT1. His-rPRMT1 shows a distinct
oligomerization pattern with a large amount of high molecular weight oligomers which
can be considered as protein aggregation (Figure 6-4). The aggregation of His-rPRMT1
can be partially removed by DTT. Yet the tagless PRMT1 mainly exists in the dimeric
form, which does not change with the DTT treatment. Although the addition of affinity
tags greatly eases the purification steps, it may significantly alter the protein
characteristics, such as enzymatic activity and oligomerization patterns.
Our observations indicate an effect of the oligomeric states of PRMT1 on the
enzymatic activity. A negative correlation was suggested between the high molecular
weight oligomers of His-rPRMT1 (>2000 kD) and its enzymatic activity; and the dimeric
tagless PRMT1 has higher activity than the multimers forms of His-PRMT1. Consistently,
the dimeric form of tag-labeled PRMT1 was reported to be the active form of PRMT1 in
vitro and in vivo (25, 26). Interestingly, the recent transient kinetic study of His-rPRMT1
showed that high-order His-rPRMT1 multimers (~250 kD) is the most active form in the
range of 0-0.5 M PRMT1 (27). Together with our observations, different oligomeric
states of His-rPRMT1 are shown to correlate with distinct methylation activity. Notably,
the size-exclusion chromatography in our research was performed under a high PRMT1
concentration (1 mg/ml, or 23.8M), which is significantly higher than the enzyme
concentration used in the activity assays (0.1M). Due to the fact that the
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oligomerization states can be influenced by the protein concentration, we also performed
cross-linking experiments to determine the oligomeric state at 0.1 M PRMT1 (data not
shown). Similar effects of DTT were observed with His-PRMT1 in cross-linking
experiments with the dimer form increasing as more DTT was added in to the solution.
Thus, our results indicated a connection between the oligomeric form of PRMT1 and its
enzymatic activity.
We also noted that the enzymatic activity of His-rat PRMT1 continues to increase
over that of the tagless rPRMT1 when higher DTT concentrations are present (Figure
6-3). This may in part be due to the observed low stability of rat PRMT1 purified as a
tagless construct (data not shown). In fact, it prompted us to look at the human construct
which is more easily expressed and purified with a His-tag that can be cleaved afterwards.
With human PRMT1, the His-tag also decreases the enzymatic activity and appears to be
associated with a change in oligomeric state, some of which can be restored by DTT (data
not shown). Preliminary data suggested that DTT still has some effect on the cleaved
hPRMT1 enzyme (data not shown) implying that some oxidative event may still exist the
tagless enzyme which is associated with a decrease in activity, some of which can be
recovered with reductant.
The fact that DTT changes the protein characteristics of rat and human PRMT1 leads
us to hypothesize that PRMT1 incurs oxidative damage. Indeed, PRMT1 was identified
as a target of the endogenous oxidative product 4-hydroxy-2-nonenal (HNE) (28); and
HNE inhibited the catalytic activity of PRMT1 (29). The most likely oxidative damage
occurs on cysteine residues, which can be oxidized to cystine generating a disulfide bond.
Also the thiol group (-SH) in cysteine can be oxidized to the sulfenyl moiety (-SOH),
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which can be reduced by many antioxidants in vivo, as well as DTT. The sulfenyl group
can be further oxidized to the sulfinyl (-SO2H), and sulfonyl moiety (-SO3H), which
cannot be reduced by DTT (reviewed in (30)). Thus, some of the 11 cysteine residues in
His-PRMT1 may have been oxidized to Cys–SOH which further influences the
enzymatic activity. Based on the crystal structure of PRMT1 (25), we hypothesize that
Cys-101 may play a critical role in PRMT1 oxidation, which is located on the solvent
accessible surface and makes direct contact with AdoMet. In a previous study, Cys-101 is
suggested to be a potential oxidative site with heightened nucleophilic and reductive
catalysis (or “hyper-reactive” cysteines) based on a C101A mutant (29). Site-directed
mutagenesis is underway to generate a C101S mutant to investigate whether the DTT
effect still occurs on C101S-PRMT1.
In all, our results showed that the affinity tag influences the enzymatic activity and
protein oligomerization of His-PRMT1. These influences can be recovered by DTT,
indicating possible oxidative damages on His-rPRMT1. Further experiments will be
performed to find out the possible oxidative sites as well as the cause of the oxidative
damages.
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CHAPTER 7
GENERATION AND SELECTION OF RNA APTAMERS TARGETING
ASYMMETRIC DIMETHYLARGININE (ADMA)

ABSTRACT
Free asymmetric dimethylarginine (fADMA) is a potent inhibitor of nitric oxide
synthase in vivo. Increased plasma levels of fADMA are shown to be highly involved in
cardiovascular and renal diseases. Recently, the concentration of plasma fADMA has
been suggested as a novel cardiovascular risk factor to predict cardiovascular conditions
in clinical trials (1, 2). Thus, specific methods for quickly and quantitatively measuring
the plasma fADMA level are valuable for diagnostic and therapeutic purposes. As an
alternative to antibodies, RNA aptamers display high binding affinity and specificity
against selected biological molecules. Herein, we aimed to develop RNA aptamers
targeting ADMA. Systematic evolution of ligands by exponential enrichment (SELEX)
was performed against ADMA-coated agarose beads. Binding specificity for the
methylated guanidino moiety was controlled with the counter selection against arginine
recognition. 20-30 selection cycles of SELEX were carried out. The binding affinity and
specificity of the RNA pools generated in these cycles were tested via two well-accepted
binding assays, an affinity chromatography and a filter-based binding assay. However, the
binding results from these two assays did not agree with each other, with the possible
reasons further discussed. Therefore, another novel scintillation proximity assay is under
development in order to measure the ADMA-binding affinity and specificity of the RNA
pools conveniently and quantitatively. Further experiments will be required to generate a
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reliable binding assay for screening the selected RNAs and investigate the sequence and
structural properties of the RNA aptamers.

INTRODUCTION
Free asymmetric dimethylarginine (ADMA), an analog of

L-arginine,

is an

endogenous inhibitor of nitric oxide (NO) synthase (3) which is highly involved in
cardiovascular and renal diseases (4-7). Free ADMA is released to the plasma after the
arginine-methylated proteins are degraded in vivo. fADMA can be eliminated by the
enzyme dimethylarginine dimethylaminohydrolase (DDAH), which hydrolyzes fADMA
to dimethylamine and L-citrulline (8, 9). The reduction of DDAH activity under oxidative
stress appears to be the main reason for increased ADMA accumulation (7, 10). Elevated
plasma concentrations of fADMA have been observed in several clinical conditions
including aging (11, 12), hypercholesterolemia (13, 14), hypertension (12, 15, 16), and
diabetes (11, 17-19). A growing body of literature supports that the plasma fADMA level
can be used as a cardiovascular risk factor to predict the cardiovascular outcome for
patients (1, 2, 20-25).
Although the biological functions of both free and protein-bound ADMA are
becoming well accepted, the analytical tools for quantitatively detecting ADMA remain
limited. Often analysis of fADMA involves liquid chromatography/tandem mass
spectrometry (LC-MS/MS), which is very precise and accurate for analyzing plasma or
urine samples, but loses the sensitivity and specificity in small tissue samples (26). Also
the process of LC-MS/MS analysis is time-consuming and laborious, which makes it
difficult for clinical applications. HPLC analysis has also been used but is also
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time-consuming and requires special equipment (27). A precise and sensitive method is
required to handle a variety of sample matrices in a short amount of time.
Due to their unique and diverse conformations, RNAs are becoming important
biopolymers for target recognition. The RNA aptamer technology has been broadly used
for generating antibody-like molecules against selected targets (28). Compared to
antibodies, RNA aptamers produced by chemical synthesis are conveniently available, of
which the characteristics can be easily changed on demand by chemical modifications.
Thus, aptamers become a convenient and valuable tool with high affinity and specificity
for target molecules. Moreover, diagnostic and therapeutic approaches of RNA aptamers
have been applied for diseases such as age-related macular degeneration (AMD) and
inflammatory diseases (reviewed in (29)). Collectively, we decided to generate an RNA
aptamer specifically targeting ADMA.
Aptamers are generated through the in vitro selection termed SELEX (Systematic
Evolution of Ligands by EXponential enrichment) (30), which is a powerful tool to select
nucleic acids with a desired property from libraries of synthetic DNA or RNA with up to
1012 different sequences and possible 3-dimensional structures (31). From the SELEX
procedure, the initial library of oligonucleotides is screened by repeated selection and
amplification based on the affinity and specificity for the target molecule so that selected
aptamers are enriched after each cycle (Figure 7-1). The ADMA-binding affinity of the
RNA pools was measured via the ADMA-resin binding reaction (Figure 7-1 Step c) as
well as a modified filter-based binding assay. Both methods are commonly used in
aptamer

development.

However,

the

binding

percentage

observed

from

the

ADMA-affinity column did not agree with the binding affinity tested in the
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membrane-based binding assay. Thus, we are developing a scintillation proximity assay
(SPA) in order to minimize artifacts and measure the ADMA-binding affinity. The
potential aptamers will be sequenced and further studied for their structural properties.

Figure 7-1. Scheme of the SELEX procedure. a) The initial ssDNA pool was transcribed
into the RNA pool; b), specificity module (counter selection step) removes RNAs
unspecifically binding to arginine residues and the agarose resin; c) affinity module
(positive selection) collects RNAs bound to the ADMA resins; d-f) selected RNAs are
recovered and reverse-transcribed to ssDNA, which is further amplified for the next cycle
of selection.

EXPERIMENTAL PROCEDURES
SELEX procedure: Target and Library Preparation
N-hydroxysuccinimide (NHS)-activated SepharoseTM 4 Fast Flow resins (GE
Healthcare) were used to immobilize the arginine or fADMA molecules. The coupling
step was performed at 4 ºC overnight in the coupling buffer (50 mM arginine or ADMA
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in 0.2 M NaHCO3, 0.5 M NaCl, pH 8.3) according to the manufacturer’s procedure. The
Arg- or ADMA-coated resins were packed into columns for further RNA selection.
The initial single strand DNA (ssDNA) libraries were purchased, or received as a
generous gift from the Ellington Lab (UT Austin, TX). Each element of the ssDNA
random library was composed of 35 or 40 randomized nucleotides ﬂanked by 5’ and 3’
primer sites designated as N35 or N40 ssDNA library, respectively (i.e. 5’CACAGCGGGACAGTTTAGC-[N35]-GGTAGGTGGGTGCGTCTAAA-3’).

Each

ssDNA library was ampliﬁed by PCR and then transcribed to generate the corresponding
RNA random pools using an AmpliScribe™ T7-Flash™ Transcription Kit (Epicentre
Biotechnologies, Madison, WI). In vitro transcription reactions took place at 42 ºC for
2.5-3 hours or at 37 ºC for 6 hours, and the DNA template was then digested using
Turbo DNase I (Ambion, Austin, TX).
The RNA library was puriﬁed by urea-polyacrylamide gel electrophoresis (PAGE)
followed by gel extraction and ethanol precipitation. The targeted RNA band in the
urea-PAGE gel was visualized under a hand-hold UV illuminator on the top of a thin
layer chromatography (TLC) plate, thanks to the fact RNAs block the fluorescence of
TLC plate under UV light. The targeted RNAs were located and removed from the gel.
The sliced gel pieces were then crushed in 400 L of 300 mM NaOAc, stirred vigorously
with Vortex Genie® 2 Shaker, and heated at 75 ºC for 5-10 min for a sufficient RNA
extraction. The gel pieces were then removed by centrifuging at 14,000 RPM for 3-5 min
and washed with another 600-800 L of 300 mM NaOAc. The combined supernatant
from each washing step was further filtered with the centrifugal tube filters (2.2 m). The
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purified RNA was then precipitated from the filtered supernatant using 100% EtOH and
trace amount of glycogene at -80 ºC for >20 min, centrifuged at 14,000 RPM for 40 min.
The RNA pellet was then washed with 70% EtOH and dried by Savant SpeedVac
Concentrator (Thermo). The dried RNA pellet was further resuspended in 20 L of
diethyl pyrocarbonate (DEPC)-treated H2O with the final RNA concentration determined
by NanoDrop (Thermo Fisher Scientific).

SELEX procedure: Affinity and specificity modules
Both arginine and ADMA columns were rinsed with 2 mL of binding buffer (50 mM
HEPES, 250 mM NaCl, 5 mM MgCl2, pH 7.5). The resuspended RNA pool was
denatured by heating at 65 ºC for 10 min within 100 L of binding buffer and then
cooled to room temperature (RT) for recovery. The recovered RNAs were loaded onto the
ADMA column followed by light agitation and incubation for 0.5-1 hour at RT.
Unspecific binding events were mostly eliminated by several washing steps with binding
buffer. Tightly binding RNAs were then eluted using 3 volumes of 6 mM fADMA elution
buffer and concentrated by EtOH precipitation and resuspension. The RNA binding
percentage of each cycle was then calculated based on the amount of RNA eluted from
the ADMA column over the total amount of RNA loaded onto the column.
Every three cycles, the Arg-column was used as the speciﬁcity module, to avoid
accumulating sequences that unspecifically bind to agarose beads or arginines (instead of
the methylated guanidino moiety). In this negative selection, RNA pools from gel
extraction were directly loaded on the Arg-column. Solution from flow-through and three
washing steps was collected and processed through the ADMA-column for a following
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positive selection as described above. After each counter selection step, the RNA binding
percentage dropped dramatically. The eluted RNAs were then reversed transcribed with
SuperScript® Reverse Transcriptase (Invitrogen) into ssDNA. Each SELEX cycle
finished with a PCR amplification and EtOH clean-up.

Filter-based binding assay development
To confirm the RNA binding percentage obtained by affinity chromatography (the
ADMA column binding), another approach was utilized, derived from a commonly-used
membrane binding assay. RNA aptamers were labeled with radioactive -32P-ATP during
in vitro transcription. Peptides derived from the N-terminus of the histone H4 protein
containing arginine, MMA or ADMA at Arg-3 (SGRGKGGKGLGKGGAKRHRKV)
were selected as a bona fide substrate for binding assays (250 M peptides in 100 μL of
50 mM sodium phosphate buffer pH 7.6). Due to the positively-charged characteristic of
the H4 peptides, the labeled RNAs bound to the H4 peptides were separated from the
unbound RNAs through a 0.45 μm pore-size negatively-charged nitrocellulose membrane
(Millipore, MA) to capture the peptides together with the bound RNAs. Another piece of
positively-charged nylon membrane was placed below the nitrocellulose membrane in
order to seize all the unbound RNA as a positive control. All the binding assays were
performed with a 48-well Bio-Dot SF Apparatus (Bio-Rad Laboratories). The membranes
were then quickly washed three times with 1 mL of the TBE buffer, removed from the
apparatus, and dried in the hood. The amount of radioactivity on the membrane was
measured by autoradiograph.

Cloning of the selected RNA
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Based on the binding assays stated previously, SELEX cycles N35-R10, N35-R14,
and N40-R10 were selected for cloning and further sequencing. ssDNA pools from these
cycles were processed with the NcoI restriction enzyme, and cloned into the E. coli XL1Blue cells using the pGEM plasmid kit (Invitrogen) to create a DNA library. Three to five
colonies from the transformation of each DNA pool were randomly picked. Selected
aptamers were extracted and purified with the Qiagen Plasmid Mini Kit (Qiagen) for the
future sequencing experiments.

RESULTS AND DISCUSSION
Overview of the SELEX process
In the SELEX process, two libraries of single strand DNA (ssDNA) molecules, N35
and N40, were used as the initial pools, consisting of a random 35- or 40-nucleotide
region flanked by constant primer regions, respectively. Starting with the transcribed
RNA pools, affinity chromatography, as a canonical method to select aptamers, was
applied with the columns derivatized with ADMA or arginine. The ADMA column was
used as affinity selection. The amount of RNA molecules eluted with ADMA was
measured, based on which the RNA binding percentage of each cycle was calculated to
monitor the aptamer enrichment. For every 2-3 rounds of affinity selection and
amplification, counter selection was employed for binding specificity control with the
arginine column. Non-binding RNAs in the flow-through of the arginine selection were
directly loaded to the ADMA-affinity column in order to gain aptamers only binding to
the methyl guanidino moiety of ADMA.
After 8 or 9 rounds of SELEX process, the population of the ADMA-specific
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aptamers started to increase for both the N35 and N40 libraries (Table 7-1, data not
shown for the first 6 or 8 rounds). In fact, even when the counter selection was employed,
7-8 % of the applied RNAs eluted with ADMA at Round 10 for both N35 and N40
libraries. By reasoning that the relatively high ADMA concentration in the affinity
column could lead to enrichment of unspecific or weak binding RNAs, the ADMA
column was diluted by 10-fold to select aptamers with higher binding affinity. Such
dilution leads to a dramatic drop in the ADMA-eluted fraction. The binding percentage
never exceeded more than 2% in the following five rounds (Table 7-1).
As a commonly-used selection method in SELEX, affinity chromatography monitors
the RNA binding affinity and specificity by measuring the RNA binding percentage after
the positive and/or negative selection. In the growing body of literature about aptamers
targeting various biological molecules, the RNA elution percentage was observed to be
varied from as low as 2% (32) to more than 50% (33). Therefore, no rule of thumb can be

Table 7-1. The binding percentage of RNA aptamers from each round with or without the
counter selection with arginine-column.
N35
N40
Rounds

Arg-selection

R9
R10
R11

/
Yes
/

R12
R13
R14
R18
|
R30
*NA: Not available

/
Yes
Yes
Yes
|
/

Binding %

Rounds
Arg-selection
R7
Yes
R9
/
5.70%
R10
Yes
R11
/
8.00%
6.35%
R12
/
The ADMA-column was diluted 1:10.
1.75%
R13
Yes
0.60%
R14
Yes
0.31%
R15
/
2.11%
R18
Yes
|
|
|
13.10%
R20
Yes

Binding %
0.49%
1.50%
7.70%
2.85%
5.70%
0.69%
0.20%
0.30%
2.23%
|
4.45%
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concluded for the RNA binding percentage in order to judge whether the SELEX cycle
has been performed enough times. Considering the high binding percentage after the
negative selection, ssDNA pools from N35-R10 and N40-R10 (bold faced in Table 7-1)
were selected as the top choices for further binding and sequencing experiments.

Filter-binding assays with selected SELEX cycles
From the SELEX process, RNA libraries were created in each cycle, of which the
binding affinity and specificity were measured against fADMA. Due to the fact that the
affinity chromatography only measures the concentrations of the applied and eluted RNA
molecules based on UV absorbance, the accuracy of such measurement is questionable
especially under the low binding affinity after Round 12 for both libraries. To better
approximate the fraction of ADMA-bound aptamers after each round, we attempted to
modify a conventional nitrocellulose-binding assay, which utilizes a piece of
nitrocellulose filter membrane to lock the proteins, and therefore, bind the RNA/protein
complexes with the unbound RNAs washed out.
In order to confirm that our peptides containing methylarginines would be locked by
the nitrocellulose membrane, we first compared the binding efficiency of the
nitrocellulose membranes with the well-developed ZipTip® assay (34). Methylation
reactions were performed with the tritiated S-adenysol-L-methionine (3H-AdoMet) along
with the H4-21 peptide substrate, the histone H4 protein, and the hnRNP K protein. The
radioactivity incorporation measured by the ZipTip® assay was used as the standard value
to assess the binding efficiency of nitrocellulose membranes with different pore sizes and
different washing procedures (Figure 7-2). Briefly, the amount of radioactivity retained
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on the 0.45 m nitrocellulose membrane with a more stringent washing procedure (light
grey bars) was the closest to what obtained in the ZipTip® assay (crossing bars). Due to the

positive charge on AdoMet, the nitrocellulose membrane tends to bind both
peptides/proteins and the methyl group donor 3H-AdoMet, which probably leads to the
higher radioactivity observed in all nitrocellulose binding assays than in the ZipTip®
assay. Therefore, a more rigorous washing procedure was required to remove the bound
3

H-AdoMet and lower the inaccurately high radioactivity (Figure 7-2, light vs dark grey

bars). Moreover, the nitrocellulose membranes with smaller pore sizes (0.2 m) also lead
to a high degree of AdoMet binding which was difficult for further removal in the

4

2.5 10

Radioactivity (DPM)

2 10

4

ZipTip
0.2 um
0.45 um -1
0.45 um -2

4

1.5 10

1 10

4

5000

0

H4-21

H4 protein

hnRNP K

Figure 7-2. The binding efficiency of nitrocellulose membranes with different pore sizes
and different washing procedures. Separate methylation reactions were performed with
3
H-AdoMet and the H4-21 peptide, the histone H4 and hnRNP K proteins. Peptides or
proteins were isolated and analyzed with ZipTip® assays, and nitrocellulose membranes
(0.2 M or 0.45 M). Two washing procedures were performed to remove bound
3
H-AdoMet on the nitrocellulose membranes, one with 1 mL of 50 mM sodium
phosphate buffer (pH 7.6) (0.45 m-2, dark grey bars), the other with 2 mL of 50 mM
sodium phosphate buffer (pH 7.6) with 100 mM NaCl (black and light grey bars).
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washing steps. Therefore, the nitrocellulose membrane (0.45 m) was chosen for further
aptamer selection with a stringent step-wise washing procedure.

In our modified binding assay, RNA aptamers from selected SELEX cycles were
labeled with -32P-ATP in the in vitro transcription step for accurate quantification. The
negatively-charged

nitrocellulose

membrane

was

used

to

retain

peptides

or

ADMA/arginine coated resins and isolate target-binding RNAs from non-binding RNA
molecules. Moreover, a piece of positively-charged nylon membrane was placed
underneath to capture the free RNA aptamers flowing through the nitrocellulose
membrane in order to gain the total amount of RNA (Figure 7-3A). The 32P-labeled RNA
library was incubated with the target peptides or resins on the nitrocellulose membrane.
All binding assays were performed in a 48- or 96-well apparatus connected to the vacuum
manifold (Figure 7-3A). Different from the SELEX process, solutions from in vitro
transcription were directly loaded onto the membrane without the gel-purification step in
order to minimize the radioactive waste. Followed by the washing procedure, the
radioactivity retained on both membranes was then detected and measured by
autoradiography (Figure 7-3B).
From the autoradiogram of the nylon membrane, the amount of free

32

P-RNAs can

be estimated as a positive control to confirm that a similar amount of RNA molecules was
generated in the in vitro transcription step with ssDNA libraries from different SELEX
cycles. The radioactivity retained on the nitrocellulose membranes identified the RNA
libraries that bound to the specific targets. Figure 7-3B clearly showed that most RNAs
directly flow through the nitrocellulose membrane without binding to the Arg- or
ADMA-resins. RNAs from some SELEX cycles showed high binding affinity towards
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Figure 7-3. Nitrocellulose filter binding assay. (A) Scheme of the filter-binding assay
performed in the 48-well apparatus. (B)Autoradiographs of the nitrocellulose and nylon
membranes with arginine- or ADMA-coated beads. The SELEX cycles tested are labeled
on both membranes for the N35 and N40 libraries.
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arginine instead of ADMA, such as Round 10, 12, and 16 from the N35 library.
Surprisingly, RNAs from Round 7 with the N40 library showed a high ADMA-binding
affinity and no arginine-binding property, indicating a high ADMA-binding specificity
(circled in Figure 7-3B).
More filter-binding assays were performed with promising SELEX cycles to confirm
the observed high ADMA-binding specificity. However, results from repeated assays
were not clear or reproducible (data not shown). The radioactivity signals on the
nitrocellulose membrane were difficult to distinguish from the background noise,
especially when peptidyl-ADMA was used as the binding target instead of the
ADMA-beads. More importantly, the binding affinity tested by the nitrocellulose-binding
assay was different from the results of affinity chromatography. For example, Round 10
from both N35 and N40 libraries showed a high RNA binding percentage with the
ADMA-column after the arginine selection (Table 7-1). However, the nitrocellulose
membrane for these two SELEX cycles (Figure 7-3B) retained either little amount of
radioactivity (N40-R10) or a large amount of

32

P-RNA bound to arginine-beads

(N35-R10). Such a difference between two binding assays might result from the
unpurified RNA pools tested in the nitrocellulose-binding assay. Without the
gel-purification step, solutions from in vitro transcription contain the RNA primers, initial
DNA pools, and enzymes, which can potentially influence the RNA binding events.
Moreover, the binding efficiency and specificity of the nitrocellulose membranes remains
unclear, especially with peptides surrounded by a large amount of RNAs. Although it is
shown the methylated H4-21 peptides could be captured by the nitrocellulose membrane
(Figure 7-2), the existence of the RNA pool along with other components could
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potentially mask the positive charges on the peptide leading to inefficient binding.
Therefore, the binding affinity measured by the affinity chromatography might be more
accurate, despite the fact that its RNA quantification method based on UV absorption is
not as sensitive or accurate as radioactivity incorporation used in filter-binding assays.

CONCLUSION
As a significant metabolite, fADMA is involved in many biological pathways.
Dysregulation of the plasma fADMA concentrations is observed in various human
diseases. Therefore, it is important to develop a convenient analysis tool to quickly detect
and measure the amount of fADMA in various samples. Herein, we determined to
generate RNA aptamers specifically targeting ADMA. RNA libraries were generated
from SELEX cycles, of which the binding affinity and specificity was analyzed by
affinity chromatography and filter-binding assay. Despite of the technical difficulties in
both methods, ssDNA pools from N35-R10, N35-R14 and N40-R10 were cloned for
further sequencing.
To obtain a more accurate and reproducible binding result, the scintillation proximity
assay (SPA) is currently under development with radiolabeled RNAs targeting the
ADMA-coated SPA beads. With the SPA, we can spontaneously screen the binding
affinity of RNA aptamers and measure the binding affinity of selected RNA pools. Future
experiments will focus on obtaining promising RNA aptamer sequences and looking for
the structural details of the binding event. Further investigations can be performed to
generate a diagnostic or analysis tool based on the ADMA-targeted aptamer.
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CHAPTER 8
SUMMARY AND FUTURE DIRECTIONS

For all types of post-translational modifications (PTMs), it is essential to control the
specificity for accurately regulating the downstream effects. As one of the significant
post-translational modifications, protein arginine methylation, catalyzed by protein
arginine methyltransferases (PRMTs), is involved in a wide variety of fundamental
cellular pathways and human diseases (reviewed in Chapter 2). As the predominant
PRMTs in vivo (1), PRMT1 has broad substrate specificity, with many protein substrates
containing multiple methylation sites. Moreover, PRMT1 was shown to generate a
distinctive MMA−ADMA pattern in vivo, with some arginines fully dimethylated and
others only mono- or partially dimethylated (2-4). Importantly, the biological
consequence of arginine methylation is determined by the degree (mono- /dimethylation)
and type of arginine dimethylation (asymmetric/symmetric). Thus, a fine-tuned
regulation is required for the diverse, yet high product specificity of PRMT1; however
the current knowledge of the fundamental regulation of PRMT product specificity
remains limited.
A strong foundation has been established by this work in understanding the
molecular origins of the product specificity of PRMT1 and the kinetic mechanism
regulating product generation. For each project, summary and future directions along
with existing preliminary data are described below.

The conserved methionines in the active site of PRMT1 specify MMA, ADMA, and
SDMA formation.
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In protein lysine methylation, the Phe/Tyr “switch” model has been well studied to
regulate mono-, di-, and trimethylation in lysine methyltransferases (5-7), which leads us
to believe that a similar model of a single residue altering product specificity could exist
in arginine methyltransferases as well. By dissecting the active site of PRMT1, we
identified that two conserved active site residues, Met-48 and Met-155, play a significant
role in enzymatic activity and product specificity (Chapter 3). Both Met-48 and Met-155
regulate PRMT1 mono- versus asymmetric dimethylation (see Figure 3-2). Using single
turnover experiments to analyze each methyl transfer step separately, Met-48 shows a
differential effect on the first and second methylation rates, where the turnover of
monomethyl peptides is severely impaired leading to the accumulation of final MMA
products (see Figure 3-5). Thus investigation of the two conserved active-site
methionines provided the first insight into the intrinsic regulation of MMA versus ADMA
formation (8).
Met-48 discriminates between ADMA and SDMA formation — Before the crystal
structure of PRMT5 was solved, sequence alignment of Type I and II PRMTs indicates
that the equivalent residue of Met-155 was serine, a smaller amino acid. Therefore,
Met-155 was previously hypothesized to specify ADMA and SDMA formation between
Type I and II PRMTs by providing steric hindrance in the active site (9-11). However,
M48L-, M48A-, M155L-, and M155A-PRMT1 exclusively generate MMA and ADMA
(8, 12). When the crystal structure of human PRMT5 was solved (13), Phe-397 was
found at the same location in the active site of PRMT5 as Met-48 in rat PRMT1 (see
Figure 2-5). By western blotting, a F397M-PRMT5 mutant was shown to generate both
ADMA and SDMA (13). Although we did not observe SDMA formation with M48L or
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M155A mutants previously, we further generated M48F-PRMT1 mutant and analyzed
the product formation with trace amount of tritium incorporation by reverse phase HPLC.
A small amount of the tritium-labeled products eluted at the retention time of SDMA
(data not shown). We further confirmed SDMA formation by electron transfer
dissociation (ETD) and orbitrap mass spectrometry (MS) with our new collaborator Dr.
Qu (at SUNY Buffalo). ETD-MS is capable of accurately locating the methylation site
and distinguishing between asymmetric and symmetric dimethylation (14). ETD-MS
analyses proved that M48F-PRMT1 generates MMA, ADMA, and a very small amount
of SDMA (Table 8-1). Thus, our results indicate that Met-48 dictates ADMA synthesis
over SDMA. By characterizing the two conserved methionines in the PRMT1 active site,
Met-48 and Met-155 are shown to govern the product formation of rat PRMT1 specifying
MMA/ADMA generation, as well as ADMA/SDMA formation.

Table 8-1. Product analysis of M48F-PRMT1 by electron transfer dissociation and
orbitrap mass spectrometry (the SDMA-peptide was squared).
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Computer simulation to understand the energetics of the PRMT1 product specificity
— To further understand the product specificity of PRMT1 as well as changes of the
product specificities as a result of M48F mutation, we pursued computer simulations to
examine the energy origin for the product specificity of wild type PRMT1 and the M48F
mutant. This approach has been applied for studies with protein lysine methyltransferases
(PKMTs) suggesting that, at least in some cases, the energetics of the methyltransfer
reactions may determine the product specificity of PKMTs (6, 15-17). However, no such
research has been done with PRMTs. We are collaborating with Dr. Acevedo (Auburn
University) to perform the hybrid quantum mechanical/molecular mechanical (QM/MM)
free energy simulations for methyl-transfer processes in PRMT1 and M48F-PRMT1. Due
to the fact that the N-terminal helix may be significantly involved in catalysis, yet the
current crystal structure of PRMT1 does not show electron density of that helix (see
Figure 2-6), Dr. Acevedo and his student built in the N-terminal helix to supply residues
to the active site (Figure 8-1). Also, the original crystal structure lacks the electron
density of the whole peptide substrate, except for the single arginine bound in the active
site (9). Therefore, modeling the entire peptide substrates in is currently underway for
future simulation. After the preparation is finished, the energy barrier for Arg  MMA
and MMA  ADMA will be calculated as well as the changes from M48F mutation in
order to understand how the energy landscape contributes to the product specificity of
PRMT1.
Identification of the automethylation site(s) in M48L-PRMT1 — We previously
reported the automethylation characteristics of the M48L and M155A mutants (Figure
3-3), indicating a change in the PRMT1 product specificity. Due to the fact that PRMT1
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Figure 8-1. The N-terminal helix of rat PRMT1 was built in the existing crystal structure
(1OR8) for further investigation. The modeled region is shown in orange, with the
original crystal structure of PRMT1 shown in cyan.

prefers arginine residues within the “RGG” or “RXR” canonical sequences in an
unstructured loop (18-20), we hypothesize that Arg-353 is likely to be methylated as it is
in the “RMR” sequence and the last amino acid on the C-terminus of PRMT1. To identify
the position of automethylation, we generated M48L-R353K mutant to investigate
whether automethylation of M48L disappeared with the R353K mutation. After
M48L-R353K was generated, its enzymatic activity was first tested with the R3 peptide
(acGGRGGFGGRGGFGGRGGFG), which showed about one third of the methylation
rates compared to M48L (data not shown). Automethylation assays were then performed
as described in Chapter 3. The amount of tritium incorporation reduced by >90% when
Arg-353 was mutated to lysine (Figure 8-2A), indicating that Arg-353 is likely the
automethylation site for M48L-PRMT1.
Product specificity changed with the R353K mutation in M48L-PRMT1 — We made
the interesting observation that M48L-PRMT1 can barely methylate the arginine residue
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at the center of the peptide substrate (Table 3-4), such as the KRK peptide
(acKGGFGGRGGFGGKW). We further tested whether the M48L-R353K mutant
maintains such substrate recognition ability with the KRK peptide and the RKK peptide
(acGGRGGFGGKGGFGGKW). Surprisingly, M48L-R353K cannot methylate either the
RKK peptide or the KRK peptide (see Figure 8-2B), suggesting that M48L-R353K
cannot recognize the arginine residues on the N-terminus or at the center of the
single-arginine containing peptide. Considering that M48L-R353K shows a relatively
good activity with the R3 peptide, we hypothesize that M48L-R353K has a high
preference to the C-terminal arginines, or the activity of M48L-R353K requires multiple
arginine residues in the peptide substrates. To answer these questions, we ordered the
KKR peptide with a single arginine on the C-terminus. Further experiments will be
performed to find out the product specificity of M48L-R353K. If M48L-R353K does
show a C-terminal preference, the product specificity of M48L-R353K is completely

Figure 8-2. Automethylation (A) and product specificity investigation (B) of
M48L-R353K compared to M48L. Both the automethylation and the activity assays were
performed the same as described in Chapter 3.
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reversed from wild type PRMT1 or M48L, which has a strong preference to the
N-terminal and center-located arginines (Table 3-3). A single mutant R353K-PRMT1 is
also generated to investigate whether the change in product specificity is due to the
R353K mutation or is a synergy from both the M48L and R353K mutations. From the
crystal structure of PRMT1 (9), Arg-353 is ~17 Å away from Met-48 and the active site,
and ~13 Å away from the putative peptide binding grooves. Our observations indicate
that the distal residues in PRMT1 also have an effect on the enzymatic activity and
substrate recognition.

The kinetic mechanism of PRMT1-catalyzed dimethylation
We previously showed that the conserved active site residues govern the deposition
of methyl marks (MMA, ADMA, or SDMA); however it is not sufficient to explain the
distinctive methylation pattern of PRMT1 in vivo, as well as substrate recognition of
PRMT1 among multiple arginines. We further explored the product specificity of
PRMT1 from a substrate-centered perspective (Chapter 4). With multi-arginine peptide
substrates, we found that PRMT1 shows less preference to the C-terminal arginines,
similar with the physiological methylation patterns observed in vivo. With a single
targeted arginine, we identified that the amino acids flanking the substrate arginine
influences the final MMA or ADMA status. To conveniently study the processivity of
PRMT1-catalyzed dimethylation, which also influences the MMA and ADMA
distribution, double turnover experiments were designed based on single turnover
experiments. Results showed that PRMT1 dimethylates the peptide substrates in a
semi-processive manner, consistent with the rapid equilibrium random mechanism
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proposed by Obianyo and co-workers (21). Interestingly, the degree of processivity is
dependent on the substrate sequences, which explained the controversial observations
between the distributive and partial processive mechanism of PRMT1 based on two
different peptide substrates (21, 22). Thus, our results recognize a novel
substrate-induced mechanism for modulating PRMT1 product specificity (23).
Single turnover experiments to understand the semi-processivity of PRMT1— Among
the handful of publications regarding kinetic mechanisms of PRMT1, our research (23)
and steady state data from Thompson and colleagues (21) suggest a partially processive
or semi-processive mechanism; while a recent transient kinetic study (24) proposed a
completely dissociative mechanism (reviewed in Chapter 5). To understand the
controversy, we further investigated the PRMT1 mechanism using transient kinetics and
single turnover experiments to understand the microscopic steps in PRMT1-catalyzed
methylation reactions (Chapter 5). Single turnover experiments with the eIF4A1 peptide
pair indicate that the unmodified peptide is a slightly better substrate than the
monomethyl substrate under single turnover conditions (see Table 5-2).
We previously observed that different peptide substrates have distinct degrees of
processivity (see Table 4-5). What leads to the different degrees of processivity? Is it due
to the methylation rates of the first and second methyl group transfer? If a peptide has a
higher methylation rate of the MMAADMA step than the ArgMMA step, it would
probably show a higher degree of processivity. In the transient kinetic analysis of PRMT1
(24), the 2nd methylation step (MMAADMA) is shown to be much slower than the 1st
step (ArgMMA) with a fluorescein-tagged H4 peptide. However, in our studies, the
untagged H4-21 peptide shows a high degree of processivity (see Table 4-5). To answer
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these questions, the methylation rates of other peptide pairs were further tested with
single turnover experiments. Same protocols were followed as stated in Chapter 5 with
reactions initiated by peptide substrates. Two typical single turnover curves from the
H4-21-CH3 and RKK-CH3 peptide were shown in Figure 8-3. Combined with previous
data (Chapter 3, 4, and 5), Table 8-2 summarizes the maximal product concentration A0
and methylation rate kobs of all four peptide pairs (except for the H4-21 peptide, of which

Figure 8-3. Single turn-over experiments of PRMT1 with monomethylated H4-21 and
RKK peptide substrates. The data were fitted into equation: y= Ao *(1-exp(-b*x)).

Table 8-2. Different peptide substrates lead to distinct chemistry rates for the first and
second methylation steps.
Arg  MMA

MMA ADMA

A0 (M)

kobs (x10 s )

A0 (M)

kobs (x10 s )

MMA:
ADMA

H4-21

/

/

15.2 ± 0.6

6.7 ± 1.4

0.97 : 1

eIF4A1

10.8 ± 0.3

3.8 ± 0.1

13.0 ± 0.3

2.6 ± 0.2

1.50 : 1

KRK

20.3 ± 0.3

2.0 ± 0.1

15.0 ± 1.1

2.9 ± 0.1

4.10 : 1

RKK

14.5 ± 1.8

7.3 ± 3.7

13.1 ± 0.8

5.5 ± 1.6

4.73 : 1

Peptide

-2

-1

-2

-1
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the tritium incorporation was too scattered to achieve a reliable single turnover curve).
Based on the preliminary data here, we cannot find any clear clues of the relationship
between the degree of processivity and the methylation rates of each methyl group
transfer step. Thus, the substrate-dependent processivity is uncoupled with the methyl
transfer rates, which is more complex than previously thought.
Transient

kinetic

study

using

stopped-flow

measurements

to

understand

PRMT1-AdoMet and PRMT1-peptide interactions — To gain more insight into the
microscopic steps in PRMT1-catalyzed dimethylation, stopped-flow rapid mixing was
applied to measure the rate of AdoMet or peptide binding based on the intrinsic
fluorescence of PRMT1. Surprisingly, no reliable binding curve can be achieved in the
absence of the reductant dithiothreitol (DTT) (Chapter 5, data not shown). In the presence
of DTT, AdoMet binding process showed two phases, which may indicate the initial
binding step and a conformational change after the PRMT1-AdoMet complex formed
(see Figure 5-3). As we are now aware that the His6-tag influences the oligomerization
states of PRMT1, which can be partially recovered by DTT (Chapter 6), the same
stopped-flow measurements will be performed with the tagless PRMT1 to find out the
real kon and koff for AdoMet and peptide binding.
The differential effects of DTT in steady-state kinetics and single turnover
experiments — To understand more about the DTT enhancement of the enzymatic
activity of rat PRMT1 under steady state (see Figure 6-1), single turnover experiments
with the addition of DTT was performed using the eIF4A1 peptide with His-rPRMT1
pre-incubated with 1 mM DTT. Surprisingly, barely any turnover can be detected in the
presence of DTT under the single turnover conditions (data not shown). It is unknown
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why DTT increases the activity under steady state (low enzyme, high peptide
concentration), yet diminishes the methylation activity under single turnover conditions
(high enzyme, high peptide). One hypothesis is that some PRMT1 inhibitors may
co-purify with His-rPRMT1 which can be activated by the reductant DTT. Under low
PRMT1 concentrations (0.1 M), inhibitors may also be too dilute to impede the reaction.
When high concentrations of PRMT1 (21.0 M) were used in the single turnover
experiments, the amount of inhibitors also greatly increased, sufficient to eliminate the
enzymatic activity of PRMT1. Also, single turnover experiments were performed at 22 C,
while the steady state kinetic studies were at 37 ºC. Different temperatures may also
influence the effect of DTT and/or the inhibitors.
The oxidative damage in His-rPRMT1 — As the protein characteristics of PRMT1
can be partially revived by DTT, we hypothesize that His-rat PRMT1 incurs oxidative
damage, which likely influences the enzymatic activity and protein oligomerization
(discussed in Chapter 6). To further examine the protein oxidation, Ellman's reagent
(5,5'-dithiobis-(2-nitrobenzoic acid) or DTNB) was used to quantitate the free thiol
groups in the protein (25). Based on the preliminary data, two (2) of the 11 cysteines in
rat PRMT1 can be detected on the solvent accessible surface of His-rPRMT1 (data not
shown). Further experiments will be performed to quantitate the sulfenyl groups (-SOH)
in His-rPRMT1. Site directed mutagenesis is currently underway to target the role of
single cysteine residue in rPRMT1 oxidation.
Overexpression of PRMT1 and enhancement of PRMT1 activity was observed under
oxidative stress, correlated with the accumulation of intracellular reactive oxygen species
(ROS), and eventually enhanced oxidative stress-induced apoptosis (26, 27). Oxidative
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stress was suggested as one of the stimuli regulating PRMT1, of which the mechanism
remains uncertain (28). Due to the fact that protein cysteine oxidation is a significant
pathway for cellular signal transduction (reviewed in (29)), PRMT1 may be regulated by
oxidative stress through selective oxidation of Cys-101 or other cysteine residues.
Therefore, it will be of great significance to identify the oxidation sites of PRMT1 and
the downstream effects of PRMT1 oxidation.

Other ongoing projects
The amino acids flanking the substrate arginine influences the steady state kinetics
and product formation of PRMT1— We previously identified the effect of flanking amino
acid sequence on methylated product distribution (see Figure 4-3). Peptides with the
canonical “RGG” amino acids sequence were fully dimethylated, while the peptides with
“RYG” or “RSG” were only monomethylated or partially dimethylated. Besides the
effect on the end-product formation, the flanking amino acid sequences also influence the
steady state characteristics of PRMT1. The RGA peptide (acKGGFGGRGAFGGKW)
and RGA-CH3 peptide (acKGGFGGRmeGAFGGKW) were tested to identify if the
sequence context near the substrate arginine dictated how the substrate was methylated.
The RGA-peptide (see Figure 8-4) and the RGA-CH3 peptide (data not shown) both
displayed substrate inhibition at high substrate concentrations (>600 M), an observation
which may prove to be biologically important.Although the mechanism of RGA-caused
substrate inhibition is unknown, ignoring it and truncating the data can lead to mistaken
estimates of kinetic parameters. Interestingly, DNA methyltransfearse 1 (DNMT1), a
maintenance methyltransferase, is subject to strong substrate inhibition by unmethylated
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DNA (30, 31). The probable biological reason for such inhibition may be to guarantee the
unmethylated region remaining unmethylated and ensure the faithful reproduction of
DNA methylation patterns (32). The same biological reason may also apply to the
RGA-induced substrate inhibition that is to maintain the substrate specificity of PRMT1.
Our results indicate that protein substrates that are methylated in the context of sequences
other than a glycine/arginine rich motif may undergo such inhibition in cells.

Methylation Rate (M/min)
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[RGA peptide] (M)

Figure 8-4. The RGA peptides (acKGGFGGRGAFGGKW) caused substrate inhibition at
high substrate concentrations. Reactions were performed following the same protocol as
the continuous spectrophotometric kinetic assays stated in Chapter 3. The data was fitted
into equation: v = Vmax[S] / (Ks + [S] + [S]2/Ki), where [S] is the substrate concentration,
and Vmax, Ks, and Ki are constants independent of [S].

Quantitation of the endogenous PRMT1 concentration in healthy and disease cell
lines — For all the kinetic reactions performed in vitro, we always question whether the
results are physiologically relevant and what is the endogenous concentration of PRMT1
in the cell. To answer these questions, we performed western blotting to estimate the
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endogenous concentration of human PRMT1. Cell lysates from healthy lung and brain
tissues and the corresponding tumor tissues were tested as well as lysates from A549 lung
cancer cell, BT-20 breast carcinoma cells, and Hela cells (Figure 8-5). The tag-cleaved
human PRMT1 was used for quantitation. We identified that 10 nM of PRMT1 is our
detection limit (see Figure 8-5). Most tissue samples were beyond our detection limit, yet
an overexpression of PRMT1 in lung tumor cells can be clearly observed, consistent with
previous observations (33). We also tested heart and liver cell lysate as well as their
tumor cell lysate, yet no obvious signal could be detected with western blotting (data not
shown). Comparing the three cancer cell lines, A549 cells showed a higher PRMT1
concentration (42 nM) than BT-20 and Hela cells (~23 nM) quantitated from the
hPRMT1 standards (Table 8-3).
In order to quantitate the endogenous PRMT1 concentrations, Hela cells were used
for calculation as the bona fide model with an average cell mass of 3x108 cells/g, and an
average cell volume of ~3000 m3 (34). As the cell lysate samples contain a total of 500
g of protein, we estimate that the total sample comes from 1.7x106 cells, as each Hela
cell approximately contains 300 pg of protein (35). Based on the PRMT1 concentration
of Hela cells quantitated from Figure 8-4 (24 nM), the whole cell lysate contains 4.5

Figure 8-5. Western blotting against anti-hPRMT1 to quantitate the endogenous PRMT1
concentrations in various cell lysates.
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pmole of PRMT1 in 1.7x10 cells. Calculated from the individual cell volume, the
6

endogenous PRMT1 concentration in Hela cells is 2.5 M. The PRMT1 concentrations in
A549 and BT-20 cells were then approximated assuming that these two cell lines share
the same cellular parameters as Hela cells (see Table 8-3). Although quantitation from
western blotting was not very accurate, it provides us the first insight into the
physiological concentrations of PRMT1 in a low micromolar range, which is directive for
future experimental designs.

Table 8-3. The endogenous PRMT1 concentrations quantitated in different cell lysates
A549
Hela
BT-20

[PRMT1] in gel (nM)

Estimated endogenous [PRMT1] (M)

42
24
22

4.7
2.5
2.6

Summary
This dissertation focused on understanding the product specificity of PRMT1 and the
kinetic mechanism that regulates the final distribution of methylation products. As part of
the puzzle has been solved, many opportunities are available for further research with
PRMT1, such as profiling the energetic barriers for methyl group transfer, investigating
the oxidative damage in PRMT1, as well as the cause of the substrate inhibition from
peptide substrates containing non-canonical “RGG” amino acid sequences. It is hoped
that this dissertation can provide a foundation and direction for future research that will
answer the significant remaining questions of PRMT1.
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FASEB Summer Research Conference, Biological Methylation, Snowmass,
CO
Gui, S., Wooderchak-Donahue, W.L., Hevel, J.M. “Modulation of
protein arginine methyltransferase 1 product formation”
243rd ACS National Meeting & Exposition, San Diego, CA
Gui, S., Hevel, J.M. “Insights into the molecular origins of PRMT1
product specificity: A tale of two conserved Met residues”
st
1 Annual Biochemistry Department Retreat, USU, Logan, UT
Research overview of the Hevel laboratory “Protein arginine
methyltransferases:
diverse biological roles, complex product
formation, and unsettled regulation”
1st Annual Biochemistry Department Retreat, USU, Logan, UT
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Gui, S., Wooderchak-Donahue, W.L., Hevel, J.M. “Insights into the
molecular origins of PRMT1 product specificity: A tale of two
conserved Met residues” (oral presentation)
07/2010
Gordon Research Conference, Enzymes, Coenzymes & Metabolic
Pathways, Waterville Valley, NH
Gui, S., Hevel, J.M. “Modulation of protein arginine methyltransferase
1 product formation”
06/2010
FASEB Summer Research Conference on Biological Methylation, Carefree,
AZ
Gui, S., Wooderchak-Donahue, W.L., Suh-Lailam, B.B., Hevel, J.M.
“Modulation of protein arginine methyltransferase 1 product formation”
03/2010 Intermountain Graduate Research Symposium, Logan, UT
Gui, S., Wooderchak, W.L., Hevel, J.M. “Molecular dissection of the
active site of Protein Arginine Methyltransferase 1: identification of
residues which control substrate specificity and activity” (oral
presentation, won 3rd place in the Biochemistry section)
03/2009 237th ACS National Meeting, Salt Lake City, UT
Gui, S., Wooderchak, W.L., Hevel, J.M. “Determinants of Protein
Arginine Methyltransferase 1 (PRMT1)-catalyzed ADMA Formation”
03/2009 Intermountain Graduate Research Symposium, Logan, UT
Gui, S., Wooderchak, W.L., Hevel, J.M. “Determinants of Protein
Arginine Methyltransferase 1 -catalyzed ADMA Formation”
*Speaker of the presentation underlined

HONORS & AWARDS
Department of Chemistry/Biochemistry Travel Award – Utah State University
2012
American Heart Association Spring 2011 ONE YEAR Predoctoral Fellowship 2011
Department of Chemistry/Biochemistry Travel Award – Utah State University
2011
Graduate Student Senate Travel Award – Utah State University
2011
Graduate Student Senate Travel Award – Utah State University
2009
Department of Chemistry/Biochemistry Travel Award – Utah State University
2008
Graduate Student Senate Travel Award – Utah State University
2008
GlaxoSmithKline Scholarship of China Pharmaceutical University, China
2007
GlaxoSmithKline Scholarship of China Pharmaceutical University, China
2006
People’s Scholarship of Nanjing University, China
2005
People’s Scholarship of Nanjing University, China
2004
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MAJOR RESEARCH PROJECTS
1. Characterization of the active site of Protein Arginine Methyltransferase 1 (PRMT1)
2. Profiling the determinants of PRMT1 substrate recognition
3. Kinetic mechanism of PRMT1 and determinants of PRMT1-catalyzed asymmetric
dimethylarginine (ADMA) formation
4. Explore the influences of different protein tags and buffering systems on the protein
characteristics of PRMT1, especially on enzymatic activity and substrate specificity
5. Product analysis of M48F-PRMT1, a hybrid type of PRMT generating both
asymmetric and symmetric dimethyl arginine.
6. Product analysis of TbPRMT7 and the determinants of PRMT7 generating only
monomethylarginine.
7. Generating an ADMA-specific aptamer and developing a SPA-bead screening
method for aptamer selection
TEACHING EXPERIENCE
Teaching Assistant – Biochemistry Laboratory (Spring 2009)
Teaching Assistant – Principles of Chemistry I Laboratory (Fall 2007 and 2008)
Teaching Assistant – Principles of Chemistry II Laboratory (Spring 2008)
For all the laboratory instructions I gave, each section contains ~ 20-25 students. I
gave a short lecture at the beginning of each experiment and monitored student
experiments and graded submitted assignments.
SERVICE AND LEADERSHIP
2010 – 2012
06/2010

Graduate Advisor of Chemistry Club, Utah State University
Volunteer Coordinator, Science demonstration in Edith Bowen
Elementary School, Logan UT
09/2007
Volunteer Coordinator, Top of Utah Marathon, Logan UT
09/2004 – 06/2007 Student Committee Leader, Biochemical Pharmaceutical Major,
Nanjing University & China Pharmaceutical University
09/2003 – 06/2005 Coordinator, Advertising Department, Nanjing University
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LIST OF REFEREES
Joan M. Hevel, Ph.D.
Associate Professor
Department of Chemistry and Biochemistry
Utah State University
0300 Old Main Hill
Logan, UT 84322
joanie.hevel@usu.edu
(435) 797-1622 (phone)
Sean J. Johnson, Ph.D.
R. Gaurth Hansen Assistant Professor
Department of Chemistry and Biochemistry
Utah State University
0300 Old Main Hill
Logan, UT 84322
Sean.Johnson@usu.edu
(435) 797-2089 (phone)
Lance C. Seefeldt, Ph.D.
Professor
Department of Chemistry and Biochemistry
Utah State University
0300 Old Main Hill
Logan, UT 84322
lance.seefeldt@usu.edu
(435) 797-3964 (phone)
Alvan C. Hengge, Ph.D.
Professor and Department Head
Department of Chemistry and Biochemistry
Utah State University
0300 Old Main Hill
Logan, UT 84322
alvan.hengge@usu.edu
(435) 797-3442 (phone)

